WO2022231872A1 - Kcnt1 inhibitors and methods of use - Google Patents
Kcnt1 inhibitors and methods of use Download PDFInfo
- Publication number
- WO2022231872A1 WO2022231872A1 PCT/US2022/025045 US2022025045W WO2022231872A1 WO 2022231872 A1 WO2022231872 A1 WO 2022231872A1 US 2022025045 W US2022025045 W US 2022025045W WO 2022231872 A1 WO2022231872 A1 WO 2022231872A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mmol
- compound
- alkyl
- disorder
- disorder associated
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 55
- 239000003112 inhibitor Substances 0.000 title description 3
- 101150046522 KCNT1 gene Proteins 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 163
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 114
- 230000035772 mutation Effects 0.000 claims abstract description 90
- 208000035475 disorder Diseases 0.000 claims abstract description 89
- 101000944018 Homo sapiens Potassium channel subfamily T member 1 Proteins 0.000 claims abstract description 73
- 102100033508 Potassium channel subfamily T member 1 Human genes 0.000 claims abstract description 71
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 43
- 230000008587 neuronal excitability Effects 0.000 claims abstract description 42
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 36
- 150000003839 salts Chemical class 0.000 claims description 69
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 59
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims description 29
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims description 28
- 208000014644 Brain disease Diseases 0.000 claims description 28
- 208000032274 Encephalopathy Diseases 0.000 claims description 28
- 229910052757 nitrogen Inorganic materials 0.000 claims description 28
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 27
- 208000035051 Malignant migrating focal seizures of infancy Diseases 0.000 claims description 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 26
- 206010010904 Convulsion Diseases 0.000 claims description 25
- 229910052739 hydrogen Inorganic materials 0.000 claims description 25
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 24
- 206010021750 Infantile Spasms Diseases 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 24
- 201000006791 West syndrome Diseases 0.000 claims description 23
- 208000013257 developmental and epileptic encephalopathy Diseases 0.000 claims description 23
- 125000001424 substituent group Chemical group 0.000 claims description 23
- 206010015037 epilepsy Diseases 0.000 claims description 22
- 230000001037 epileptic effect Effects 0.000 claims description 20
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 18
- 208000008233 autosomal dominant nocturnal frontal lobe epilepsy Diseases 0.000 claims description 16
- 208000013575 epilepsy of infancy with migrating focal seizures Diseases 0.000 claims description 16
- 208000002193 Pain Diseases 0.000 claims description 15
- 206010061334 Partial seizures Diseases 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 14
- 201000008009 Early infantile epileptic encephalopathy Diseases 0.000 claims description 13
- 201000007186 focal epilepsy Diseases 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 208000035899 Infantile spasms syndrome Diseases 0.000 claims description 11
- 206010059027 Brugada syndrome Diseases 0.000 claims description 10
- 208000007101 Muscle Cramp Diseases 0.000 claims description 10
- 208000003251 Pruritus Diseases 0.000 claims description 10
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 9
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 9
- 206010071545 Early infantile epileptic encephalopathy with burst-suppression Diseases 0.000 claims description 9
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 claims description 8
- 206010003119 arrhythmia Diseases 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 208000010125 myocardial infarction Diseases 0.000 claims description 8
- 208000036546 leukodystrophy Diseases 0.000 claims description 7
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 claims description 6
- 230000000747 cardiac effect Effects 0.000 claims description 6
- 230000004064 dysfunction Effects 0.000 claims description 6
- 208000020016 psychiatric disease Diseases 0.000 claims description 6
- 201000008914 temporal lobe epilepsy Diseases 0.000 claims description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 5
- 206010003591 Ataxia Diseases 0.000 claims description 5
- 208000020925 Bipolar disease Diseases 0.000 claims description 5
- 208000000094 Chronic Pain Diseases 0.000 claims description 5
- 201000006347 Intellectual Disability Diseases 0.000 claims description 5
- 208000000209 Isaacs syndrome Diseases 0.000 claims description 5
- 208000020358 Learning disease Diseases 0.000 claims description 5
- 208000034800 Leukoencephalopathies Diseases 0.000 claims description 5
- 208000019695 Migraine disease Diseases 0.000 claims description 5
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 5
- 208000029578 Muscle disease Diseases 0.000 claims description 5
- 208000021642 Muscular disease Diseases 0.000 claims description 5
- 206010061533 Myotonia Diseases 0.000 claims description 5
- 206010072359 Neuromyotonia Diseases 0.000 claims description 5
- 208000005392 Spasm Diseases 0.000 claims description 5
- 206010043994 Tonic convulsion Diseases 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 5
- 208000005298 acute pain Diseases 0.000 claims description 5
- 230000036506 anxiety Effects 0.000 claims description 5
- 208000029560 autism spectrum disease Diseases 0.000 claims description 5
- 230000002068 genetic effect Effects 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 201000003723 learning disability Diseases 0.000 claims description 5
- 208000024714 major depressive disease Diseases 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 206010027599 migraine Diseases 0.000 claims description 5
- 208000004296 neuralgia Diseases 0.000 claims description 5
- 230000007996 neuronal plasticity Effects 0.000 claims description 5
- 208000021722 neuropathic pain Diseases 0.000 claims description 5
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- 208000018198 spasticity Diseases 0.000 claims description 5
- 201000007547 Dravet syndrome Diseases 0.000 claims description 4
- 101000631760 Homo sapiens Sodium channel protein type 1 subunit alpha Proteins 0.000 claims description 4
- 101000684826 Homo sapiens Sodium channel protein type 2 subunit alpha Proteins 0.000 claims description 4
- 101000684820 Homo sapiens Sodium channel protein type 3 subunit alpha Proteins 0.000 claims description 4
- 101000654381 Homo sapiens Sodium channel protein type 8 subunit alpha Proteins 0.000 claims description 4
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims description 4
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 claims description 4
- 102100028910 Sodium channel protein type 1 subunit alpha Human genes 0.000 claims description 4
- 102100023150 Sodium channel protein type 2 subunit alpha Human genes 0.000 claims description 4
- 102100023720 Sodium channel protein type 3 subunit alpha Human genes 0.000 claims description 4
- 102100031371 Sodium channel protein type 8 subunit alpha Human genes 0.000 claims description 4
- 208000003078 Generalized Epilepsy Diseases 0.000 claims description 3
- 201000001993 idiopathic generalized epilepsy Diseases 0.000 claims description 3
- 208000012054 malignant migrating partial seizures of infancy Diseases 0.000 claims description 3
- 208000008882 Benign Neonatal Epilepsy Diseases 0.000 claims description 2
- 208000020749 Benign familial neonatal-infantile seizures Diseases 0.000 claims description 2
- 208000024658 Epilepsy syndrome Diseases 0.000 claims description 2
- 208000002877 Epileptic Syndromes Diseases 0.000 claims description 2
- 208000002091 Febrile Seizures Diseases 0.000 claims description 2
- 108010006746 KCNQ2 Potassium Channel Proteins 0.000 claims description 2
- 208000037158 Partial Epilepsies Diseases 0.000 claims description 2
- 206010071141 Rasmussen encephalitis Diseases 0.000 claims description 2
- 208000004160 Rasmussen subacute encephalitis Diseases 0.000 claims description 2
- 208000032212 benign familial infantile 3 seizures Diseases 0.000 claims description 2
- 208000017888 childhood-onset epilepsy syndrome Diseases 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 201000002933 epilepsy with generalized tonic-clonic seizures Diseases 0.000 claims description 2
- 102000005453 KCNQ2 Potassium Channel Human genes 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 58
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 259
- 239000000243 solution Substances 0.000 description 145
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 141
- 238000003786 synthesis reaction Methods 0.000 description 132
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 131
- 239000011541 reaction mixture Substances 0.000 description 131
- 230000015572 biosynthetic process Effects 0.000 description 130
- 235000019439 ethyl acetate Nutrition 0.000 description 113
- 239000012044 organic layer Substances 0.000 description 113
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 95
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 92
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 77
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 66
- 229910052938 sodium sulfate Inorganic materials 0.000 description 64
- -1 sodium-activated potassium Chemical class 0.000 description 62
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 58
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 57
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 57
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 56
- 239000007787 solid Substances 0.000 description 56
- 239000012267 brine Substances 0.000 description 55
- 125000005842 heteroatom Chemical group 0.000 description 51
- 230000002829 reductive effect Effects 0.000 description 51
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 50
- 125000004432 carbon atom Chemical group C* 0.000 description 50
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 50
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 47
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 44
- 239000003480 eluent Substances 0.000 description 39
- 125000000623 heterocyclic group Chemical group 0.000 description 39
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 38
- 238000004128 high performance liquid chromatography Methods 0.000 description 38
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 36
- 239000007832 Na2SO4 Substances 0.000 description 36
- 239000003921 oil Substances 0.000 description 36
- 235000019198 oils Nutrition 0.000 description 36
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 35
- 125000003118 aryl group Chemical group 0.000 description 34
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 33
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 32
- 238000003818 flash chromatography Methods 0.000 description 31
- 235000019253 formic acid Nutrition 0.000 description 29
- 235000011152 sodium sulphate Nutrition 0.000 description 28
- 239000000377 silicon dioxide Substances 0.000 description 26
- 238000005160 1H NMR spectroscopy Methods 0.000 description 25
- 238000000746 purification Methods 0.000 description 24
- 125000000217 alkyl group Chemical group 0.000 description 23
- 125000001072 heteroaryl group Chemical group 0.000 description 23
- 125000004452 carbocyclyl group Chemical group 0.000 description 22
- 201000010099 disease Diseases 0.000 description 22
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 21
- 125000000304 alkynyl group Chemical group 0.000 description 21
- QVHJQCGUWFKTSE-YFKPBYRVSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)OC(C)(C)C QVHJQCGUWFKTSE-YFKPBYRVSA-N 0.000 description 20
- 239000007821 HATU Substances 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- 238000004440 column chromatography Methods 0.000 description 20
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 20
- 125000003342 alkenyl group Chemical group 0.000 description 19
- 229910052760 oxygen Inorganic materials 0.000 description 19
- 239000002904 solvent Substances 0.000 description 18
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 17
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 17
- 239000001301 oxygen Substances 0.000 description 17
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 16
- 229910000027 potassium carbonate Inorganic materials 0.000 description 16
- 229910052717 sulfur Inorganic materials 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 239000011593 sulfur Substances 0.000 description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 15
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 238000002953 preparative HPLC Methods 0.000 description 12
- 125000004122 cyclic group Chemical group 0.000 description 11
- 229940086542 triethylamine Drugs 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 10
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 10
- 125000004093 cyano group Chemical group *C#N 0.000 description 10
- 125000004404 heteroalkyl group Chemical group 0.000 description 10
- 235000019341 magnesium sulphate Nutrition 0.000 description 10
- 150000003254 radicals Chemical class 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 description 9
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 125000000753 cycloalkyl group Chemical group 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 6
- 102220035874 rs587777264 Human genes 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- AQUQLOWJSBFHBD-UHFFFAOYSA-N 2-methyl-5-(trifluoromethyl)pyrazole-3-carboxylic acid Chemical compound CN1N=C(C(F)(F)F)C=C1C(O)=O AQUQLOWJSBFHBD-UHFFFAOYSA-N 0.000 description 5
- SQNIIPKNSYEVNO-JTQLQIEISA-N C[C@@H](C1=NC(N2CCC(C)(C)CC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O Chemical compound C[C@@H](C1=NC(N2CCC(C)(C)CC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O SQNIIPKNSYEVNO-JTQLQIEISA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 102220532523 N-acetylgalactosamine-6-sulfatase_F346L_mutation Human genes 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 102000004257 Potassium Channel Human genes 0.000 description 5
- 102220415677 c.2771C>T Human genes 0.000 description 5
- 230000000155 isotopic effect Effects 0.000 description 5
- 125000006574 non-aromatic ring group Chemical group 0.000 description 5
- 108020001213 potassium channel Proteins 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102200056393 rs10455840 Human genes 0.000 description 5
- 102200098272 rs199474686 Human genes 0.000 description 5
- 102220010715 rs397515402 Human genes 0.000 description 5
- 102200012204 rs61730509 Human genes 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 4
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- FARGXEGAXPERSU-YUMQZZPRSA-N C[C@@H](C1=NC(N2C[C@@H](C)CCC2)=NO1)N Chemical compound C[C@@H](C1=NC(N2C[C@@H](C)CCC2)=NO1)N FARGXEGAXPERSU-YUMQZZPRSA-N 0.000 description 4
- CBPZDIOKJWBNPZ-IUCAKERBSA-N C[C@@H](C1=NC(N2C[C@H](C)OCC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O Chemical compound C[C@@H](C1=NC(N2C[C@H](C)OCC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O CBPZDIOKJWBNPZ-IUCAKERBSA-N 0.000 description 4
- GYYNPCHFTPLEGR-ZJUUUORDSA-N C[C@@H](C1=NC(N2[C@H](C)CCCC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O Chemical compound C[C@@H](C1=NC(N2[C@H](C)CCCC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O GYYNPCHFTPLEGR-ZJUUUORDSA-N 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 102200098271 rs199474678 Human genes 0.000 description 4
- 102220010720 rs397515406 Human genes 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- KLLKFJJEGVJMMC-LURJTMIESA-N (1S)-1-(3-pyrrolidin-1-yl-1,2,4-oxadiazol-5-yl)ethanamine Chemical compound C[C@H](N)c1nc(no1)N1CCCC1 KLLKFJJEGVJMMC-LURJTMIESA-N 0.000 description 3
- BNMLTRMGEVRHKF-QMMMGPOBSA-N (1S)-1-[3-(azepan-1-yl)-1,2,4-oxadiazol-5-yl]ethanamine Chemical compound C[C@H](N)c1nc(no1)N1CCCCCC1 BNMLTRMGEVRHKF-QMMMGPOBSA-N 0.000 description 3
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- BXEASFYXQCYZTR-SSDOTTSWSA-N (2R)-2-methylpiperidine-1-carbonitrile Chemical compound C[C@@H]1CCCCN1C#N BXEASFYXQCYZTR-SSDOTTSWSA-N 0.000 description 3
- JRDOYXRJHWDOPL-ZCFIWIBFSA-N (2R)-N'-hydroxy-2-methylpiperidine-1-carboximidamide Chemical compound C[C@@H]1CCCCN1\C(N)=N\O JRDOYXRJHWDOPL-ZCFIWIBFSA-N 0.000 description 3
- JRDOYXRJHWDOPL-LURJTMIESA-N (2S)-N'-hydroxy-2-methylpiperidine-1-carboximidamide Chemical compound C[C@H]1CCCCN1\C(N)=N\O JRDOYXRJHWDOPL-LURJTMIESA-N 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- IRBUJENWPDKMMR-SSDOTTSWSA-N (3R)-3-methylpiperidine-1-carbonitrile Chemical compound C[C@@H]1CCCN(C#N)C1 IRBUJENWPDKMMR-SSDOTTSWSA-N 0.000 description 3
- IRBUJENWPDKMMR-ZETCQYMHSA-N (3S)-3-methylpiperidine-1-carbonitrile Chemical compound C[C@H]1CCCN(C#N)C1 IRBUJENWPDKMMR-ZETCQYMHSA-N 0.000 description 3
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 3
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 3
- 125000006706 (C3-C6) carbocyclyl group Chemical group 0.000 description 3
- SGLNAYCOTOUZOA-UHFFFAOYSA-N 1,1-diethyl-2-hydroxyguanidine Chemical compound CCN(CC)C(N)=NO SGLNAYCOTOUZOA-UHFFFAOYSA-N 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 3
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 3
- MEMOERUGQGDKAL-UHFFFAOYSA-N 3,3-difluoropiperidine-1-carbonitrile Chemical compound N#CN(CCC1)CC1(F)F MEMOERUGQGDKAL-UHFFFAOYSA-N 0.000 description 3
- JAWHMMFUUZPRNI-UHFFFAOYSA-N 3-(trifluoromethyl)piperidine-1-carbonitrile Chemical compound FC(F)(F)C1CCCN(C1)C#N JAWHMMFUUZPRNI-UHFFFAOYSA-N 0.000 description 3
- RXSCEBGAFFWFJS-UHFFFAOYSA-N 3-methylpyrrolidine-1-carbonitrile Chemical compound CC1CCN(C#N)C1 RXSCEBGAFFWFJS-UHFFFAOYSA-N 0.000 description 3
- KUPICCWIGKOYDJ-UHFFFAOYSA-N 4-methylpiperidine-1-carbonitrile Chemical compound CC1CCN(C#N)CC1 KUPICCWIGKOYDJ-UHFFFAOYSA-N 0.000 description 3
- 125000006164 6-membered heteroaryl group Chemical group 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 3
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 3
- YFDFVEFYUGDYHF-VIFPVBQESA-N CC(C)CN(C)C1=NOC([C@H](C)NC(C2=CC(C(F)(F)F)=NN2C)=O)=N1 Chemical compound CC(C)CN(C)C1=NOC([C@H](C)NC(C2=CC(C(F)(F)F)=NN2C)=O)=N1 YFDFVEFYUGDYHF-VIFPVBQESA-N 0.000 description 3
- MLTMCVBJMGEHCT-QMMMGPOBSA-N CC(C)CNC1=NOC([C@H](C)NC(C2=CC(C(F)(F)F)=NN2C)=O)=N1 Chemical compound CC(C)CNC1=NOC([C@H](C)NC(C2=CC(C(F)(F)F)=NN2C)=O)=N1 MLTMCVBJMGEHCT-QMMMGPOBSA-N 0.000 description 3
- OTCPZXQYJJUOPU-QMMMGPOBSA-N CCN(CC)C1=NOC([C@H](C)NC(C2=CC(C(F)(F)F)=NN2C)=O)=N1 Chemical compound CCN(CC)C1=NOC([C@H](C)NC(C2=CC(C(F)(F)F)=NN2C)=O)=N1 OTCPZXQYJJUOPU-QMMMGPOBSA-N 0.000 description 3
- IQCCWMPYHUJLMR-VIFPVBQESA-N CCN(CC)C1=NOC([C@H](C)NC(OC(C)(C)C)=O)=N1 Chemical compound CCN(CC)C1=NOC([C@H](C)NC(OC(C)(C)C)=O)=N1 IQCCWMPYHUJLMR-VIFPVBQESA-N 0.000 description 3
- CLLRCUMESVRIRK-BYPYZUCNSA-N C[C@@H](C1=NC(Br)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O Chemical compound C[C@@H](C1=NC(Br)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O CLLRCUMESVRIRK-BYPYZUCNSA-N 0.000 description 3
- IXCOVVNTVMGXIE-VIFPVBQESA-N C[C@@H](C1=NC(N(CCC2)CC2(F)F)=NO1)NC(OC(C)(C)C)=O Chemical compound C[C@@H](C1=NC(N(CCC2)CC2(F)F)=NO1)NC(OC(C)(C)C)=O IXCOVVNTVMGXIE-VIFPVBQESA-N 0.000 description 3
- HSYRWCWUQAWJPU-IENPIDJESA-N C[C@@H](C1=NC(N(CCC2)CC2C(F)(F)F)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O Chemical compound C[C@@H](C1=NC(N(CCC2)CC2C(F)(F)F)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O HSYRWCWUQAWJPU-IENPIDJESA-N 0.000 description 3
- BSYMPARBMOYTIO-RGURZIINSA-N C[C@@H](C1=NC(N(CCC2)CC2C(F)(F)F)=NO1)NC(OC(C)(C)C)=O Chemical compound C[C@@H](C1=NC(N(CCC2)CC2C(F)(F)F)=NO1)NC(OC(C)(C)C)=O BSYMPARBMOYTIO-RGURZIINSA-N 0.000 description 3
- NVLPBHMQBJJWSZ-GKAPJAKFSA-N C[C@@H](C1=NC(N2CC(C)CC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O Chemical compound C[C@@H](C1=NC(N2CC(C)CC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O NVLPBHMQBJJWSZ-GKAPJAKFSA-N 0.000 description 3
- FNBDMBFJKHLSGU-AXDSSHIGSA-N C[C@@H](C1=NC(N2CC(C)CC2)=NO1)NC(OC(C)(C)C)=O Chemical compound C[C@@H](C1=NC(N2CC(C)CC2)=NO1)NC(OC(C)(C)C)=O FNBDMBFJKHLSGU-AXDSSHIGSA-N 0.000 description 3
- UHWRYBDSZVHOSB-QMMMGPOBSA-N C[C@@H](C1=NC(N2CC3(CC3)CCC2)=NO1)N Chemical compound C[C@@H](C1=NC(N2CC3(CC3)CCC2)=NO1)N UHWRYBDSZVHOSB-QMMMGPOBSA-N 0.000 description 3
- UJFQAHUBWMIHFM-JTQLQIEISA-N C[C@@H](C1=NC(N2CCC(C)CC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O Chemical compound C[C@@H](C1=NC(N2CCC(C)CC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O UJFQAHUBWMIHFM-JTQLQIEISA-N 0.000 description 3
- SVTGNTYEANXOBP-NSHDSACASA-N C[C@@H](C1=NC(N2CCC(C)CC2)=NO1)NC(OC(C)(C)C)=O Chemical compound C[C@@H](C1=NC(N2CCC(C)CC2)=NO1)NC(OC(C)(C)C)=O SVTGNTYEANXOBP-NSHDSACASA-N 0.000 description 3
- OYYODYFVGRHTFN-NSHDSACASA-N C[C@@H](C1=NC(N2CCCCCC2)=NO1)NC(OC(C)(C)C)=O Chemical compound C[C@@H](C1=NC(N2CCCCCC2)=NO1)NC(OC(C)(C)C)=O OYYODYFVGRHTFN-NSHDSACASA-N 0.000 description 3
- XXIJNOLHFJCMEE-YUMQZZPRSA-N C[C@@H](C1=NC(N2[C@@H](C)CCCC2)=NO1)N Chemical compound C[C@@H](C1=NC(N2[C@@H](C)CCCC2)=NO1)N XXIJNOLHFJCMEE-YUMQZZPRSA-N 0.000 description 3
- PBEXMCPRBDTOLC-QWRGUYRKSA-N C[C@@H](C1=NC(N2[C@@H](C)CCCC2)=NO1)NC(OC(C)(C)C)=O Chemical compound C[C@@H](C1=NC(N2[C@@H](C)CCCC2)=NO1)NC(OC(C)(C)C)=O PBEXMCPRBDTOLC-QWRGUYRKSA-N 0.000 description 3
- XXIJNOLHFJCMEE-SFYZADRCSA-N C[C@@H](C1=NC(N2[C@H](C)CCCC2)=NO1)N Chemical compound C[C@@H](C1=NC(N2[C@H](C)CCCC2)=NO1)N XXIJNOLHFJCMEE-SFYZADRCSA-N 0.000 description 3
- PBEXMCPRBDTOLC-MNOVXSKESA-N C[C@@H](C1=NC(N2[C@H](C)CCCC2)=NO1)NC(OC(C)(C)C)=O Chemical compound C[C@@H](C1=NC(N2[C@H](C)CCCC2)=NO1)NC(OC(C)(C)C)=O PBEXMCPRBDTOLC-MNOVXSKESA-N 0.000 description 3
- SHFVBMYCMQWCFU-JTQLQIEISA-N C[C@@H](C1=NC(NCC2=CC=CC=C2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O Chemical compound C[C@@H](C1=NC(NCC2=CC=CC=C2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O SHFVBMYCMQWCFU-JTQLQIEISA-N 0.000 description 3
- HEIXEIODPHUJDD-LURJTMIESA-N C[C@@H](CCC1)CN1/C(\N)=N\O Chemical compound C[C@@H](CCC1)CN1/C(\N)=N\O HEIXEIODPHUJDD-LURJTMIESA-N 0.000 description 3
- HEIXEIODPHUJDD-ZCFIWIBFSA-N C[C@H](CCC1)CN1/C(\N)=N\O Chemical compound C[C@H](CCC1)CN1/C(\N)=N\O HEIXEIODPHUJDD-ZCFIWIBFSA-N 0.000 description 3
- BXEASFYXQCYZTR-ZETCQYMHSA-N C[C@H]1CCCCN1C#N Chemical compound C[C@H]1CCCCN1C#N BXEASFYXQCYZTR-ZETCQYMHSA-N 0.000 description 3
- 229940126657 Compound 17 Drugs 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- QHOZKJRIYLIDRG-UHFFFAOYSA-N N'-hydroxy-3-(trifluoromethyl)piperidine-1-carboximidamide Chemical compound O/N=C(/N)N1CCCC(C(F)(F)F)C1 QHOZKJRIYLIDRG-UHFFFAOYSA-N 0.000 description 3
- WWSSZMNTLVMOND-UHFFFAOYSA-N N'-hydroxy-3-methylpyrrolidine-1-carboximidamide Chemical compound CC1CCN(C(\N)=N\O)C1 WWSSZMNTLVMOND-UHFFFAOYSA-N 0.000 description 3
- VYVZPLAZEOJQSB-UHFFFAOYSA-N N'-hydroxy-4,4-dimethylcyclohexane-1-carboximidamide Chemical compound CC1(C)CCC(C(\N)=N\O)CC1 VYVZPLAZEOJQSB-UHFFFAOYSA-N 0.000 description 3
- HOPHQDQCFNGEKR-UHFFFAOYSA-N N'-hydroxyazepane-1-carboximidamide Chemical compound O/N=C(/N)N1CCCCCC1 HOPHQDQCFNGEKR-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 101100019748 Rattus norvegicus Kcnt1 gene Proteins 0.000 description 3
- 208000023944 Sudden Unexpected Death in Epilepsy Diseases 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 125000004450 alkenylene group Chemical group 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 125000004419 alkynylene group Chemical group 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 3
- 229910052796 boron Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 229940125810 compound 20 Drugs 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- ZZTSQZQUWBFTAT-UHFFFAOYSA-N diethylcyanamide Chemical compound CCN(CC)C#N ZZTSQZQUWBFTAT-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229950007919 egtazic acid Drugs 0.000 description 3
- 229940011399 escin Drugs 0.000 description 3
- 229930186222 escin Natural products 0.000 description 3
- XWBDWHCCBGMXKG-UHFFFAOYSA-N ethanamine;hydron;chloride Chemical compound Cl.CCN XWBDWHCCBGMXKG-UHFFFAOYSA-N 0.000 description 3
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthene Chemical compound C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 3
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- GGHFDZGENJOGQE-UHFFFAOYSA-N n'-hydroxy-4-methylpiperidine-1-carboximidamide Chemical compound CC1CCN(C(=N)NO)CC1 GGHFDZGENJOGQE-UHFFFAOYSA-N 0.000 description 3
- YVUUTZVRHZMHKM-UHFFFAOYSA-N n'-hydroxypyrrolidine-1-carboximidamide Chemical compound ON=C(N)N1CCCC1 YVUUTZVRHZMHKM-UHFFFAOYSA-N 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- QJRYYOWARFCJQZ-UHFFFAOYSA-N pyrrolidine-1-carbonitrile Chemical compound N#CN1CCCC1 QJRYYOWARFCJQZ-UHFFFAOYSA-N 0.000 description 3
- 102200071739 rs121908097 Human genes 0.000 description 3
- 102220010718 rs370521183 Human genes 0.000 description 3
- 102220010717 rs397515404 Human genes 0.000 description 3
- 102220010719 rs397515405 Human genes 0.000 description 3
- 102220032726 rs63750905 Human genes 0.000 description 3
- 102220058427 rs797044544 Human genes 0.000 description 3
- 102220278951 rs876659388 Human genes 0.000 description 3
- 102220123628 rs886043455 Human genes 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000004808 supercritical fluid chromatography Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- JTUZYPGFXCCWNP-ZETCQYMHSA-N (1S)-1-(3-piperidin-1-yl-1,2,4-oxadiazol-5-yl)ethanamine Chemical compound C[C@H](N)c1nc(no1)N1CCCCC1 JTUZYPGFXCCWNP-ZETCQYMHSA-N 0.000 description 2
- QVHJQCGUWFKTSE-RXMQYKEDSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound OC(=O)[C@@H](C)NC(=O)OC(C)(C)C QVHJQCGUWFKTSE-RXMQYKEDSA-N 0.000 description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 2
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 description 2
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 2
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 2
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 2
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 2
- BAXVUWJYBUKCOI-UHFFFAOYSA-N 3,3-dimethylpiperidine-1-carbonitrile Chemical compound CC1(C)CCCN(C1)C#N BAXVUWJYBUKCOI-UHFFFAOYSA-N 0.000 description 2
- IRBUJENWPDKMMR-UHFFFAOYSA-N 3-methylpiperidine-1-carbonitrile Chemical compound CC1CCCN(C#N)C1 IRBUJENWPDKMMR-UHFFFAOYSA-N 0.000 description 2
- KTLQFULJDKYJDM-UHFFFAOYSA-N 4,4-dimethylpiperidine-1-carbonitrile Chemical compound CC1(C)CCN(CC1)C#N KTLQFULJDKYJDM-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 2
- 102220548450 CBY1-interacting BAR domain-containing protein 1_L274I_mutation Human genes 0.000 description 2
- YQTHYXFIMXSESE-QMMMGPOBSA-N C[C@@H](C1=NC(N2CC(C)(C)CCC2)=NO1)N Chemical compound C[C@@H](C1=NC(N2CC(C)(C)CCC2)=NO1)N YQTHYXFIMXSESE-QMMMGPOBSA-N 0.000 description 2
- OROLQWMUDVJBEK-NSHDSACASA-N C[C@@H](C1=NC(N2CC(C)(C)CCC2)=NO1)NC(OC(C)(C)C)=O Chemical compound C[C@@H](C1=NC(N2CC(C)(C)CCC2)=NO1)NC(OC(C)(C)C)=O OROLQWMUDVJBEK-NSHDSACASA-N 0.000 description 2
- FARGXEGAXPERSU-MQWKRIRWSA-N C[C@@H](C1=NC(N2CC(C)CCC2)=NO1)N Chemical compound C[C@@H](C1=NC(N2CC(C)CCC2)=NO1)N FARGXEGAXPERSU-MQWKRIRWSA-N 0.000 description 2
- GTYWDWDTPIGIJG-DTIOYNMSSA-N C[C@@H](C1=NC(N2CC(C)CCC2)=NO1)NC(OC(C)(C)C)=O Chemical compound C[C@@H](C1=NC(N2CC(C)CCC2)=NO1)NC(OC(C)(C)C)=O GTYWDWDTPIGIJG-DTIOYNMSSA-N 0.000 description 2
- PBAJLVFKMKSMNR-NSHDSACASA-N C[C@@H](C1=NC(N2CC3(CC3)CCC2)=NO1)NC(OC(C)(C)C)=O Chemical compound C[C@@H](C1=NC(N2CC3(CC3)CCC2)=NO1)NC(OC(C)(C)C)=O PBAJLVFKMKSMNR-NSHDSACASA-N 0.000 description 2
- OUWCRAILCCLXRE-NSHDSACASA-N C[C@@H](C1=NC(N2CCC(C)(C)CC2)=NO1)NC(OC(C)(C)C)=O Chemical compound C[C@@H](C1=NC(N2CCC(C)(C)CC2)=NO1)NC(OC(C)(C)C)=O OUWCRAILCCLXRE-NSHDSACASA-N 0.000 description 2
- LVMBTKRJLNEKIC-VIFPVBQESA-N C[C@@H](C1=NC(N2CCCC2)=NO1)NC(OC(C)(C)C)=O Chemical compound C[C@@H](C1=NC(N2CCCC2)=NO1)NC(OC(C)(C)C)=O LVMBTKRJLNEKIC-VIFPVBQESA-N 0.000 description 2
- UPYLJJHJVQFTKU-JTQLQIEISA-N C[C@@H](C1=NC(N2CCCCC2)=NO1)NC(OC(C)(C)C)=O Chemical compound C[C@@H](C1=NC(N2CCCCC2)=NO1)NC(OC(C)(C)C)=O UPYLJJHJVQFTKU-JTQLQIEISA-N 0.000 description 2
- SBNCGZUVXZOYSK-JTQLQIEISA-N C[C@@H](C1=NC(N2CCCCCC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O Chemical compound C[C@@H](C1=NC(N2CCCCCC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O SBNCGZUVXZOYSK-JTQLQIEISA-N 0.000 description 2
- GTYWDWDTPIGIJG-QWRGUYRKSA-N C[C@@H](C1=NC(N2C[C@@H](C)CCC2)=NO1)NC(OC(C)(C)C)=O Chemical compound C[C@@H](C1=NC(N2C[C@@H](C)CCC2)=NO1)NC(OC(C)(C)C)=O GTYWDWDTPIGIJG-QWRGUYRKSA-N 0.000 description 2
- GTYWDWDTPIGIJG-MNOVXSKESA-N C[C@@H](C1=NC(N2C[C@H](C)CCC2)=NO1)NC(OC(C)(C)C)=O Chemical compound C[C@@H](C1=NC(N2C[C@H](C)CCC2)=NO1)NC(OC(C)(C)C)=O GTYWDWDTPIGIJG-MNOVXSKESA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- BLANSQXEAUEFLM-UHFFFAOYSA-N N#CN1CC2(CC2)CCC1 Chemical compound N#CN1CC2(CC2)CCC1 BLANSQXEAUEFLM-UHFFFAOYSA-N 0.000 description 2
- WALBPIQORWQGBB-UHFFFAOYSA-N N'-hydroxy-3,3-dimethylpiperidine-1-carboximidamide Chemical compound CC1(C)CCCN(C(\N)=N\O)C1 WALBPIQORWQGBB-UHFFFAOYSA-N 0.000 description 2
- HEIXEIODPHUJDD-UHFFFAOYSA-N N'-hydroxy-3-methylpiperidine-1-carboximidamide Chemical compound CC1CCCN(C(\N)=N\O)C1 HEIXEIODPHUJDD-UHFFFAOYSA-N 0.000 description 2
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 2
- SJONDFZFBJUIEF-UHFFFAOYSA-N NC(N(CCC1)CC1(F)F)=NO Chemical compound NC(N(CCC1)CC1(F)F)=NO SJONDFZFBJUIEF-UHFFFAOYSA-N 0.000 description 2
- XALZPDGOIKREGX-UHFFFAOYSA-N NC(N1CC2(CC2)CCC1)=NO Chemical compound NC(N1CC2(CC2)CCC1)=NO XALZPDGOIKREGX-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 108091022021 Sodium-Activated Potassium Channels Proteins 0.000 description 2
- 102000025233 Sodium-Activated Potassium Channels Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102220617485 Transcription elongation regulator 1_H257D_mutation Human genes 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- CMIGYELBZZWTBE-UHFFFAOYSA-N azepane-1-carbonitrile Chemical compound N#CN1CCCCCC1 CMIGYELBZZWTBE-UHFFFAOYSA-N 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 102220354066 c.1887G>C Human genes 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- WDECIBYCCFPHNR-UHFFFAOYSA-N chrysene Chemical compound C1=CC=CC2=CC=C3C4=CC=CC=C4C=CC3=C21 WDECIBYCCFPHNR-UHFFFAOYSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- VPUGDVKSAQVFFS-UHFFFAOYSA-N coronene Chemical compound C1=C(C2=C34)C=CC3=CC=C(C=C3)C4=C4C3=CC=C(C=C3)C4=C2C3=C1 VPUGDVKSAQVFFS-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002001 electrophysiology Methods 0.000 description 2
- 230000007831 electrophysiology Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000001652 frontal lobe Anatomy 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- WDKQNCOJYGKYPL-UHFFFAOYSA-N n'-hydroxypiperidine-1-carboximidamide Chemical compound ON=C(N)N1CCCCC1 WDKQNCOJYGKYPL-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Chemical group 0.000 description 2
- GBROPGWFBFCKAG-UHFFFAOYSA-N picene Chemical compound C1=CC2=C3C=CC=CC3=CC=C2C2=C1C1=CC=CC=C1C=C2 GBROPGWFBFCKAG-UHFFFAOYSA-N 0.000 description 2
- NVPICXQHSYQKGM-UHFFFAOYSA-N piperidine-1-carbonitrile Chemical compound N#CN1CCCCC1 NVPICXQHSYQKGM-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 2
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 102220205318 rs1057522978 Human genes 0.000 description 2
- 102220227835 rs1064795013 Human genes 0.000 description 2
- 102220007476 rs267606804 Human genes 0.000 description 2
- 102220023107 rs387907470 Human genes 0.000 description 2
- 102220029241 rs72558451 Human genes 0.000 description 2
- 102220129525 rs745797890 Human genes 0.000 description 2
- 102200023775 rs869025610 Human genes 0.000 description 2
- 102220105794 rs879254801 Human genes 0.000 description 2
- 102200080707 rs879255597 Human genes 0.000 description 2
- 102220117782 rs886041691 Human genes 0.000 description 2
- 229910052710 silicon Chemical group 0.000 description 2
- 239000010703 silicon Chemical group 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- QYYZXEPEVBXNNA-QGZVFWFLSA-N (1R)-2-acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-methylsulfonyl-1,3-dihydroisoindole-1-carboxamide Chemical compound C(C)(=O)N1[C@H](C2=CC=C(C=C2C1)S(=O)(=O)C)C(=O)NC1=CC=C(C=C1)C(C(F)(F)F)(C(F)(F)F)O QYYZXEPEVBXNNA-QGZVFWFLSA-N 0.000 description 1
- LBQPLVGMOIUZPL-ZCFIWIBFSA-N (2R)-2-methylmorpholine-4-carbonitrile Chemical compound C[C@@H]1CN(CCO1)C#N LBQPLVGMOIUZPL-ZCFIWIBFSA-N 0.000 description 1
- WJGQCCPNVRCAQI-DFWYDOINSA-N (2s)-2-aminopropanenitrile;hydrochloride Chemical compound Cl.C[C@H](N)C#N WJGQCCPNVRCAQI-DFWYDOINSA-N 0.000 description 1
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 description 1
- 125000006649 (C2-C20) alkynyl group Chemical group 0.000 description 1
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 description 1
- 125000006593 (C2-C3) alkynyl group Chemical group 0.000 description 1
- 125000006564 (C4-C8) cycloalkyl group Chemical group 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- HXSKIYNGAFSEDZ-UHFFFAOYSA-N 1-benzyl-2-hydroxy-1-methylguanidine Chemical compound ON=C(N)N(C)CC1=CC=CC=C1 HXSKIYNGAFSEDZ-UHFFFAOYSA-N 0.000 description 1
- IZMFTNDTIFWYCE-UHFFFAOYSA-N 1-hydroxy-2-(2-methylpropyl)guanidine Chemical compound CC(C)CN=C(N)NO IZMFTNDTIFWYCE-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- PKDPUENCROCRCH-UHFFFAOYSA-N 1-piperazin-1-ylethanone Chemical compound CC(=O)N1CCNCC1 PKDPUENCROCRCH-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- AUVALWUPUHHNQV-UHFFFAOYSA-N 2-hydroxy-3-propylbenzoic acid Chemical class CCCC1=CC=CC(C(O)=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-N 0.000 description 1
- OMGNVIJEQKWIHI-UHFFFAOYSA-N 2-methylpropylcyanamide Chemical compound CC(C)CNC#N OMGNVIJEQKWIHI-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- BXFKQBZPFQBCCO-UHFFFAOYSA-N 3,3-dimethylpiperidine;hydrochloride Chemical compound Cl.CC1(C)CCCNC1 BXFKQBZPFQBCCO-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- JEGMWWXJUXDNJN-UHFFFAOYSA-N 3-methylpiperidine Chemical compound CC1CCCNC1 JEGMWWXJUXDNJN-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- JYIZOTRGDKSBSR-VIFPVBQESA-N CC(C)CNC1=NOC([C@H](C)NC(OC(C)(C)C)=O)=N1 Chemical compound CC(C)CNC1=NOC([C@H](C)NC(OC(C)(C)C)=O)=N1 JYIZOTRGDKSBSR-VIFPVBQESA-N 0.000 description 1
- BENNPUQUXMRYNX-UHFFFAOYSA-N CC(C1=NC(N(CC2)CCN2C(C)=O)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O Chemical compound CC(C1=NC(N(CC2)CCN2C(C)=O)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O BENNPUQUXMRYNX-UHFFFAOYSA-N 0.000 description 1
- OLIOLJRHAZOFIH-UHFFFAOYSA-N CC(C1=NC(N2CCN(C)CC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O Chemical compound CC(C1=NC(N2CCN(C)CC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O OLIOLJRHAZOFIH-UHFFFAOYSA-N 0.000 description 1
- VBAPOEYPNPTIPL-YFKPBYRVSA-N C[C@@H](C#N)NC(C1=CC(C(F)(F)F)=NN1C)=O Chemical compound C[C@@H](C#N)NC(C1=CC(C(F)(F)F)=NN1C)=O VBAPOEYPNPTIPL-YFKPBYRVSA-N 0.000 description 1
- DQEDBGINHJNCSK-NSHDSACASA-N C[C@@H](C1=NC(N(C)CC2=CC=CC=C2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O Chemical compound C[C@@H](C1=NC(N(C)CC2=CC=CC=C2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O DQEDBGINHJNCSK-NSHDSACASA-N 0.000 description 1
- USNBJIVAQWTNBX-LBPRGKRZSA-N C[C@@H](C1=NC(N(C)CC2=CC=CC=C2)=NO1)NC(OC(C)(C)C)=O Chemical compound C[C@@H](C1=NC(N(C)CC2=CC=CC=C2)=NO1)NC(OC(C)(C)C)=O USNBJIVAQWTNBX-LBPRGKRZSA-N 0.000 description 1
- ZGVIYJOVEWWSBV-QMMMGPOBSA-N C[C@@H](C1=NC(N(CCC2)CC2(F)F)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O Chemical compound C[C@@H](C1=NC(N(CCC2)CC2(F)F)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O ZGVIYJOVEWWSBV-QMMMGPOBSA-N 0.000 description 1
- SNIVZWBNDWGFKX-JTQLQIEISA-N C[C@@H](C1=NC(N2CC(C)(C)CCC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O Chemical compound C[C@@H](C1=NC(N2CC(C)(C)CCC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O SNIVZWBNDWGFKX-JTQLQIEISA-N 0.000 description 1
- ZSPLXGGNRMDTKF-AXDSSHIGSA-N C[C@@H](C1=NC(N2CC(C)CCC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O Chemical compound C[C@@H](C1=NC(N2CC(C)CCC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O ZSPLXGGNRMDTKF-AXDSSHIGSA-N 0.000 description 1
- WJNBOBIMSSYNID-JTQLQIEISA-N C[C@@H](C1=NC(N2CC3(CC3)CCC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O Chemical compound C[C@@H](C1=NC(N2CC3(CC3)CCC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O WJNBOBIMSSYNID-JTQLQIEISA-N 0.000 description 1
- ABUOPZNUSXXFKB-QMMMGPOBSA-N C[C@@H](C1=NC(N2CCCC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O Chemical compound C[C@@H](C1=NC(N2CCCC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O ABUOPZNUSXXFKB-QMMMGPOBSA-N 0.000 description 1
- DTOBFHUJZPRXRD-VIFPVBQESA-N C[C@@H](C1=NC(N2CCCCC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O Chemical compound C[C@@H](C1=NC(N2CCCCC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O DTOBFHUJZPRXRD-VIFPVBQESA-N 0.000 description 1
- ZSPLXGGNRMDTKF-UWVGGRQHSA-N C[C@@H](C1=NC(N2C[C@@H](C)CCC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O Chemical compound C[C@@H](C1=NC(N2C[C@@H](C)CCC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O ZSPLXGGNRMDTKF-UWVGGRQHSA-N 0.000 description 1
- FARGXEGAXPERSU-SFYZADRCSA-N C[C@@H](C1=NC(N2C[C@H](C)CCC2)=NO1)N Chemical compound C[C@@H](C1=NC(N2C[C@H](C)CCC2)=NO1)N FARGXEGAXPERSU-SFYZADRCSA-N 0.000 description 1
- ZSPLXGGNRMDTKF-ZJUUUORDSA-N C[C@@H](C1=NC(N2C[C@H](C)CCC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O Chemical compound C[C@@H](C1=NC(N2C[C@H](C)CCC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O ZSPLXGGNRMDTKF-ZJUUUORDSA-N 0.000 description 1
- WXVBUAJRISYQBR-UWVGGRQHSA-N C[C@@H](C1=NC(N2C[C@H](C)OCC2)=NO1)NC(OC(C)(C)C)=O Chemical compound C[C@@H](C1=NC(N2C[C@H](C)OCC2)=NO1)NC(OC(C)(C)C)=O WXVBUAJRISYQBR-UWVGGRQHSA-N 0.000 description 1
- GYYNPCHFTPLEGR-UWVGGRQHSA-N C[C@@H](C1=NC(N2[C@@H](C)CCCC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O Chemical compound C[C@@H](C1=NC(N2[C@@H](C)CCCC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O GYYNPCHFTPLEGR-UWVGGRQHSA-N 0.000 description 1
- ZSPLXGGNRMDTKF-VHSXEESVSA-N C[C@H](C1=NC(N2C[C@@H](C)CCC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O Chemical compound C[C@H](C1=NC(N2C[C@@H](C)CCC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O ZSPLXGGNRMDTKF-VHSXEESVSA-N 0.000 description 1
- GTYWDWDTPIGIJG-WDEREUQCSA-N C[C@H](C1=NC(N2C[C@@H](C)CCC2)=NO1)NC(OC(C)(C)C)=O Chemical compound C[C@H](C1=NC(N2C[C@@H](C)CCC2)=NO1)NC(OC(C)(C)C)=O GTYWDWDTPIGIJG-WDEREUQCSA-N 0.000 description 1
- ZSPLXGGNRMDTKF-NXEZZACHSA-N C[C@H](C1=NC(N2C[C@H](C)CCC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O Chemical compound C[C@H](C1=NC(N2C[C@H](C)CCC2)=NO1)NC(C1=CC(C(F)(F)F)=NN1C)=O ZSPLXGGNRMDTKF-NXEZZACHSA-N 0.000 description 1
- GTYWDWDTPIGIJG-GHMZBOCLSA-N C[C@H](C1=NC(N2C[C@H](C)CCC2)=NO1)NC(OC(C)(C)C)=O Chemical compound C[C@H](C1=NC(N2C[C@H](C)CCC2)=NO1)NC(OC(C)(C)C)=O GTYWDWDTPIGIJG-GHMZBOCLSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000034308 Grand mal convulsion Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- OWIKHYCFFJSOEH-UHFFFAOYSA-N Isocyanic acid Chemical compound N=C=O OWIKHYCFFJSOEH-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- ZXOUSDJKIOOJBF-UHFFFAOYSA-N N'-hydroxy-2-methylmorpholine-4-carboximidamide Chemical compound CC1CN(C(\N)=N\O)CCO1 ZXOUSDJKIOOJBF-UHFFFAOYSA-N 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100034354 Potassium voltage-gated channel subfamily KQT member 2 Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- SLGBZMMZGDRARJ-UHFFFAOYSA-N Triphenylene Natural products C1=CC=C2C3=CC=CC=C3C3=CC=CC=C3C2=C1 SLGBZMMZGDRARJ-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- QVXFGVVYTKZLJN-KHPPLWFESA-N [(z)-hexadec-7-enyl] acetate Chemical compound CCCCCCCC\C=C/CCCCCCOC(C)=O QVXFGVVYTKZLJN-KHPPLWFESA-N 0.000 description 1
- WXIONIWNXBAHRU-UHFFFAOYSA-N [dimethylamino(triazolo[4,5-b]pyridin-3-yloxy)methylidene]-dimethylazanium Chemical compound C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 WXIONIWNXBAHRU-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- JDPAVWAQGBGGHD-UHFFFAOYSA-N aceanthrylene Chemical group C1=CC=C2C(C=CC3=CC=C4)=C3C4=CC2=C1 JDPAVWAQGBGGHD-UHFFFAOYSA-N 0.000 description 1
- 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- SQFPKRNUGBRTAR-UHFFFAOYSA-N acephenanthrylene Chemical group C1=CC(C=C2)=C3C2=CC2=CC=CC=C2C3=C1 SQFPKRNUGBRTAR-UHFFFAOYSA-N 0.000 description 1
- HXGDTGSAIMULJN-UHFFFAOYSA-N acetnaphthylene Natural products C1=CC(C=C2)=C3C2=CC=CC3=C1 HXGDTGSAIMULJN-UHFFFAOYSA-N 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- KNNXFYIMEYKHBZ-UHFFFAOYSA-N as-indacene Chemical compound C1=CC2=CC=CC2=C2C=CC=C21 KNNXFYIMEYKHBZ-UHFFFAOYSA-N 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- MEPJLBXTZZGXOV-UHFFFAOYSA-N azidocarbamic acid Chemical compound OC(=O)NN=[N+]=[N-] MEPJLBXTZZGXOV-UHFFFAOYSA-N 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- WXUFJHLDRGSBEC-UHFFFAOYSA-N benzyl(methyl)cyanamide Chemical compound N#CN(C)CC1=CC=CC=C1 WXUFJHLDRGSBEC-UHFFFAOYSA-N 0.000 description 1
- QIRSDXBXWUTMRE-UHFFFAOYSA-N benzylcyanamide Chemical compound N#CNCC1=CC=CC=C1 QIRSDXBXWUTMRE-UHFFFAOYSA-N 0.000 description 1
- UIEATEWHFDRYRU-UHFFFAOYSA-N bepridil Chemical compound C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UIEATEWHFDRYRU-UHFFFAOYSA-N 0.000 description 1
- 229960003665 bepridil Drugs 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102220357690 c.2896G>A Human genes 0.000 description 1
- 102220367514 c.625C>T Human genes 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 150000001930 cyclobutanes Chemical class 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 150000001934 cyclohexanes Chemical group 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004090 cyclononenyl group Chemical group C1(=CCCCCCCC1)* 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 150000001940 cyclopentanes Chemical class 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 150000001942 cyclopropanes Chemical class 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 125000005508 decahydronaphthalenyl group Chemical group 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 201000009028 early myoclonic encephalopathy Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- QSQIGGCOCHABAP-UHFFFAOYSA-N hexacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC6=CC=CC=C6C=C5C=C4C=C3C=C21 QSQIGGCOCHABAP-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- PKIFBGYEEVFWTJ-UHFFFAOYSA-N hexaphene Chemical compound C1=CC=C2C=C3C4=CC5=CC6=CC=CC=C6C=C5C=C4C=CC3=CC2=C1 PKIFBGYEEVFWTJ-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 201000001451 hypomyelinating leukodystrophy Diseases 0.000 description 1
- 201000003473 hypomyelinating leukoencephalopathy Diseases 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003933 intellectual function Effects 0.000 description 1
- 230000002109 interictal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000001115 mace Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- QKYWADPCTHTJHQ-UHFFFAOYSA-N n,2-dimethylpropan-1-amine Chemical compound CNCC(C)C QKYWADPCTHTJHQ-UHFFFAOYSA-N 0.000 description 1
- AWBKQZSYNWLCMW-UHFFFAOYSA-N n-(dibromomethylidene)hydroxylamine Chemical compound ON=C(Br)Br AWBKQZSYNWLCMW-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- PFTXKXWAXWAZBP-UHFFFAOYSA-N octacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC6=CC7=CC8=CC=CC=C8C=C7C=C6C=C5C=C4C=C3C=C21 PFTXKXWAXWAZBP-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OVPVGJFDFSJUIG-UHFFFAOYSA-N octalene Chemical compound C1=CC=CC=C2C=CC=CC=CC2=C1 OVPVGJFDFSJUIG-UHFFFAOYSA-N 0.000 description 1
- WTFQBTLMPISHTA-UHFFFAOYSA-N octaphene Chemical compound C1=CC=C2C=C(C=C3C4=CC5=CC6=CC7=CC=CC=C7C=C6C=C5C=C4C=CC3=C3)C3=CC2=C1 WTFQBTLMPISHTA-UHFFFAOYSA-N 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- LSQODMMMSXHVCN-UHFFFAOYSA-N ovalene Chemical compound C1=C(C2=C34)C=CC3=CC=C(C=C3C5=C6C(C=C3)=CC=C3C6=C6C(C=C3)=C3)C4=C5C6=C2C3=C1 LSQODMMMSXHVCN-UHFFFAOYSA-N 0.000 description 1
- 125000005882 oxadiazolinyl group Chemical group 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000003585 oxepinyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000012402 patch clamp technique Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- PMJHHCWVYXUKFD-UHFFFAOYSA-N penta-1,3-diene Chemical compound CC=CC=C PMJHHCWVYXUKFD-UHFFFAOYSA-N 0.000 description 1
- SLIUAWYAILUBJU-UHFFFAOYSA-N pentacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC=CC=C5C=C4C=C3C=C21 SLIUAWYAILUBJU-UHFFFAOYSA-N 0.000 description 1
- GUVXZFRDPCKWEM-UHFFFAOYSA-N pentalene Chemical compound C1=CC2=CC=CC2=C1 GUVXZFRDPCKWEM-UHFFFAOYSA-N 0.000 description 1
- JQQSUOJIMKJQHS-UHFFFAOYSA-N pentaphene Chemical compound C1=CC=C2C=C3C4=CC5=CC=CC=C5C=C4C=CC3=CC2=C1 JQQSUOJIMKJQHS-UHFFFAOYSA-N 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 125000002080 perylenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC5=CC=CC(C1=C23)=C45)* 0.000 description 1
- CSHWQDPOILHKBI-UHFFFAOYSA-N peryrene Natural products C1=CC(C2=CC=CC=3C2=C2C=CC=3)=C3C2=CC=CC3=C1 CSHWQDPOILHKBI-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- NQFOGDIWKQWFMN-UHFFFAOYSA-N phenalene Chemical compound C1=CC([CH]C=C2)=C3C2=CC=CC3=C1 NQFOGDIWKQWFMN-UHFFFAOYSA-N 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- DIJNSQQKNIVDPV-UHFFFAOYSA-N pleiadene Chemical compound C1=C2[CH]C=CC=C2C=C2C=CC=C3[C]2C1=CC=C3 DIJNSQQKNIVDPV-UHFFFAOYSA-N 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- LNKHTYQPVMAJSF-UHFFFAOYSA-N pyranthrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC3=C(C=CC=C4)C4=CC4=CC=C1C2=C34 LNKHTYQPVMAJSF-UHFFFAOYSA-N 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 102200113618 rs1800456 Human genes 0.000 description 1
- 102200121329 rs183885357 Human genes 0.000 description 1
- 102220010716 rs397515403 Human genes 0.000 description 1
- 102220117751 rs561255614 Human genes 0.000 description 1
- 102220302788 rs769855266 Human genes 0.000 description 1
- 102220028490 rs886044717 Human genes 0.000 description 1
- FMKFBRKHHLWKDB-UHFFFAOYSA-N rubicene Chemical compound C12=CC=CC=C2C2=CC=CC3=C2C1=C1C=CC=C2C4=CC=CC=C4C3=C21 FMKFBRKHHLWKDB-UHFFFAOYSA-N 0.000 description 1
- WEMQMWWWCBYPOV-UHFFFAOYSA-N s-indacene Chemical compound C=1C2=CC=CC2=CC2=CC=CC2=1 WEMQMWWWCBYPOV-UHFFFAOYSA-N 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RPKPFOKNXKRFTD-LURJTMIESA-N tert-butyl n-[(1s)-1-cyanoethyl]carbamate Chemical compound N#C[C@H](C)NC(=O)OC(C)(C)C RPKPFOKNXKRFTD-LURJTMIESA-N 0.000 description 1
- GZKKSKKIABUUCX-YFKPBYRVSA-N tert-butyl n-[(2s)-1-amino-1-oxopropan-2-yl]carbamate Chemical compound NC(=O)[C@H](C)NC(=O)OC(C)(C)C GZKKSKKIABUUCX-YFKPBYRVSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 125000005305 thiadiazolinyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005458 thianyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 125000003777 thiepinyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000005881 triazolinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000005580 triphenylene group Chemical group 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000007482 whole exome sequencing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Definitions
- KCNT1 INHIBITORS AND METHODS OF USE CROSS-REFERENCE TO RELATED APPLICATION [001] This application claims the benefit of, and relies on the filing date of, U.S. provisional patent application number 63/181,498, filed 29 April 2021, the entire disclosure of which is incorporated herein by reference. FIELD OF THE DISCLOSURE [002] The present disclosure is generally directed to KCNT1 inhibitors comprising an oxadiazole core, as well as pharmaceutical compositions and methods of treatment involving the use of such compounds.
- Potassium sodium-activated channel subfamily T member 1 (“KCNT1”) is one of the genes in a family of genes responsible for providing the instructions to make potassium channels.
- KCNT1 encodes sodium-activated potassium channels known as Slack (Sequence like a calcium-activated K + channel). These channels are found in neurons throughout the brain and can mediate a sodium-activated potassium current I KNa . This delayed outward current can regulate neuronal excitability and the rate of adaption in response to maintained stimulation.
- Abnormal Slack activity has been associated with development of early onset epilepsies and intellectual impairment.
- pharmaceutical compounds that selectively regulate sodium-activated potassium channels are useful in treating a neurological disease or disorder or a disease or condition related to excessive neuronal excitability and/or KCNT1 gain-of-function mutations.
- a disease, disorder, or condition e.g., a neurological disorder, a disorder associated with excessive neuronal excitability, or disorder associated with a gain-of-function mutation in a gene, for example, KCNT1.
- the present disclosure features a compound of Formula I having an oxadiazole core: or a pharmaceutically acceptable salt thereof, wherein R 1 is chosen from a C 1-6 alkyl, a C 1-6 haloalkyl, or a C 3-1 0cycloalkyl, wherein the C 1-6 alkyl, C 1-6 haloalkyl, and C 3-10 cycloalkyl optionally comprises a C 1-6 alkoxy or N(R 8 ) 2 substituent; R 2 is chosen from hydrogen or a C 1-4 alkyl; R3 is chosen from a C 1-6 alkyl optionally comprising a C 1-6 alkoxy substituent; R4 is chosen from hydrogen or a C 1-6 alkyl; R 5 is chosen from a C 1-6 alkyl or a C 1-6 haloalkyl; R 6 is chosen from hydrogen, a C 1-6 alkyl, a C 3-10 cycloalkyl, a phenyl, or a
- the compound of Formula I is a compound of Formula I-a: or a pharmaceutically acceptable salt thereof.
- the compound of Formula I is a compound of Formula I-b: or a pharmaceutically acceptable salt thereof.
- the compound of Formula I is a compound of Formula I-c: or a pharmaceutically acceptable salt thereof.
- the compound of Formula I is a compound of Formula I-d or Formula I-e: or a pharmaceutically acceptable salt thereof.
- R 3 is C 1-6 alkyl and R 4 is hydrogen, and in certain embodiments, R 2 is hydrogen.
- R 1 is C 1-6 alkyl, and in certain embodiments, R 1 is methyl.
- x is 1 or 2, such as 1, and in certain embodiments, R 5 is C 1-6 haloalkyl, such as -CF 3 .
- R 6 is hydrogen and R 7 is C 1- 6 alkyl, and in certain aspects, R 6 and R 7 are each C 1-6 alkyl optionally comprising a phenyl substituent.
- R 6 and R 7 are taken together with the nitrogen attached to R 6 and R 7 to form a 3-10 membered heterocyclyl ring optionally comprising one or more substituents chosen from a halogen, a C 1-6 alkyl, or a C 1-6 haloalkyl.
- a compound of the Formula (I) is chosen from:
- the present disclosure provides a method of treating neurological disorder, wherein the method comprises administering to a subject in need thereof a compound disclosed herein (e.g., compound of Formula (I), (e.g., (I-a), (I-b), (I-c), (I-d), or (I-e))) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition disclosed herein (e.g., a pharmaceutical composition comprising a compound of Formula (I), (e.g., (I-a), (I-b), (I-c), (I-d), or (I-e)), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient).
- a pharmaceutical composition comprising a compound of Formula (I), (e.g., (I-a), (I-b), (I-c), (I-d), or (I-e)
- a pharmaceutically acceptable salt thereof e.g., a pharmaceutical composition comprising a compound of Formula (I), (e.g., (I-a
- the present disclosure provides a method of treating a disorder associated with excessive neuronal excitability, wherein the method comprises administering to a subject in need thereof a compound disclosed herein (e.g., compound of Formula (I), (e.g., (I-a), (I-b), (I-c), (I-d), or (I-e))) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition disclosed herein (e.g., a pharmaceutical composition comprising a compound of Formula (I), (e.g., (I-a), (I-b), (I-c), (I-d), or (I-e)), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient).
- a pharmaceutical composition comprising a compound of Formula (I), (e.g., (I-a), (I-b), (I-c), (I-d), or (I-e)
- a pharmaceutically acceptable salt thereof e.g., a pharmaceutical composition comprising a compound of Formula (I), (
- the present disclosure provides a method of treating a disorder associated with a gain-of-function mutation of a gene (e.g., KCNT1), wherein the method comprises administering to a subject in need thereof a compound disclosed herein (e.g., a compound of Formula (I), (e.g., (I-a), (I-b), (I-c), (I-d), or (I-e))) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition disclosed herein (e.g., a pharmaceutical composition comprising a compound of Formula (I), (e.g., (I-a), (I-b), (I-c), (I-d), or (I-e)), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient).
- a compound disclosed herein e.g., a compound of Formula (I), (e.g., (I-a), (I-b), (I-c), (I-d), or (I-e)
- a pharmaceutical composition compris
- the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation of a gene is epilepsy, an epilepsy syndrome, or an encephalopathy.
- the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation of a gene is a genetic or pediatric epilepsy or a genetic or pediatric epilepsy syndrome.
- the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation of a gene is a cardiac dysfunction.
- the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation of a gene is selected from epilepsy and other encephalopathies (e.g., malignant migrating focal seizures of infancy (MMFSI) or epilepsy of infancy with migrating focal seizures (EIMFS), autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), West syndrome, infantile spasms, epileptic encephalopathy, focal epilepsy, Ohtahara syndrome, developmental and epileptic encephalopathy, Lennox-Gastaut syndrome, seizures (e.g., Generalized tonic clonic seizures, Asymmetric Tonic Se
- MMFSI malignant migrating focal seizures of infancy
- EIMFS epilepsy of infancy with migrating focal seizures
- the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation of a gene is chosen from cardiac arrhythmia, Brugada syndrome, and myocardial infarction.
- the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation of a gene is selected from pain and related conditions (e.g., neuropathic pain, acute/chronic pain, migraine, etc.).
- the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation of a gene is a muscle disorder (e.g., myotonia, neuromyotonia, cramp muscle spasms, spasticity).
- the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation of a gene is selected from itch and pruritis, ataxia or cerebellar ataxias.
- the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation of a gene is selected from psychiatric disorders (e.g., major depression, anxiety, bipolar disorder, schizophrenia).
- psychiatric disorders e.g., major depression, anxiety, bipolar disorder, schizophrenia.
- the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation in a gene is chosen from a learning disorder, Fragile X, neuronal plasticity, or an autism spectrum disorder.
- the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation of a gene is chosen from epileptic encephalopathy with SCN1A, SCN2A, and/or SCN8A mutations, early infantile epileptic encephalopathy, Dravet syndrome, Dravet syndrome with SCN1A mutation, generalized epilepsy with febrile seizures, intractable childhood epilepsy with generalized tonic-clonic seizures, infantile spasms, benign familial neonatal-infantile seizures, SCN2A epileptic encephalopathy, focal epilepsy with SCN3A mutation, cryptogenic pediatric partial epilepsy with SCN3A mutation, SCN8A epileptic encephalopathy, Rasmussen encephalitis, malignant migrating partial seizures of infancy, autosomal dominant nocturnal frontal lobe epilepsy, KCNQ2 epileptic encephal
- Exemplary diseases, disorders, or conditions include epilepsy and other encephalopathies (e.g., MMFSI or EIMFS, ADNFLE, West syndrome, infantile spasms, epileptic encephalopathy, focal epilepsy, Ohtahara syndrome, developmental and epileptic encephalopathy, Lennox-Gastaut syndrome, seizures, leukodystrophy, leukoencephalopathy, Intellectual disability, Multifocal Epilepsy, Generalized tonic clonic seizures, Drug resistant epilepsy, Temporal lobe epilepsy, cerebellar ataxia, Asymmetric Tonic Seizures), cardiac dysfunctions (e.g., cardiac arrhythmia, Brugada syndrome, sudden unexpected death in epilepsy, myocardial infarction), pain and related conditions (e.g., neuropathic pain, acute/chronic pain, migraine, etc.), muscle disorders (e.g., myotonia, neuromyotonia, cramp muscle spasms, spasticity), itch and pruriti
- the compounds described herein can be in the form of an individual enantiomer, diastereomer or geometric isomer, or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer.
- Isomers can be isolated from mixtures by methods described in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric syntheses.
- a pure enantiomeric compound is substantially free from other enantiomers or stereoisomers of the compound (i.e., in enantiomeric excess).
- an “S” form of the compound is substantially free from the “R” form of the compound and is, thus, in enantiomeric excess of the “R” form.
- enantiomerically pure or “pure enantiomer” denotes that the compound comprises more than 75% by weight, more than 80% by weight, more than 85% by weight, more than 90% by weight, more than 91% by weight, more than 92% by weight, more than 93% by weight, more than 94% by weight, more than 95% by weight, more than 96% by weight, more than 97% by weight, more than 98% by weight, more than 98.5% by weight, more than 99% by weight, more than 99.2% by weight, more than 99.5% by weight, more than 99.6% by weight, more than 99.7% by weight, more than 99.8% by weight or more than 99.9% by weight, of the enantiomer.
- the weights are based upon total weight of all enantiomers or stereoisomers of the compound.
- an enantiomerically pure compound can be present with other active or inactive ingredients.
- a pharmaceutical composition comprising enantiomerically pure R–compound can comprise, for example, about 90% excipient and about 10% enantiomerically pure R–compound.
- the enantiomerically pure R–compound in such compositions can, for example, comprise, at least about 95% by weight R–compound and at most about 5% by weight S–compound, by total weight of the compound.
- a pharmaceutical composition comprising enantiomerically pure S–compound can comprise, for example, about 90% excipient and about 10% enantiomerically pure S–compound.
- the enantiomerically pure S–compound in such compositions can, for example, comprise, at least about 95% by weight S–compound and at most about 5% by weight R–compound, by total weight of the compound.
- the active ingredient can be formulated with little or no excipient or carrier.
- Compound described herein may also comprise one or more isotopic substitutions.
- H may be in any isotopic form, including 1 H, 2 H (D or deuterium), and 3 H (T or tritium); C may be in any isotopic form, including 12 C, 13 C, and 14 C; O may be in any isotopic form, including 16 O and 18 O; F may be in any isotopic form, including 18 F and 19 F; and the like.
- the following terms are intended to have the meanings presented therewith below and are useful in understanding the description and intended scope of the present disclosure.
- pharmaceutical compositions containing such compounds and methods of using such compounds and compositions the following terms, if present, have the following meanings unless otherwise indicated.
- C 1 –6 alkyl is intended to encompass, C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 1–6 , C 1–5 , C 1–4 , C 1–3 , C 1–2 , C 2–6 , C 2–5 , C 2–4 , C 2–3 , C 3–6 , C 3–5 , C 3–4 , C 4–6 , C 4–5 , and C 5–6 alkyl.
- alkyl refers to a radical of a straight–chain or branched saturated hydrocarbon group, e.g., having 1 to 20 carbon atoms (“C 1–20 alkyl”). In some embodiments, an alkyl group has 1 to 10 carbon atoms (“C 1–10 alkyl”). In some embodiments, an alkyl group has 1 to 9 carbon atoms (“C 1–9 alkyl”). In some embodiments, an alkyl group has 1 to 8 carbon atoms (“C 1–8 alkyl”). In some embodiments, an alkyl group has 1 to 7 carbon atoms (“C 1–7 alkyl”).
- an alkyl group has 1 to 6 carbon atoms (“C 1–6 alkyl”). In some embodiments, an alkyl group has 1 to 5 carbon atoms (“C 1–5 alkyl”). In some embodiments, an alkyl group has 1 to 4 carbon atoms (“C 1–4 alkyl”). In some embodiments, an alkyl group has 1 to 3 carbon atoms (“C 1–3 alkyl”). In some embodiments, an alkyl group has 1 to 2 carbon atoms (“C 1-2 alkyl”). In some embodiments, an alkyl group has 1 carbon atom (“C 1 alkyl”).
- C 1–6 alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, hexyl, and the like.
- heteroalkyl refers to an “alkyl” group in which at least one carbon atom has been replaced with an O or S atom.
- the heteroalkyl may be, for example, an –O-C 1 -C 10 alkyl group, an -C 1 -C 6 alkylene-O-C 1 -C 6 alkyl group, or a C 1 -C 6 alkylene-OH group.
- the “heteroalkyl” may be 2-8 membered heteroalkyl, indicating that the heteroalkyl contains from 2 to 8 atoms selected from the group consisting of carbon, oxygen, nitrogen, and sulfur.
- the heteroalkyl may be a 2-6 membered, 4-8 membered, or a 5-8 membered heteroalkyl group (which may contain for example 1 or 2 heteroatoms selected from the group oxygen and nitrogen).
- the heteroalkyl is an “alkyl” group in which 1-3 carbon atoms have been replaced with oxygen atoms.
- One type of heteroalkyl group is an “alkoxy” group.
- alkenyl refers to a radical of a straight–chain or branched hydrocarbon group having from 2 to 20 carbon atoms, one or more carbon–carbon double bonds (e.g., 1, 2, 3, or 4 carbon–carbon double bonds), and optionally one or more carbon–carbon triple bonds (e.g., 1, 2, 3, or 4 carbon–carbon triple bonds) (“C 1–20 alkenyl”). In certain embodiments, alkenyl does not contain any triple bonds. In some embodiments, an alkenyl group has 2 to 10 carbon atoms (“C 1–10 alkenyl”). In some embodiments, an alkenyl group has 2 to 9 carbon atoms (“C 2–9 alkenyl”).
- an alkenyl group has 2 to 8 carbon atoms (“C 2–8 alkenyl”). In some embodiments, an alkenyl group has 2 to 7 carbon atoms (“C 2–7 alkenyl”). In some embodiments, an alkenyl group has 2 to 6 carbon atoms (“C 2–6 alkenyl”). In some embodiments, an alkenyl group has 2 to 5 carbon atoms (“C 2–5 alkenyl”). In some embodiments, an alkenyl group has 2 to 4 carbon atoms (“C 2–4 alkenyl”). In some embodiments, an alkenyl group has 2 to 3 carbon atoms (“C 2–3 alkenyl”).
- an alkenyl group has 2 carbon atoms (“C 2 alkenyl).
- the one or more carbon–carbon double bonds can be internal (such as in 2– butenyl) or terminal (such as in 1–butenyl).
- Examples of C 2–4 alkenyl groups include ethenyl (C 2 ), 1–propenyl (C 3 ), 2–propenyl (C 3 ), 1–butenyl (C 4 ), 2–butenyl (C 4 ), butadienyl (C 4 ), and the like.
- C 2–6 alkenyl groups include the aforementioned C 2–4 alkenyl groups as well as pentenyl (C 5 ), pentadienyl (C 5 ), hexenyl (C 6 ), and the like. Additional examples of alkenyl include heptenyl (C 7 ), octenyl (C 8 ), octatrienyl (C 8 ), and the like.
- alkynyl refers to a radical of a straight–chain or branched hydrocarbon group having from 2 to 20 carbon atoms, one or more carbon–carbon triple bonds (e.g., 1, 2, 3, or 4 carbon–carbon triple bonds), and optionally one or more carbon–carbon double bonds (e.g., 1, 2, 3, or 4 carbon–carbon double bonds) (“C 2–20 alkynyl”). In certain embodiments, alkynyl does not contain any double bonds. In some embodiments, an alkynyl group has 2 to 10 carbon atoms (“C 2–10 alkynyl”). In some embodiments, an alkynyl group has 2 to 9 carbon atoms (“C 2–9 alkynyl”).
- an alkynyl group has 2 to 8 carbon atoms (“C 2–8 alkynyl”). In some embodiments, an alkynyl group has 2 to 7 carbon atoms (“C 2–7 alkynyl”). In some embodiments, an alkynyl group has 2 to 6 carbon atoms (“C 2–6 alkynyl”). In some embodiments, an alkynyl group has 2 to 5 carbon atoms (“C 2–5 alkynyl”). In some embodiments, an alkynyl group has 2 to 4 carbon atoms (“C 2–4 alkynyl”). In some embodiments, an alkynyl group has 2 to 3 carbon atoms (“C 2–3 alkynyl”).
- an alkynyl group has 2 carbon atoms (“C 2 alkynyl”).
- the one or more carbon–carbon triple bonds can be internal (such as in 2–butynyl) or terminal (such as in 1–butynyl).
- Examples of C 2–4 alkynyl groups include, without limitation, ethynyl (C 2 ), 1–propynyl ( C 3 ), 2–propynyl (C 3 ), 1–butynyl (C 4 ), 2–butynyl (C 4 ), and the like.
- C 2–6 alkenyl groups include the aforementioned C 2–4 alkynyl groups as well as pentynyl (C 5 ), hexynyl (C 6 ), and the like. Additional examples of alkynyl include heptynyl (C 7 ), octynyl (C 8 ), and the like.
- alkylene alkenylene
- alkynylene refer to a divalent radical of an alkyl, alkenyl, and alkynyl group respectively.
- alkylene alkenylene
- alkynylene alkynylene
- aryl refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 ⁇ electrons shared in a cyclic array) having 6–14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system (“C 6–14 aryl”).
- an aryl group has six ring carbon atoms (“C 6 aryl”; e.g., phenyl).
- an aryl group has ten ring carbon atoms (“C 10 aryl”; e.g., naphthyl such as 1–naphthyl and 2–naphthyl). In some embodiments, an aryl group has fourteen ring carbon atoms (“C 14 aryl”; e.g., anthracyl). “Aryl” also includes ring systems wherein the aryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the radical or point of attachment is on the aryl ring, and in such instances, the number of carbon atoms continue to designate the number of carbon atoms in the aryl ring system.
- Typical aryl groups include, but are not limited to, groups derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, and trinaphthalene.
- aryl groups include phenyl, naphthyl, indenyl, and tetrahydronaphthyl.
- heteroaryl refers to a radical of a 5–10 membered monocyclic or bicyclic 4n+2 aromatic ring system (e.g., having 6 or 10 electrons shared in a cyclic array) having ring carbon atoms and 1–4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur (“5–10 membered heteroaryl”).
- the point of attachment can be a carbon or nitrogen atom, as valency permits.
- Heteroaryl bicyclic ring systems can include one or more heteroatoms in one or both rings.
- “Heteroaryl” includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the point of attachment is on the heteroaryl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heteroaryl ring system.
- Heteroaryl also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment is either on the aryl or heteroaryl ring, and in such instances, the number of ring members designates the number of ring members in the fused (aryl/heteroaryl) ring system.
- Bicyclic heteroaryl groups wherein one ring does not contain a heteroatom e.g., indolyl, quinolinyl, carbazolyl, and the like
- the point of attachment can be on either ring, i.e., either the ring bearing a heteroatom (e.g., 2–indolyl) or the ring that does not contain a heteroatom (e.g., 5–indolyl).
- a heteroaryl group is a 5–10 membered aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5–10 membered heteroaryl”).
- a heteroaryl group is a 5–8 membered aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5–8 membered heteroaryl”).
- a heteroaryl group is a 5–6 membered aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5–6 membered heteroaryl”).
- the 5–6 membered heteroaryl has 1–3 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
- the 5–6 membered heteroaryl has 1–2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5–6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur.
- Exemplary 5–membered heteroaryl groups containing one heteroatom include, without limitation, pyrrolyl, furanyl and thiophenyl.
- Exemplary 5–membered heteroaryl groups containing two heteroatoms include, without limitation, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl.
- Exemplary 5–membered heteroaryl groups containing three heteroatoms include, without limitation, triazolyl, oxadiazolyl, and thiadiazolyl.
- Exemplary 5– membered heteroaryl groups containing four heteroatoms include, without limitation, tetrazolyl.
- Exemplary 6–membered heteroaryl groups containing one heteroatom include, without limitation, pyridinyl.
- Exemplary 6–membered heteroaryl groups containing two heteroatoms include, without limitation, pyridazinyl, pyrimidinyl, and pyrazinyl.
- Exemplary 6–membered heteroaryl groups containing three or four heteroatoms include, without limitation, triazinyl and tetrazinyl, respectively.
- Exemplary 7–membered heteroaryl groups containing one heteroatom include, without limitation, azepinyl, oxepinyl, and thiepinyl.
- Exemplary 5,6–bicyclic heteroaryl groups include, without limitation, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, and purinyl.
- Exemplary 6,6–bicyclic heteroaryl groups include, without limitation, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.
- Examples of representative heteroaryls include the following: wherein each Z is selected from carbonyl, N, NR 65 , O, and S; and R 65 is independently hydrogen, C 1 -C 8 alkyl, C 3 -C 10 carbocyclyl, 4-10 membered heterocyclyl, C 6 -C 10 aryl, and 5-10 membered heteroaryl.
- “carbocyclyl” or “carbocyclic” refers to a radical of a non–aromatic cyclic hydrocarbon group having from 3 to 10 ring carbon atoms (“C 3–10 carbocyclyl”) and zero heteroatoms in the non–aromatic ring system.
- a carbocyclyl group has 3 to 8 ring carbon atoms (“C 3–8 carbocyclyl”).
- a carbocyclyl group has 3 to 6 ring carbon atoms (“C 3–6 carbocyclyl”).
- a carbocyclyl group has 5 to 10 ring carbon atoms (“C 5–10 carbocyclyl”).
- Exemplary C 3–6 carbocyclyl groups include, without limitation, cyclopropyl (C 3 ),cyclobutyl (C 4 ), cyclobutenyl (C 4 ), cyclopentyl (C 5 ), cyclopentenyl (C 5 ), cyclohexyl (C 6 ), cyclohexenyl (C 6 ), cyclohexadienyl (C 6 ), and the like.
- Exemplary C 3–8 carbocyclyl groups include, without limitation, the aforementioned C 3–6 carbocyclyl groups as well as cycloheptyl (C 7 ), cycloheptenyl (C 7 ), cycloheptadienyl (C 7 ), cycloheptatrienyl (C 7 ), cyclooctyl (C 8 ), cyclooctenyl (C 8 ), bicyclo[2.2.1]heptanyl (C 7 ), bicyclo[2.2.2]octanyl (C 8 ), and the like.
- Exemplary C 3–10 carbocyclyl groups include, without limitation, the aforementioned C 3– 8 carbocyclyl groups as well as cyclononyl (C 9 ), cyclononenyl (C 9 ), cyclodecyl (C 10 ), cyclodecenyl (C 10 ), octahydro–1H–indenyl (C9), decahydronaphthalenyl (C 10 ), spiro[4.5]decanyl (C 10 ), and the like.
- the carbocyclyl group is either monocyclic (“monocyclic carbocyclyl”) or contain a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic carbocyclyl”) and can be saturated or can be partially unsaturated.
- “Carbocyclyl” also includes ring systems wherein the carbocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups wherein the point of attachment is on the carbocyclyl ring, and in such instances, the number of carbons continue to designate the number of carbons in the carbocyclic ring system.
- cycloalkyl refers to a monovalent saturated cyclic, bicyclic, or bridged cyclic (e.g., adamantyl) hydrocarbon group of 3-12, 3-8, 4-8, or 4-6 carbons, referred to herein, e.g., as "C 4-8 cycloalkyl,” derived from a cycloalkane.
- exemplary cycloalkyl groups include, but are not limited to, cyclohexanes, cyclopentanes, cyclobutanes and cyclopropanes.
- cycloalkyl groups are optionally substituted at one or more ring positions with, for example, alkanoyl, alkoxy, alkyl, haloalkyl, alkenyl, alkynyl, amido, amidino, amino, aryl, arylalkyl, azido, carbamate, carbonate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, imino, ketone, nitro, phosphate, phosphonato, phosphinato, sulfate, sulfide, sulfonamido, sulfonyl or thiocarbonyl.
- Cycloalkyl groups can be fused to other cycloalkyl, aryl, or heterocyclyl groups. In certain embodiments, the cycloalkyl group is not substituted, i.e., it is unsubstituted.
- heterocyclyl or “heterocyclic” refers to a radical of a 3– to 10–membered non–aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon (“3–10 membered heterocyclyl”).
- heterocyclyl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits.
- a heterocyclyl group can either be monocyclic (“monocyclic heterocyclyl”) or a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic heterocyclyl”), and can be saturated or can be partially unsaturated.
- Heterocyclyl bicyclic ring systems can include one or more heteroatoms in one or both rings.
- Heterocyclyl also includes ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more carbocyclyl groups wherein the point of attachment is either on the carbocyclyl or heterocyclyl ring, or ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclyl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heterocyclyl ring system.
- a heterocyclyl group is a 5–10 membered non–aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon (“5–10 membered heterocyclyl”).
- a heterocyclyl group is a 5–8 membered non– aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5–8 membered heterocyclyl”).
- a heterocyclyl group is a 5–6 membered non–aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5–6 membered heterocyclyl”).
- the 5–6 membered heterocyclyl has 1–3 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
- the 5–6 membered heterocyclyl has 1–2 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
- the 5–6 membered heterocyclyl has one ring heteroatom selected from nitrogen, oxygen, and sulfur.
- Exemplary 3–membered heterocyclyl groups containing one heteroatom include, without limitation, azirdinyl, oxiranyl, thiorenyl.
- Exemplary 4–membered heterocyclyl groups containing one heteroatom include, without limitation, azetidinyl, oxetanyl and thietanyl.
- Exemplary 5–membered heterocyclyl groups containing one heteroatom include, without limitation, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl and pyrrolyl–2,5–dione.
- Exemplary 5–membered heterocyclyl groups containing two heteroatoms include, without limitation, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one.
- Exemplary 5–membered heterocyclyl groups containing three heteroatoms include, without limitation, triazolinyl, oxadiazolinyl, and thiadiazolinyl.
- Exemplary 6–membered heterocyclyl groups containing one heteroatom include, without limitation, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl.
- Exemplary 6–membered heterocyclyl groups containing two heteroatoms include, without limitation, piperazinyl, morpholinyl, dithianyl, dioxanyl. Exemplary 6–membered heterocyclyl groups containing two heteroatoms include, without limitation, triazinanyl. Exemplary 7–membered heterocyclyl groups containing one heteroatom include, without limitation, azepanyl, oxepanyl and thiepanyl. Exemplary 8–membered heterocyclyl groups containing one heteroatom include, without limitation, azocanyl, oxecanyl and thiocanyl.
- Exemplary 5-membered heterocyclyl groups fused to a C 6 aryl ring include, without limitation, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl, and the like.
- Exemplary 6-membered heterocyclyl groups fused to an aryl ring include, without limitation, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like.
- Hetero when used to describe a compound or a group present on a compound means that one or more carbon atoms in the compound or group have been replaced by a nitrogen, oxygen, or sulfur heteroatom. Hetero may be applied to any of the hydrocarbyl groups described above such as alkyl, e.g., heteroalkyl; carbocyclyl, e.g., heterocyclyl; aryl, e.g,. heteroaryl; and the like having from 1 to 5, and particularly from 1 to 3 heteroatoms. [0051] As used herein, “cyano” refers to -CN.
- halo or ”halogen refers to fluoro (F), chloro (Cl), bromo (Br) and iodo (I). In certain embodiments, the halo group is either fluoro or chloro.
- haloalkyl refers to an alkyl group substituted with one or more halogen atoms.
- nitro refers to -NO 2 .
- substituted means that at least one hydrogen present on a group (e.g., a carbon or nitrogen atom) is replaced with a permissible substituent, e.g., a substituent which upon substitution results in a stable compound, e.g., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction.
- a “substituted” group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent is either the same or different at each position.
- Nitrogen atoms can be substituted or unsubstituted as valency permits, and include primary, secondary, tertiary, and quarternary nitrogen atoms.
- Pharmaceutically acceptable salts of the compounds described herein include those derived from suitable inorganic and organic acids and bases.
- pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
- salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2–hydroxy–ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2– naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pec
- Pharmaceutically acceptable salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (C 1–4 alkyl) 4 salts.
- Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
- Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate.
- a “subject” to which administration is contemplated includes, but is not limited to, humans (i.e., a male or female of any age group, e.g., a pediatric subject (e.g, an infant, child, adolescent) or an adult subject (e.g., a young adult, middle–aged adult, or senior adult)) and/or a non-human animal, e.g., a mammal such as primates (e.g., cynomolgus monkeys, rhesus monkeys), cattle, pigs, horses, sheep, goats, rodents, cats, and/or dogs.
- the subject is a human.
- the subject is a non-human animal.
- the terms “human,” “patient,” and “subject” are used interchangeably herein.
- Disease, disorder, and condition are used interchangeably herein.
- the terms “treat,” “treating” and “treatment” contemplate an action that occurs while a subject is suffering from the specified disease, disorder or condition, which reduces the severity of the disease, disorder or condition, or retards or slows the progression of the disease, disorder or condition (also “therapeutic treatment”).
- the “effective amount” of a compound or pharmaceutically acceptable salt thereof refers to an amount sufficient to elicit the desired biological response.
- the effective amount of a compound or pharmaceutically acceptable salt thereof as disclosed herein may vary depending on such factors as the desired biological endpoint, the pharmacokinetics of the compound or pharmaceutically acceptable salt thereof, the disease being treated, the mode of administration, and the age, weight, health, and condition of the subject.
- a “therapeutically effective amount” of a compound or pharmaceutically acceptable salt thereof is an amount sufficient to provide a therapeutic benefit in the treatment of a disease, disorder or condition, or to delay or minimize one or more symptoms associated with the disease, disorder or condition.
- a therapeutically effective amount of a compound or pharmaceutically acceptable salt thereof means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment of the disease, disorder or condition.
- the term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of disease or condition, or enhances the therapeutic efficacy of another therapeutic agent.
- methods of treating comprising administering the compounds disclosed herein or a pharmaceutically acceptable salt or a pharmaceutically acceptable composition thereof, as a prophylactic before a subject begins to suffer from the specified disease, disorder or condition.
- prophylactic treatment contemplates an action that occurs before a subject begins to suffer from the specified disease, disorder or condition.
- a “prophylactically effective amount” of a compound or pharmaceutically acceptable salt thereof is an amount sufficient to prevent a disease, disorder or condition, or one or more symptoms associated with the disease, disorder or condition, or prevent its recurrence.
- a prophylactically effective amount of a compound or pharmaceutically acceptable salt thereof means an amount of a therapeutic agent, alone or in combination with other agents, which provides a prophylactic benefit in the prevention of the disease, disorder or condition.
- the term “prophylactically effective amount” can encompass an amount that improves overall prophylaxis or enhances the prophylactic efficacy of another prophylactic agent.
- a “disorder associated with a gain-of-function mutation in KCNT1” refers to a disorder that is associated with, is partially or completely caused by, or has one or more symptoms that are partially or completely caused by, a mutation in KCNT1 that results in a gain- of-function phenotype, i.e. an increase in activity of the potassium channel encoded by KCNT1 resulting in an increase in whole cell current.
- a “gain-of-function mutation” is a mutation in KCNT1 that results in an increase in activity of the potassium channel encoded by KCNT1. Activity can be assessed by, for example, ion flux assay or electrophysiology (e.g.
- a gain-of-function mutation results in an increase of at least or about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 125%, 150%, 175%, 200%, 225%, 250%, 275%, 300%, 325%, 350%, 375%, 400% or more compared to the activity of a potassium channel encoded by a wild-type KCNT1.
- the compound of Formula I is a compound of Formula I-a: or a pharmaceutically acceptable salt thereof.
- the compound of Formula I is a compound of Formula I-b: or a pharmaceutically acceptable salt thereof.
- the compound of Formula I is a compound of Formula I-c: or a pharmaceutically acceptable salt thereof.
- the compound of Formula I is a compound of Formula I-d or I-e: or a pharmaceutically acceptable salt thereof.
- R 3 is C 1-6 alkyl and R 4 is hydrogen.
- R2 is hydrogen.
- R 1 is C 1-6 alkyl. In some embodiments, R 1 is methyl. In some embodiments, x is 1 or 2. In some embodiments, x is 1. [0078] In some embodiments, R 5 is C 1-6 haloalkyl. In some embodiments, R 5 is -CF3. [0079] In some embodiments, R 6 is hydrogen and R 7 is C 1-6 alkyl. [0080] In some embodiments, R 6 and R 7 are each C 1-6 alkyl optionally comprising a phenyl substituent.
- R 6 and R 7 are taken together with the nitrogen attached to R 6 and R 7 to form a 3-10 membered heterocyclyl ring optionally comprising one or more substituents chosen from a halogen, a C 1-6 alkyl, or a C 1-6 haloalkyl.
- the compound is chosen from:
- a pharmaceutical composition comprising a compound disclosed herein or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
- Scheme 1 The synthetic route illustrated in Scheme 1 depicts an exemplary procedure for preparing intermediate F. In the first step, amine A is treated with cyanogen bromide to provide nitrile B, which is then treated with hydroxylamine to provide N-hydroxyimidamide C.
- the compounds and compositions described above and herein can be used to treat a neurological disease, a disorder associated with excessive neuronal excitability, or disorder associated with a gain-of-function mutation in a gene (e.g., KCNT1).
- a neurological disease e.g., KCNT1
- a disorder associated with excessive neuronal excitability e.g., KCNT1
- a gain-of-function mutation e.g., KCNT1
- Exemplary diseases, disorders, or conditions include epilepsy and other encephalopathies (e.g., MMFSI or EIMFS, ADNFLE, West syndrome, infantile spasms, epileptic encephalopathy, developmental and epileptic encephalopathy (DEE), early infantile epileptic encephalopathy (EIEE), generalized epilepsy, focal epilepsy, multifocal epilepsy, temporal lobe epilepsy, Ohtahara syndrome, early myoclonic encephalopathy, Lennox-Gastaut syndrome, drug-resistant epilepsy, seizures (e.g., frontal lobe seizures, generalized tonic clonic seizures, asymmetric tonic seizures, focal seizures), leukodystrophy, hypomyelinating leukodystrophy, leukoencephalopathy, and sudden unexpected death in epilepsy, cardiac dysfunctions (e.g., cardiac arrhythmia, Brugada syndrome, myocardial infarction), pulmonary vasculopathy / hemorrh
- the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation in a gene is selected from EIMFS, ADNFLE and West syndrome.
- the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation in a gene is selected from infantile spasms, epileptic encephalopathy, focal epilepsy, Ohtahara syndrome, developmental and epileptic encephalopathy, and Lennox-Gastaut syndrome.
- the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation in a gene is seizure.
- the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation in a gene is selected from cardiac arrhythmia, Brugada syndrome, and myocardial infarction.
- the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation in a gene is chosen from a learning disorder, Fragile X, intellectual function, neuronal plasticity, psychiatric disorders, or an autism spectrum disorder.
- the compounds and compositions thereof can be administered to a subject with a neurological disorder, a disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation in a gene such as KCNT1 (e.g., EIMFS, ADNFLE, West syndrome, infantile spasms, epileptic encephalopathy, focal epilepsy, Ohtahara syndrome, developmental and epileptic encephalopathy, Lennox-Gastaut syndrome, seizures, cardiac arrhythmia, Brugada syndrome, and myocardial infarction).
- KCNT1 e.g., EIMFS, ADNFLE, West syndrome, infantile spasms, epileptic encephalopathy, focal epilepsy, Ohtahara syndrome, developmental and epileptic encephalopathy, Lennox-Gastaut syndrome, seizures, cardiac arrhythmia, Brugada syndrome, and myocardial infarction.
- EIMFS is a rare and debilitating genetic condition characterized by an early onset (before 6 months of age) of almost continuous heterogeneous focal seizures, where seizures appear to migrate from one brain region and hemisphere to another.
- Patients with EIMFS are generally intellectually impaired, non-verbal and non-ambulatory. While several genes have been implicated to date, the gene that is most commonly associated with EIMFS is KCNT1.
- ADNFLE has a later onset than EIMFS, generally in mid-childhood, and is generally a less severe condition.
- ADNFLE is associated with genes encoding several neuronal nicotinic acetylcholine receptor subunits
- mutations in the KCNT1 gene have been implicated in more severe cases of the disease (Heron et al. (2012) Nat Genet. 44: 1188-1190).
- Functional studies of the mutated KCNT1 genes associated with ADNFLE indicated that the underlying mutations (M896I, R398Q, Y796H and R928C) were dominant, gain-of-function mutations (Milligan et al. (2015) Ann Neurol.
- West syndrome is a severe form of epilepsy composed of a triad of infantile spasms, an interictal electroencephalogram (EEG) pattern termed hypsarrhythmia, and mental retardation, although a diagnosis can be made one of these elements is missing. Mutations in KCNT1, including G652V and R474H, have been associated with West syndrome (Fukuoka et al. (2017) Brain Dev 39:80-83 and Ohba et al. (2015) Epilepsia 56:el21-el28).
- KCNT1 for example, epilepsy and other encephalopathies (e.g., MMFSI or EIMFS, ADNFLE, West syndrome, infantile spasms, epileptic encephalopathy, focal epilepsy, Ohtahara syndrome, DEE, Lennox-Gastaut syndrome, seizures, leukodystrophy, leukoencephalopathy, intellectual disability, Multifocal Epilepsy, Generalized tonic clonic seizures, drug-resistant epilepsy, Temporal lobe epilepsy, cerebellar ataxia, Asymmetric Tonic Seizures); cardiac dysfunctions (e.g., cardiac arrhythmia,
- the subject presenting with a disorder that may be associated with a gain-of-function mutation in KCNT1 is genotyped to confirm the presence of a known gain- of-function mutation in KCNT1 prior to administration of the compounds or a pharmaceutically acceptable salt thereof or and compositions disclosed herein.
- whole exome sequencing can be performed on the subject.
- Gain-of-function mutations associated with EIMFS may include, but are not limited to, V271F, G288S, R428Q, R474Q, R474H, R474C, I760M, A934T, P924L, G243S, H257D, A259D, R262Q, Q270E, L274I, F346L, C377S, R398Q, P409S, A477T, F502V, M516V, Q550del, K629E, K629N, I760F, E893K, M896K, R933G, R950Q, and K1154Q.
- Gain-of-function mutations associated with ADNFLE may include, but are not limited to, M896I, R398Q, Y796H, R928C, and G288S.
- Gain-of-function mutations associated with West syndrome may include, but are not limited to, G652V and R474H.
- Gain-of-function mutations associated with temporal lobe epilepsy may include, but are not limited to, R133H and R565H.
- Gain-of-function mutations associated with Lennox-Gastaut may include, but are not limited to, R209C.
- Gain-of-function mutations associated with seizures may include, but are not limited to, A259D, G288S, R474C, R474H.
- Gain-of-function mutations associated with leukodystrophy may include, but are not limited to, G288S and Q906H.
- Gain-of-function mutations associated with Multifocal Epilepsy may include, but are not limited to, V340M.
- Gain-of-function mutations associated with early-onset epilepsy may include, but are not limited to, F346L and A934T.
- Gain-of-function mutations associated with Early-onset epileptic encephalopathies (EOEE) may include, but are not limited to, R428Q.
- Gain-of-function mutations associated with developmental and epileptic encephalopathies may include, but are not limited to, F346L, R474H, and A934T.
- Gain-of-function mutations associated with epileptic encephalopathies may include, but are not limited to, L437F, Y796H, P924L, and R961H.
- Gain-of-function mutations associated with Early Infantile Epileptic Encephalopathy (EIEE) may include, but are not limited to, M896K.
- Gain-of- function mutations associated with drug-resistant epilepsy and generalized tonic-clonic seizure may include, but are not limited to, F346L.
- Gain-of-function mutations associated with migrating partial seizures of infancy may include, but are not limited to, R428Q.
- Gain-of-function mutations associated with Leukoencephalopathy may include, but are not limited to, F932I.
- Gain-of-function mutations associated with NFLE may include, but are not limited to, A934T and R950Q.
- Gain- of-function mutations associated with Ohtahara syndrome may include, but are not limited to, A966T.
- Gain-of-function mutations associated with infantile spasms may include, but are not limited to, P924L.
- Gain-of-function mutations associated with Brugada Syndrome may include, but are not limited to, R1106Q.
- Gain-of-function mutations associated with Brugada Syndrome may include, but are not limited to, R474H.
- the subject is first genotyped to identify the presence of a mutation in KCNT1 and this mutation is then confirmed to be a gain-of-function mutation using standard in vitro assays, such as those described in Milligan et al. (2015) Ann Neurol. 75(4): 581- 590.
- the presence of a gain-of-function mutation is confirmed when the expression of the mutated KCNT1 allele results an increase in whole cell current compared to the whole cell current resulting from expression of wild-type KCNT1, as may be assessed using whole-cell electrophysiology (such as described in Milligan et al. (2015) Ann Neurol.75(4): 581-590; Barcia et al. (2012) Nat Genet.
- This increase of whole cell current can be, for example, an increase of at least or about 50%, 100%, 150%, 200%, 250%, 300%, 350%, 400% or more.
- the subject can then be confirmed to have a disease or condition associated with a gain-of- function mutation in KCNT1.
- the subject is confirmed as having a KCNT1 allele containing a gain-of-function mutation (e.g.
- the compounds disclosed herein e.g., a compound of Formula (I), (e.g., (I-a), (I- b), (I-c), (I-d), or (I-e)) or a pharmaceutically acceptable salt thereof) or the pharmaceutical composition disclosed herein (e.g., a pharmaceutical composition comprising a compound disclosed herein (e.g., a compound of Formula (I), (e.g., (I-a), (I-b), (I-c), (I-d), or (I-e)) or a pharmaceutically acceptable salt thereof), and a pharmaceutically acceptable excipient) can also be used therapeutically for conditions associated with excessive neuronal excitability where the excessive neuronal excitability is not necessarily the result of a gain-of-function mutation in KCNT1.
- the compounds disclosed herein e.g., a compound of Formula (I), (e.g., (I-a), (I-b), (I-c), (I-d), or (I-e)) or a pharmaceutically acceptable salt thereof) or the pharmaceutical composition disclosed herein (e.g., a pharmaceutical composition comprising a compound disclosed herein (e.g., a compound of Formula (I), (e.g., (I-a), (I-b), (I-c), (I-d), or (I-e)) or a pharmaceutically acceptable salt thereof), and a pharmaceutically acceptable excipient) can be used to treat a subject with conditions associated with excessive neuronal excitability, for example, epilepsy and other encephalopathies (e.g., EIMFS, ADNF
- compositions and Routes of Administration [0099] Compounds disclosed herein and pharmaceutically acceptable salts thereof are usually administered in the form of pharmaceutical compositions. Therefore, disclosed herein are pharmaceutical compositions that contain, as the active ingredient, one or more of the compounds described, or a pharmaceutically acceptable salt or ester thereof, and one or more pharmaceutically acceptable excipients, carriers, including inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants.
- the pharmaceutical compositions may be administered alone or in combination with other therapeutic agents.
- compositions may be prepared in a manner disclosed in the pharmaceutical art, including, for example, in Remington’s Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, Pa.17 th Ed. (1985); and Modern Pharmaceutics, Marcel Dekker, Inc. 3 rd Ed. (G. S. Banker & C. T. Rhodes, Eds.).
- compositions may be administered in either single or multiple doses by any of the accepted modes of administration of agents having similar utilities, for example as described in those patents and patent applications incorporated by reference, including rectal, buccal, intranasal and transdermal routes, by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, as an inhalant, or via an impregnated or coated device such as a stent, for example, or an artery- inserted cylindrical polymer.
- One mode for administration is parenteral, particularly by injection.
- Aqueous solutions in saline are also conventionally used for injection.
- Ethanol, glycerol, propylene glycol, liquid polyethylene glycol, and the like (and suitable mixtures thereof), cyclodextrin derivatives, and vegetable oils may also be employed.
- the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
- Sterile injectable solutions are prepared by incorporating a compound or pharmaceutically acceptable salt thereof as disclosed herein in the appropriate solvent with various other ingredients as enumerated above, as desired, followed by filtered sterilization.
- dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the desired other ingredients from those enumerated above.
- exemplary methods of preparation include vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- Oral administration is another route for administration of the compounds or pharmaceutically acceptable salts thereof as disclosed herein. Administration may be via capsule or enteric coated tablets, or the like.
- the active ingredient may be diluted by an excipient and/or enclosed within such a carrier that can be in the form of a capsule, sachet, paper or other container.
- a carrier that can be in the form of a capsule, sachet, paper or other container.
- the excipient serves as a diluent, it can be in the form of a solid, semi-solid, or liquid material (as above), which acts as a vehicle, carrier or medium for the active ingredient.
- compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, sterile injectable solutions, and sterile packaged powders.
- compositions disclosed herein can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl and propylhydroxy- benzoates; sweetening agents; and flavoring agents.
- compositions disclosed herein can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
- Controlled release drug delivery systems for oral administration include osmotic pump systems and dissolutional systems containing polymer- coated reservoirs or drug-polymer matrix formulations. Examples of controlled release systems are given in U.S. Pat. Nos.3,845,770; 4,326,525; 4,902,514; and 5,616,345.
- Another embodiment for use in the methods disclosed herein employs transdermal delivery devices (“patches”). Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds or pharmaceutically acceptable salts thereof in controlled amounts.
- transdermal patches for the delivery of pharmaceutical agents is described, for example, in U.S. Pat. Nos. 5,023,252, 4,992,445 and 5,001,139. Such patches may be constructed for continuous, pulsatile, or on-demand delivery of pharmaceutical agents.
- the compositions disclosed herein may be formulated in a unit dosage form.
- unit dosage forms refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient (e.g., a tablet, capsule, ampoule).
- the compounds or pharmaceutically acceptable salt thereof are generally administered in a pharmaceutically effective amount.
- each dosage unit contains from about 1 mg to about 2 g of a compound or pharmaceutically acceptable salt thereof as described herein, and for parenteral administration, preferably from about 0.1 to about 700 mg of a compound or pharmaceutically acceptable salt thereof as described herein.
- the amount of the compound or pharmaceutically acceptable salt thereof actually administered usually will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound or pharmaceutically acceptable salt thereof administered and its relative activity, the age, weight, and response of the individual patient, the severity of the patient’s symptoms, and the like.
- the principal active ingredient may be mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound or pharmaceutically acceptable salt thereof.
- a pharmaceutical excipient When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
- the tablets or pills disclosed herein may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action, or to protect from the acid conditions of the stomach.
- the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
- compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
- the liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described herein.
- the compositions are administered by the oral or nasal respiratory route for local or systemic effect.
- compositions in preferably pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a facemask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, such as orally or nasally, from devices that deliver the formulation in an appropriate manner.
- a pharmaceutical composition comprising a compound, or pharmaceutically acceptable salt thereof, as disclosed herein and a pharmaceutically acceptable carrier.
- NMR nuclear magnetic resonance spectroscopy
- LCMS liquid chromatography mass spectrometry
- the reaction mixture was concentrated under reduced pressure.
- the residue was diluted with EtOAc (50 mL) and washed with water (20 mL).
- the organic layer was again washed with water (20 mL x 2) and brine.
- the organic layer was separated, dried over magnesium sulfate, and filtered.
- the organic layer was evaporated under reduced pressure to give the residue.
- the residue was purified by flash column chromatography using 100-200 mesh silica and 30 % EtOAc in hexane as an eluent to give A7 (150 mg, 0.14 mmol) as a liquid.
- A-15c 1-hydroxy-3-isobutyl-guanidine [00145] A mixture of A-15b (1 g, 10.19 mmol), hydroxylamine hydrochloride (0.92 g, 13.25 mmol) and TEA (2.84mL, 20.38mmol) in ethanol (10 mL) was heated at 80 oC for 16 hours. The solvent was removed, and the residue was triturated with diethyl ether and dried using vacuum to give A-15c as a solid, which was used directly for the next step without further purification.
- A-17b (3.6 g, 14.4 mmol, 51 % yield) as a solid.
- Synthesis of benzyl(methyl)cyanamide (A-17c) [00154] To a stirred solution of A-17b (2 g, 15.13 mmol) in DMF (10 mL) was added K 2 C O 3 (2.3g, 16.65 mmol) and methyl iodide (0.95 mL, 15.13 mmol) at 0 °C and then stirred at room temperature for 12 hours. The reaction mixture was diluted with EtOAc (30 mL) and water (20 mL), and the organic layer was separated.
- reaction mixture was filtered through a pad of celite. The filtrate was concentrated under reduced pressure. The residue was diluted with EtOAc (30 mL) and washed with water (15 mL). The organic layer was again washed with water (10 mL x 2) and brine (10 mL). The organic layer was dried over anhydrous sodium sulphate, filtered, and evaporated to give A24 (0.85 g, 6.71 mmol, 91.06% yield) as an oil.
- the reaction mixture was heated at 100 oC for 12 hours.
- the reaction mixture was cooled to room temperature and concentrated under reduced pressure.
- the mixture was treated with water (30 mL) and extracted with ethyl acetate (2 x 30 mL).
- the organic layer was washed with brine (20 mL), dried over Na 2 SO 4 , and concentrated.
- the residue was purified by column chromatography on silica gel with 38% EtOAc/PE to afford A30 (398 mg, 1.34 mmol, 27% yield).
- reaction mixture was heated at 100 oC for 16 hours.
- the reaction mixture was cooled to room temperature and concentrated under reduced pressure.
- the mixture was treated with water (20 mL) and extracted with ethyl acetate (2 x 30 mL). The organic layer was washed with brine (20 mL), dried over Na 2 SO 4 , and concentrated.
- the residue was purified by column chromatography on silica gel with 35% EtOAc/PE to afford A34 (340 mg, 1.09 mmol, 14% yield).
- reaction mixture was stirred for 5 minutes, and cyanogen bromide (792 mg, 7.48 mmol) in DCM (20.0 mL) was added drop-wise.
- the reaction mixture was warmed to room temperature and stirred for 1 hour.
- the reaction mixture was treated with water (30 mL) and extracted with DCM (2 x 30 mL).
- the organic layer was washed with brine (30 mL), dried over anhydrous Na 2 SO 4 , and concentrated to afford A40 (380 mg) as a liquid.
- the compound was used for the next step without further purification.
- reaction mixture was heated at 100 oC for 16 hours.
- the reaction mixture was cooled to room temperature and concentrated under reduced pressure.
- the mixture was treated with water (20 mL) and extracted with ethyl acetate (2 x 30 mL). The organic layer was washed with brine (20 mL), dried over Na 2 SO 4 , and concentrated.
- the residue was purified by column chromatography on silica gel with 38% EtOAc/PE to afford A42 (205 mg, 0.64 mmol, 39% yield).
- the reaction mixture was slowly warmed to room temperature and stirred for 4 hours.
- the mixture was concentrated under reduced pressure and treated with ice water (10 mL).
- the mixture was treated with 10% NaHCO 3 solution (8.0 mL) and extracted with DCM (3 x 30 mL).
- the organic layer was washed with brine (20 mL), dried over Na 2 SO 4 , and concentrated to afford A43 (100 mg). The residue was used in the next step without further purification.
- reaction mixture was filtered through celite, and the filtrate was evaporated to give a residue, which was diluted with ethyl acetate and washed with water and brine.
- organic layer was dried over sodium sulphate and evaporated to afford A46 (4 g, 32.14 mmol, 63 % yield) as a liquid, which was directly used in the next step.
- reaction was diluted with water and extracted with ethyl acetate (3 times). The combined organic layer was washed with water and brine, dried over sodium sulphate, and evaporated to give a residue, which was purified by combi-flash chromatography in ethyl acetate: hexane and further by prep HPLC to afford desired A53 (400 mg, 1.41 mmol, 36 % yield) as a solid.
- reaction mixture was concentrated under reduced pressure.
- the residue was diluted with EtOAc (50 mL) and water (20 mL).
- the separated organic layer was washed with water (20 mL x 2) and saturated brine solution (20 mL), dried over anhydrous MgSO4, and evaporated to dryness to give a residue, which was purified by flash column chromatography using silica gel and 30-35% EtOAc in hexane as an eluent to give A58 (0.4 g, 0.91 mmol) as a solid.
- reaction mixture was stirred at 80 °C for 6 hours.
- the reaction mixture was quenched using water (10 mL) and diluted with ethyl acetate (100 mL x2), and the organic layer was separated. The organic layer was then dried using sodium sulphate, filtered, and evaporated to give a residue, which was purified using column chromatography using 100-200 silica gel and 30-80% EtOAc/Hexane eluent to give A63 (1.1 g, 3.64 mmol, 59% yield).
- reaction mixture was quenched using water (10 mL) and diluted with EtOAc (100 mL x 2). The organic layer was separated, dried over Na 2 SO 4 , filtered, and evaporated to give a residue. The residue was purified by column chromatography using 100-200 silica and 30-80% EtOAc/hexane as an eluent to give A73 (1.2 g, 8.507 mmol, 84 % yield) as a solid.
- reaction mixture was stirred at 80 °C for 16 hours.
- the solvent was removed to give a residue, which was triturated with diethyl ether and dried under reduced pressure to give A78 (1.2g, 4.58 mmol, 74 % yield) as a solid which was used for next step without further purification.
- reaction mixture was quenched using water (10 mL) and diluted with EtOAc (50x2 ml). The organic layer was separated, dried over Na 2 SO 4 , filtered, and evaporated to give a residue, which was purified by column chromatography using 100-200 silica and 30-80% EtOAc/Hexane as an eluent to give A83 (450 mg, 1.98 mmol, 68 % yield).
- reaction mixture was quenched with water (10 mL) and diluted with EtOAc (50 x 2mL).
- the organic layer was separated, dried over Na 2 SO 4 , filtered, and evaporated under reduced pressure to get a residue, which was purified by column chromatography using 100-200 silica and 30-80% EtOAc/Hexane as an eluent to get A84 (100 mg, 0.123 mmol, 5 % yield) as a solid.
- reaction mixture was quenched using water (10 mL) and diluted with DCM (50mL), and the organic layer was separated. The organic layer was dried over Na 2 SO 4 , filtered, and evaporated under reduced pressure to get a residue, which was purified by column chromatography using 100- 200 silica and 30-80% EtOAc/Hexane as an eluent to give 25 (5mg, 0.0119mmol, 4 % yield) as a solid.
- KCNT1-WT-Basal – Patch Clamp Assay Inhibition of KCNT1 (of KCNT1 (KNa1.1, Slack) was evaluated using a tetracycline inducible cell line (HEK-TREX). Currents were recorded using the SyncroPatch 384PE automated, patch clamp system. Pulse generation and data collection were performed with PatchController384 V1.3.0 and DataController384 V1.2.1 (Nanion Technologies). The access resistance and apparent membrane capacitance were estimated using built-in protocols. Current were recorded in perforated patch mode (10 ⁇ M escin) from a population of cells.
- the cells were lifted, triturated, and resuspended at 800,000 cells/ml. The cells were allowed to recover in the cell hotel prior to experimentation. Currents were recorded at room temperature.
- the extracellular solution was used as the wash, reference and compound delivery solution.
- the extracellular solution was used as the wash, reference and compound delivery solution.
- the compound plate was created at 2x concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well.
- the amount of DMSO in the extracellular solution was held constant at the level used for the highest tested concentration. A holding potential of -80 mV with a 100ms step to 0mV was used.
- the embodiments encompass all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the listed claims is introduced into another claim.
- any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim.
- elements are presented as lists, e.g., in Markush group format, each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It should it be understood that, in general, where the embodiment, or aspects of the embodiment, is/are referred to as comprising particular elements and/or features, certain embodiments or aspects of the embodiments consist, or consist essentially of, such elements and/or features.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Disclosed herein are compounds and compositions useful for preventing and/or treating a neurological disorder, a disorder associated with excessive neuronal excitability, or a disorder associated with a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disorder, a disorder associated with excessive neuronal excitability, or disorder associated with a gain-of-function mutation in a gene such as KCNT1 are also provided herein.
Description
KCNT1 INHIBITORS AND METHODS OF USE CROSS-REFERENCE TO RELATED APPLICATION [001] This application claims the benefit of, and relies on the filing date of, U.S. provisional patent application number 63/181,498, filed 29 April 2021, the entire disclosure of which is incorporated herein by reference. FIELD OF THE DISCLOSURE [002] The present disclosure is generally directed to KCNT1 inhibitors comprising an oxadiazole core, as well as pharmaceutical compositions and methods of treatment involving the use of such compounds. BACKGROUND OF THE DISCLOSURE [003] Potassium sodium-activated channel subfamily T member 1 (“KCNT1”) is one of the genes in a family of genes responsible for providing the instructions to make potassium channels. KCNT1 encodes sodium-activated potassium channels known as Slack (Sequence like a calcium-activated K+ channel). These channels are found in neurons throughout the brain and can mediate a sodium-activated potassium current IKNa. This delayed outward current can regulate neuronal excitability and the rate of adaption in response to maintained stimulation. Abnormal Slack activity has been associated with development of early onset epilepsies and intellectual impairment. Accordingly, pharmaceutical compounds that selectively regulate sodium-activated potassium channels, e.g., abnormal KCNT1 or abnormal IKNa, are useful in treating a neurological disease or disorder or a disease or condition related to excessive neuronal excitability and/or KCNT1 gain-of-function mutations. SUMMARY OF THE DISCLOSURE [004] Described herein are compounds and compositions useful for preventing and/or treating a disease, disorder, or condition, e.g., a neurological disorder, a disorder associated with excessive neuronal excitability, or disorder associated with a gain-of-function mutation in a gene, for example, KCNT1.
[005] In one aspect, the present disclosure features a compound of Formula I having an oxadiazole core:
or a pharmaceutically acceptable salt thereof, wherein R1 is chosen from a C1-6alkyl, a C1-6haloalkyl, or a C3-10cycloalkyl, wherein the C1-6alkyl, C1-6haloalkyl, and C3-10cycloalkyl optionally comprises a C1-6alkoxy or N(R8)2 substituent; R2 is chosen from hydrogen or a C1-4alkyl; R3 is chosen from a C1-6alkyl optionally comprising a C1-6alkoxy substituent; R4 is chosen from hydrogen or a C1-6alkyl; R5 is chosen from a C1-6alkyl or a C1-6haloalkyl; R6 is chosen from hydrogen, a C1-6alkyl, a C3-10cycloalkyl, a phenyl, or a 3-10 membered heterocyclyl, wherein the C1-6alkyl, C3-10cycloalkyl, phenyl, or 3-10 membered heterocyclyl may optionally comprise one or more substituents chosen from a halogen, -CN, -OH, a C1-6alkyl, a C1- 6haloalkyl, a C1-6alkoxy, a phenyl, a C3-10cycloalkyl, or a 3-10 membered heterocyclyl; R7 is chosen from a C1-6alkyl, a C3-10cycloalkyl, a phenyl, or a 3-10 membered heterocyclyl, wherein the C1-6alkyl, C3-10cycloalkyl, phenyl, or 3-10 membered heterocyclyl may optionally comprise one or more substituents chosen from a halogen, -CN, -OH, a C1-6alkyl, a C1-6haloalkyl, a C1-6alkoxy, a phenyl, a C3-10cycloalkyl, or a 3-10 membered heterocyclyl; or R6 and R7 are taken together with the nitrogen attached to R6 and R7 to form a 3-10 membered heterocyclyl ring optionally comprising one or more substituents chosen from a halogen, -CN, -OH, a C1-6alkyl, a C1-6haloalkyl, a phenyl, a C3-10cycloalkyl, or a 3-10 membered heterocyclyl, wherein the C1-6alkyl is optionally substituted with an oxo; each R8 is independently chosen from hydrogen or a C1-6alkyl; and x is 0, 1 or 2. [006] In some embodiments, the compound of Formula I is a compound of Formula I-a:
or a pharmaceutically acceptable salt thereof. [007] In some embodiments, the compound of Formula I is a compound of Formula I-b:
or a pharmaceutically acceptable salt thereof. [008] In some embodiments, the compound of Formula I is a compound of Formula I-c:
or a pharmaceutically acceptable salt thereof. [009] In some embodiments, the compound of Formula I is a compound of Formula I-d or Formula I-e:
or a pharmaceutically acceptable salt thereof. [0010] In certain embodiments disclosed herein, in a compound of the Formula (I) or pharmaceutically acceptable salt thereof, R3 is C1-6alkyl and R4 is hydrogen, and in certain embodiments, R2 is hydrogen. In certain embodiments, R1 is C1-6alkyl, and in certain embodiments, R1 is methyl. In certain embodiments, x is 1 or 2, such as 1, and in certain embodiments, R5 is C1-6haloalkyl, such as -CF3. In certain aspects, R6 is hydrogen and R7 is C1- 6alkyl, and in certain aspects, R6 and R7 are each C1-6alkyl optionally comprising a phenyl substituent. In certain embodiments, R6 and R7 are taken together with the nitrogen attached to R6 and R7 to form a 3-10 membered heterocyclyl ring optionally comprising one or more substituents chosen from a halogen, a C1-6alkyl, or a C1-6haloalkyl.
[0011] In certain embodiments, a compound of the Formula (I) is chosen from:
or a pharmaceutically acceptable salt thereof. [0012] In one aspect, the present disclosure provides a method of treating neurological disorder, wherein the method comprises administering to a subject in need thereof a compound disclosed herein (e.g., compound of Formula (I), (e.g., (I-a), (I-b), (I-c), (I-d), or (I-e))) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition disclosed herein (e.g., a pharmaceutical composition comprising a compound of Formula (I), (e.g., (I-a), (I-b), (I-c), (I-d), or (I-e)), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient). [0013] In another aspect, the present disclosure provides a method of treating a disorder associated with excessive neuronal excitability, wherein the method comprises administering to a subject in need thereof a compound disclosed herein (e.g., compound of Formula (I), (e.g., (I-a), (I-b), (I-c), (I-d), or (I-e))) or a pharmaceutically acceptable salt thereof or a pharmaceutical
composition disclosed herein (e.g., a pharmaceutical composition comprising a compound of Formula (I), (e.g., (I-a), (I-b), (I-c), (I-d), or (I-e)), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient). [0014] In another aspect, the present disclosure provides a method of treating a disorder associated with a gain-of-function mutation of a gene (e.g., KCNT1), wherein the method comprises administering to a subject in need thereof a compound disclosed herein (e.g., a compound of Formula (I), (e.g., (I-a), (I-b), (I-c), (I-d), or (I-e))) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition disclosed herein (e.g., a pharmaceutical composition comprising a compound of Formula (I), (e.g., (I-a), (I-b), (I-c), (I-d), or (I-e)), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient). [0015] In some embodiments, the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation of a gene (e.g., KCNT1) is epilepsy, an epilepsy syndrome, or an encephalopathy. [0016] In some embodiments, the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation of a gene (e.g., KCNT1) is a genetic or pediatric epilepsy or a genetic or pediatric epilepsy syndrome. [0017] In some embodiments, the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation of a gene (e.g., KCNT1) is a cardiac dysfunction. [0018] In some embodiments, the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation of a gene (e.g., KCNT1) is selected from epilepsy and other encephalopathies (e.g., malignant migrating focal seizures of infancy (MMFSI) or epilepsy of infancy with migrating focal seizures (EIMFS), autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), West syndrome, infantile spasms, epileptic encephalopathy, focal epilepsy, Ohtahara syndrome, developmental and epileptic encephalopathy, Lennox-Gastaut syndrome, seizures (e.g., Generalized tonic clonic seizures, Asymmetric Tonic Seizures), leukodystrophy, leukoencephalopathy, intellectual disability, Multifocal Epilepsy, Drug resistant epilepsy, Temporal lobe epilepsy, cerebellar ataxia). [0019] In some embodiments, the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation of a
gene (e.g., KCNT1) is chosen from cardiac arrhythmia, Brugada syndrome, and myocardial infarction. [0020] In some embodiments, the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation of a gene (e.g., KCNT1) is selected from pain and related conditions (e.g., neuropathic pain, acute/chronic pain, migraine, etc.). [0021] In some embodiments, the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation of a gene (e.g., KCNT1) is a muscle disorder (e.g., myotonia, neuromyotonia, cramp muscle spasms, spasticity). [0022] In some embodiments, the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation of a gene (e.g., KCNT1) is selected from itch and pruritis, ataxia or cerebellar ataxias. [0023] In some embodiments, the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation of a gene (e.g., KCNT1) is selected from psychiatric disorders (e.g., major depression, anxiety, bipolar disorder, schizophrenia). [0024] In some embodiments, the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation in a gene (e.g., KCNT1) is chosen from a learning disorder, Fragile X, neuronal plasticity, or an autism spectrum disorder. [0025] In some embodiments, the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation of a gene (e.g., KCNT1) is chosen from epileptic encephalopathy with SCN1A, SCN2A, and/or SCN8A mutations, early infantile epileptic encephalopathy, Dravet syndrome, Dravet syndrome with SCN1A mutation, generalized epilepsy with febrile seizures, intractable childhood epilepsy with generalized tonic-clonic seizures, infantile spasms, benign familial neonatal-infantile seizures, SCN2A epileptic encephalopathy, focal epilepsy with SCN3A mutation, cryptogenic pediatric partial epilepsy with SCN3A mutation, SCN8A epileptic encephalopathy, Rasmussen encephalitis, malignant migrating partial seizures of infancy, autosomal dominant nocturnal frontal lobe epilepsy, KCNQ2 epileptic encephalopathy, or KCNT1 epileptic encephalopathy.
[0026] Other objects and advantages will become apparent to those skilled in the art from a consideration of the ensuing Detailed Description, Examples, and Claims. DETAILED DESCRIPTION OF THE DISCLOSURE [0027] Provided herein are compounds and compositions useful for preventing and/or treating a disease, disorder, or condition described herein, e.g., a neurological disorder, a disorder associated with excessive neuronal excitability, or a disorder associated with gain-of-function mutations in a gene (e.g., KCNT1). Exemplary diseases, disorders, or conditions include epilepsy and other encephalopathies (e.g., MMFSI or EIMFS, ADNFLE, West syndrome, infantile spasms, epileptic encephalopathy, focal epilepsy, Ohtahara syndrome, developmental and epileptic encephalopathy, Lennox-Gastaut syndrome, seizures, leukodystrophy, leukoencephalopathy, Intellectual disability, Multifocal Epilepsy, Generalized tonic clonic seizures, Drug resistant epilepsy, Temporal lobe epilepsy, cerebellar ataxia, Asymmetric Tonic Seizures), cardiac dysfunctions (e.g., cardiac arrhythmia, Brugada syndrome, sudden unexpected death in epilepsy, myocardial infarction), pain and related conditions (e.g., neuropathic pain, acute/chronic pain, migraine, etc.), muscle disorders (e.g., myotonia, neuromyotonia, cramp muscle spasms, spasticity), itch and pruritis, ataxia and cerebellar ataxias, and psychiatric disorders (e.g., major depression, anxiety, bipolar disorder, schizophrenia). Definitions Chemical definitions [0028] Definitions of specific functional groups and chemical terms are described in more detail below. The chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in Thomas Sorrell, Organic Chemistry, University Science Books, Sausalito, 1999; Smith and March, March’s Advanced Organic Chemistry, 5th Edition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; and Carruthers, Some Modern Methods of Organic Synthesis, 3rd Edition, Cambridge University Press, Cambridge, 1987.
[0029] Compounds described herein can comprise one or more asymmetric centers, and thus can exist in various isomeric forms, e.g., enantiomers and/or diastereomers. For example, the compounds described herein can be in the form of an individual enantiomer, diastereomer or geometric isomer, or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer. Isomers can be isolated from mixtures by methods described in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric syntheses. See, for example, Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, Stereochemistry of Carbon Compounds (McGraw–Hill, NY, 1962); and Wilen, Tables of Resolving Agents and Optical Resolutions p. 268 (E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972). The compounds described herein encompass both individual isomers substantially free of other isomers, and alternatively, mixtures of various isomers. [0030] As used herein a pure enantiomeric compound is substantially free from other enantiomers or stereoisomers of the compound (i.e., in enantiomeric excess). In other words, an “S” form of the compound is substantially free from the “R” form of the compound and is, thus, in enantiomeric excess of the “R” form. The term “enantiomerically pure” or “pure enantiomer” denotes that the compound comprises more than 75% by weight, more than 80% by weight, more than 85% by weight, more than 90% by weight, more than 91% by weight, more than 92% by weight, more than 93% by weight, more than 94% by weight, more than 95% by weight, more than 96% by weight, more than 97% by weight, more than 98% by weight, more than 98.5% by weight, more than 99% by weight, more than 99.2% by weight, more than 99.5% by weight, more than 99.6% by weight, more than 99.7% by weight, more than 99.8% by weight or more than 99.9% by weight, of the enantiomer. In certain embodiments, the weights are based upon total weight of all enantiomers or stereoisomers of the compound. [0031] In the compositions provided herein, an enantiomerically pure compound can be present with other active or inactive ingredients. For example, a pharmaceutical composition comprising enantiomerically pure R–compound can comprise, for example, about 90% excipient and about 10% enantiomerically pure R–compound. In certain embodiments, the enantiomerically pure R–compound in such compositions can, for example, comprise, at least about 95% by weight R–compound and at most about 5% by weight S–compound, by total weight of the compound.
For example, a pharmaceutical composition comprising enantiomerically pure S–compound can comprise, for example, about 90% excipient and about 10% enantiomerically pure S–compound. In certain embodiments, the enantiomerically pure S–compound in such compositions can, for example, comprise, at least about 95% by weight S–compound and at most about 5% by weight R–compound, by total weight of the compound. In certain embodiments, the active ingredient can be formulated with little or no excipient or carrier. [0032] Compound described herein may also comprise one or more isotopic substitutions. For example, H may be in any isotopic form, including 1H, 2H (D or deuterium), and 3H (T or tritium); C may be in any isotopic form, including 12C, 13C, and 14C; O may be in any isotopic form, including 16O and 18O; F may be in any isotopic form, including 18F and 19F; and the like. [0033] The following terms are intended to have the meanings presented therewith below and are useful in understanding the description and intended scope of the present disclosure. When describing the embodiments, which may include compounds and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing such compounds and methods of using such compounds and compositions, the following terms, if present, have the following meanings unless otherwise indicated. It should also be understood that when described herein any of the moieties defined forth below may be substituted with a variety of substituents, and that the respective definitions are intended to include such substituted moieties within their scope as set out below. Unless otherwise stated, the term “substituted” is to be defined as set out below. It should be further understood that the terms “groups” and “radicals” can be considered interchangeable when used herein. The articles “a” and “an” may be used herein to refer to one or to more than one (i.e. at least one) of the grammatical objects of the article. By way of example “an analogue” means one analogue or more than one analogue. [0034] When a range of values is listed, it is intended to encompass each value and sub– range within the range. For example, “C1–6 alkyl” is intended to encompass, C1, C2, C3, C4, C5, C6, C1–6, C1–5, C1–4, C1–3, C1–2, C2–6, C2–5, C2–4, C2–3, C3–6, C3–5, C3–4, C4–6, C4–5, and C5–6 alkyl. [0035] As used herein, “alkyl” refers to a radical of a straight–chain or branched saturated hydrocarbon group, e.g., having 1 to 20 carbon atoms (“C1–20 alkyl”). In some embodiments, an alkyl group has 1 to 10 carbon atoms (“C1–10 alkyl”). In some embodiments, an alkyl group has 1 to 9 carbon atoms (“C1–9 alkyl”). In some embodiments, an alkyl group has 1 to 8 carbon atoms (“C1–8 alkyl”). In some embodiments, an alkyl group has 1 to 7 carbon atoms (“C1–7 alkyl”). In
2ome embodiments, an alkyl group has 1 to 6 carbon atoms (“C1–6 alkyl”). In some embodiments, an alkyl group has 1 to 5 carbon atoms (“C1–5 alkyl”). In some embodiments, an alkyl group has 1 to 4 carbon atoms (“C1–4 alkyl”). In some embodiments, an alkyl group has 1 to 3 carbon atoms (“C1–3 alkyl”). In some embodiments, an alkyl group has 1 to 2 carbon atoms (“C1-2 alkyl”). In some embodiments, an alkyl group has 1 carbon atom (“C1 alkyl”). Examples of C1–6 alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, hexyl, and the like. [0036] The term “heteroalkyl” as used herein refers to an “alkyl” group in which at least one carbon atom has been replaced with an O or S atom. The heteroalkyl may be, for example, an –O-C1-C10alkyl group, an -C1-C6alkylene-O-C1-C6alkyl group, or a C1-C6 alkylene-OH group. In certain embodiments, the “heteroalkyl” may be 2-8 membered heteroalkyl, indicating that the heteroalkyl contains from 2 to 8 atoms selected from the group consisting of carbon, oxygen, nitrogen, and sulfur. In yet other embodiments, the heteroalkyl may be a 2-6 membered, 4-8 membered, or a 5-8 membered heteroalkyl group (which may contain for example 1 or 2 heteroatoms selected from the group oxygen and nitrogen). In certain embodiments, the heteroalkyl is an “alkyl” group in which 1-3 carbon atoms have been replaced with oxygen atoms. One type of heteroalkyl group is an “alkoxy” group. [0037] As used herein, “alkenyl” refers to a radical of a straight–chain or branched hydrocarbon group having from 2 to 20 carbon atoms, one or more carbon–carbon double bonds (e.g., 1, 2, 3, or 4 carbon–carbon double bonds), and optionally one or more carbon–carbon triple bonds (e.g., 1, 2, 3, or 4 carbon–carbon triple bonds) (“C1–20alkenyl”). In certain embodiments, alkenyl does not contain any triple bonds. In some embodiments, an alkenyl group has 2 to 10 carbon atoms (“C1–10alkenyl”). In some embodiments, an alkenyl group has 2 to 9 carbon atoms (“C2–9 alkenyl”). In some embodiments, an alkenyl group has 2 to 8 carbon atoms (“C2–8 alkenyl”). In some embodiments, an alkenyl group has 2 to 7 carbon atoms (“C2–7 alkenyl”). In some embodiments, an alkenyl group has 2 to 6 carbon atoms (“C2–6 alkenyl”). In some embodiments, an alkenyl group has 2 to 5 carbon atoms (“C2–5 alkenyl”). In some embodiments, an alkenyl group has 2 to 4 carbon atoms (“C2–4 alkenyl”). In some embodiments, an alkenyl group has 2 to 3 carbon atoms (“C2–3 alkenyl”). In some embodiments, an alkenyl group has 2 carbon atoms (“C2 alkenyl). The one or more carbon–carbon double bonds can be internal (such as in 2– butenyl) or terminal (such as in 1–butenyl). Examples of C2–4 alkenyl groups include ethenyl (C2), 1–propenyl (C3), 2–propenyl (C3), 1–butenyl (C4), 2–butenyl (C4), butadienyl (C4), and the like.
Examples of C2–6 alkenyl groups include the aforementioned C2–4 alkenyl groups as well as pentenyl (C5), pentadienyl (C5), hexenyl (C6), and the like. Additional examples of alkenyl include heptenyl (C7), octenyl (C8), octatrienyl (C8), and the like. [0038] As used herein, “alkynyl” refers to a radical of a straight–chain or branched hydrocarbon group having from 2 to 20 carbon atoms, one or more carbon–carbon triple bonds (e.g., 1, 2, 3, or 4 carbon–carbon triple bonds), and optionally one or more carbon–carbon double bonds (e.g., 1, 2, 3, or 4 carbon–carbon double bonds) (“C2–20 alkynyl”). In certain embodiments, alkynyl does not contain any double bonds. In some embodiments, an alkynyl group has 2 to 10 carbon atoms (“C2–10 alkynyl”). In some embodiments, an alkynyl group has 2 to 9 carbon atoms (“C2–9 alkynyl”). In some embodiments, an alkynyl group has 2 to 8 carbon atoms (“C2–8 alkynyl”). In some embodiments, an alkynyl group has 2 to 7 carbon atoms (“C2–7 alkynyl”). In some embodiments, an alkynyl group has 2 to 6 carbon atoms (“C2–6 alkynyl”). In some embodiments, an alkynyl group has 2 to 5 carbon atoms (“C2–5 alkynyl”). In some embodiments, an alkynyl group has 2 to 4 carbon atoms (“C2–4 alkynyl”). In some embodiments, an alkynyl group has 2 to 3 carbon atoms (“C2–3 alkynyl”). In some embodiments, an alkynyl group has 2 carbon atoms (“C2 alkynyl”). The one or more carbon–carbon triple bonds can be internal (such as in 2–butynyl) or terminal (such as in 1–butynyl). Examples of C2–4 alkynyl groups include, without limitation, ethynyl (C2), 1–propynyl ( C3), 2–propynyl (C3), 1–butynyl (C4), 2–butynyl (C4), and the like. Examples of C2–6 alkenyl groups include the aforementioned C2–4 alkynyl groups as well as pentynyl (C5), hexynyl (C6), and the like. Additional examples of alkynyl include heptynyl (C7), octynyl (C8), and the like. [0039] As used herein, “alkylene,” “alkenylene,” and “alkynylene,” refer to a divalent radical of an alkyl, alkenyl, and alkynyl group respectively. When a range or number of carbons is provided for a particular “alkylene,” “alkenylene,” or “alkynylene,” group, it is understood that the range or number refers to the range or number of carbons in the linear carbon divalent chain. “Alkylene,” “alkenylene,” and “alkynylene,” groups may be substituted or unsubstituted with one or more substituents as described herein. [0040] As used herein, “aryl” refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 π electrons shared in a cyclic array) having 6–14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system (“C6–14 aryl”). In some embodiments, an aryl group has six ring carbon atoms (“C6 aryl”;
e.g., phenyl). In some embodiments, an aryl group has ten ring carbon atoms (“C10 aryl”; e.g., naphthyl such as 1–naphthyl and 2–naphthyl). In some embodiments, an aryl group has fourteen ring carbon atoms (“C14 aryl”; e.g., anthracyl). “Aryl” also includes ring systems wherein the aryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the radical or point of attachment is on the aryl ring, and in such instances, the number of carbon atoms continue to designate the number of carbon atoms in the aryl ring system. Typical aryl groups include, but are not limited to, groups derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, and trinaphthalene. Particularly aryl groups include phenyl, naphthyl, indenyl, and tetrahydronaphthyl. [0041] As used herein, “heteroaryl” refers to a radical of a 5–10 membered monocyclic or bicyclic 4n+2 aromatic ring system (e.g., having 6 or 10 electrons shared in a cyclic array) having ring carbon atoms and 1–4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur (“5–10 membered heteroaryl”). In heteroaryl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. Heteroaryl bicyclic ring systems can include one or more heteroatoms in one or both rings. “Heteroaryl” includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the point of attachment is on the heteroaryl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heteroaryl ring system. “Heteroaryl” also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment is either on the aryl or heteroaryl ring, and in such instances, the number of ring members designates the number of ring members in the fused (aryl/heteroaryl) ring system. Bicyclic heteroaryl groups wherein one ring does not contain a heteroatom (e.g., indolyl, quinolinyl, carbazolyl, and the like) the point of attachment can be on either ring, i.e., either the ring bearing a heteroatom (e.g., 2–indolyl) or the ring that does not contain a heteroatom (e.g., 5–indolyl).
[0042] In some embodiments, a heteroaryl group is a 5–10 membered aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5–10 membered heteroaryl”). In some embodiments, a heteroaryl group is a 5–8 membered aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5–8 membered heteroaryl”). In some embodiments, a heteroaryl group is a 5–6 membered aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5–6 membered heteroaryl”). In some embodiments, the 5–6 membered heteroaryl has 1–3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5–6 membered heteroaryl has 1–2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5–6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur. [0043] Exemplary 5–membered heteroaryl groups containing one heteroatom include, without limitation, pyrrolyl, furanyl and thiophenyl. Exemplary 5–membered heteroaryl groups containing two heteroatoms include, without limitation, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5–membered heteroaryl groups containing three heteroatoms include, without limitation, triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary 5– membered heteroaryl groups containing four heteroatoms include, without limitation, tetrazolyl. Exemplary 6–membered heteroaryl groups containing one heteroatom include, without limitation, pyridinyl. Exemplary 6–membered heteroaryl groups containing two heteroatoms include, without limitation, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6–membered heteroaryl groups containing three or four heteroatoms include, without limitation, triazinyl and tetrazinyl, respectively. Exemplary 7–membered heteroaryl groups containing one heteroatom include, without limitation, azepinyl, oxepinyl, and thiepinyl. Exemplary 5,6–bicyclic heteroaryl groups include, without limitation, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, and purinyl. Exemplary 6,6–bicyclic heteroaryl groups include, without limitation, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.
[0044] Examples of representative heteroaryls include the following:
wherein each Z is selected from carbonyl, N, NR65, O, and S; and R65 is independently hydrogen, C1-C8 alkyl, C3-C10 carbocyclyl, 4-10 membered heterocyclyl, C6-C10 aryl, and 5-10 membered heteroaryl. [0045] As used herein, “carbocyclyl” or “carbocyclic” refers to a radical of a non–aromatic cyclic hydrocarbon group having from 3 to 10 ring carbon atoms (“C3–10 carbocyclyl”) and zero heteroatoms in the non–aromatic ring system. In some embodiments, a carbocyclyl group has 3 to 8 ring carbon atoms (“C3–8 carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms (“C3–6 carbocyclyl”). In some embodiments, a carbocyclyl group has 5 to 10 ring carbon atoms (“C5–10 carbocyclyl”). Exemplary C3–6 carbocyclyl groups include, without limitation, cyclopropyl (C3),cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), and the like. Exemplary C3–8 carbocyclyl groups include, without limitation, the aforementioned C3–6 carbocyclyl groups as well as cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (C8), cyclooctenyl (C8), bicyclo[2.2.1]heptanyl (C7), bicyclo[2.2.2]octanyl (C8), and the like. Exemplary C3–10 carbocyclyl groups include, without limitation, the aforementioned C3– 8 carbocyclyl groups as well as cyclononyl (C9), cyclononenyl (C9), cyclodecyl (C10), cyclodecenyl (C10), octahydro–1H–indenyl (C9), decahydronaphthalenyl (C10), spiro[4.5]decanyl (C10), and the like. As the foregoing examples illustrate, in certain embodiments, the carbocyclyl group is either monocyclic (“monocyclic carbocyclyl”) or contain a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic carbocyclyl”) and can be saturated or can be partially
unsaturated. “Carbocyclyl” also includes ring systems wherein the carbocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups wherein the point of attachment is on the carbocyclyl ring, and in such instances, the number of carbons continue to designate the number of carbons in the carbocyclic ring system. [0046] The term “cycloalkyl” refers to a monovalent saturated cyclic, bicyclic, or bridged cyclic (e.g., adamantyl) hydrocarbon group of 3-12, 3-8, 4-8, or 4-6 carbons, referred to herein, e.g., as "C4-8cycloalkyl," derived from a cycloalkane. Exemplary cycloalkyl groups include, but are not limited to, cyclohexanes, cyclopentanes, cyclobutanes and cyclopropanes. Unless specified otherwise, cycloalkyl groups are optionally substituted at one or more ring positions with, for example, alkanoyl, alkoxy, alkyl, haloalkyl, alkenyl, alkynyl, amido, amidino, amino, aryl, arylalkyl, azido, carbamate, carbonate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, imino, ketone, nitro, phosphate, phosphonato, phosphinato, sulfate, sulfide, sulfonamido, sulfonyl or thiocarbonyl. Cycloalkyl groups can be fused to other cycloalkyl, aryl, or heterocyclyl groups. In certain embodiments, the cycloalkyl group is not substituted, i.e., it is unsubstituted. [0047] As used herein, “heterocyclyl” or “heterocyclic” refers to a radical of a 3– to 10–membered non–aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon (“3–10 membered heterocyclyl”). In heterocyclyl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. A heterocyclyl group can either be monocyclic (“monocyclic heterocyclyl”) or a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic heterocyclyl”), and can be saturated or can be partially unsaturated. Heterocyclyl bicyclic ring systems can include one or more heteroatoms in one or both rings. “Heterocyclyl” also includes ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more carbocyclyl groups wherein the point of attachment is either on the carbocyclyl or heterocyclyl ring, or ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclyl ring, and in such instances, the number of ring
members continue to designate the number of ring members in the heterocyclyl ring system. [0048] In some embodiments, a heterocyclyl group is a 5–10 membered non–aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon (“5–10 membered heterocyclyl”). In some embodiments, a heterocyclyl group is a 5–8 membered non– aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5–8 membered heterocyclyl”). In some embodiments, a heterocyclyl group is a 5–6 membered non–aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5–6 membered heterocyclyl”). In some embodiments, the 5–6 membered heterocyclyl has 1–3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5–6 membered heterocyclyl has 1–2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5–6 membered heterocyclyl has one ring heteroatom selected from nitrogen, oxygen, and sulfur. [0049] Exemplary 3–membered heterocyclyl groups containing one heteroatom include, without limitation, azirdinyl, oxiranyl, thiorenyl. Exemplary 4–membered heterocyclyl groups containing one heteroatom include, without limitation, azetidinyl, oxetanyl and thietanyl. Exemplary 5–membered heterocyclyl groups containing one heteroatom include, without limitation, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl and pyrrolyl–2,5–dione. Exemplary 5–membered heterocyclyl groups containing two heteroatoms include, without limitation, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one. Exemplary 5–membered heterocyclyl groups containing three heteroatoms include, without limitation, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6–membered heterocyclyl groups containing one heteroatom include, without limitation, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6–membered heterocyclyl groups containing two heteroatoms include, without limitation, piperazinyl, morpholinyl, dithianyl, dioxanyl. Exemplary 6–membered heterocyclyl groups containing two heteroatoms include, without limitation, triazinanyl. Exemplary 7–membered heterocyclyl groups containing one heteroatom include, without limitation, azepanyl, oxepanyl and thiepanyl. Exemplary 8–membered heterocyclyl groups containing one heteroatom include, without limitation, azocanyl, oxecanyl and thiocanyl. Exemplary 5-membered heterocyclyl groups fused
to a C6 aryl ring (also referred to herein as a 5,6-bicyclic heterocyclic ring) include, without limitation, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl, and the like. Exemplary 6-membered heterocyclyl groups fused to an aryl ring (also referred to herein as a 6,6-bicyclic heterocyclic ring) include, without limitation, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like. [0050] “Hetero” when used to describe a compound or a group present on a compound means that one or more carbon atoms in the compound or group have been replaced by a nitrogen, oxygen, or sulfur heteroatom. Hetero may be applied to any of the hydrocarbyl groups described above such as alkyl, e.g., heteroalkyl; carbocyclyl, e.g., heterocyclyl; aryl, e.g,. heteroaryl; and the like having from 1 to 5, and particularly from 1 to 3 heteroatoms. [0051] As used herein, “cyano” refers to -CN. [0052] As used herein, “halo” or ”halogen” refers to fluoro (F), chloro (Cl), bromo (Br) and iodo (I). In certain embodiments, the halo group is either fluoro or chloro. [0053] As used herein, “haloalkyl” refers to an alkyl group substituted with one or more halogen atoms. [0054] As used herein, “nitro” refers to -NO2. [0055] As used herein, “oxo” refers to -C=O. [0056] In general, the term “substituted”, whether preceded by the term “optionally” or not, means that at least one hydrogen present on a group (e.g., a carbon or nitrogen atom) is replaced with a permissible substituent, e.g., a substituent which upon substitution results in a stable compound, e.g., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction. Unless otherwise indicated, a “substituted” group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent is either the same or different at each position. [0057] Nitrogen atoms can be substituted or unsubstituted as valency permits, and include primary, secondary, tertiary, and quarternary nitrogen atoms. Exemplary nitrogen atom substituents include, but are not limited to, hydrogen, –OH, –ORaa, –N(Rcc)2, –CN, –C(=O)Raa, –C(=O)N(Rcc)2, –CO2Raa, –SO2Raa, –C(=NRbb)Raa, –C(=NRcc)ORaa, – C(=NRcc)N(Rcc)2, –SO2N(Rcc)2, –SO2Rcc, –SO2ORcc, –SORaa, –C(=S)N(Rcc)2, –
C(=O)SRcc, –C(=S)SRcc, –P(=O)2Raa, –P(=O)(Raa)2, –P(=O)2N(Rcc)2, –P(=O)(NRcc)2, C1–10 alkyl, C1–10 perhaloalkyl, C2–10 alkenyl, C2–10 alkynyl, C3–10 carbocyclyl, 3–14 membered heterocyclyl, C6–14 aryl, and 5–14 membered heteroaryl, or two Rcc groups attached to a nitrogen atom are joined to form a 3–14 membered heterocyclyl or 5–14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rdd groups, and wherein Raa, Rbb, Rcc and Rdd are as defined above. [0058] These and other exemplary substituents are described in more detail in the Detailed Description, Examples, and Claims. The disclosure is not intended to be limited in any manner by the above exemplary listing of substituents. Other definitions [0059] The terms “in some embodiments,” “in other embodiments,” or the like, refer to embodiments of all aspects of the disclosure, unless the context clearly indicated otherwise. [0060] The term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. The general concept of pharmaceutically acceptable salts has been discussed in the art, including, for example, Berge et al., which describes pharmaceutically acceptable salts in detail in J Pharmaceutical Sciences (1977) 66: 1-19. Pharmaceutically acceptable salts of the compounds described herein include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2–hydroxy–ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2– naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate,
3–phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p–toluenesulfonate, undecanoate, valerate salts, and the like. Pharmaceutically acceptable salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+(C1–4alkyl)4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate. [0061] As used herein, a “subject” to which administration is contemplated includes, but is not limited to, humans (i.e., a male or female of any age group, e.g., a pediatric subject (e.g, an infant, child, adolescent) or an adult subject (e.g., a young adult, middle–aged adult, or senior adult)) and/or a non-human animal, e.g., a mammal such as primates (e.g., cynomolgus monkeys, rhesus monkeys), cattle, pigs, horses, sheep, goats, rodents, cats, and/or dogs. In certain embodiments, the subject is a human. In certain embodiments, the subject is a non-human animal. The terms “human,” “patient,” and “subject” are used interchangeably herein. [0062] Disease, disorder, and condition are used interchangeably herein. [0063] As used herein, and unless otherwise specified, the terms “treat,” “treating” and “treatment” contemplate an action that occurs while a subject is suffering from the specified disease, disorder or condition, which reduces the severity of the disease, disorder or condition, or retards or slows the progression of the disease, disorder or condition (also “therapeutic treatment”). [0064] In general, the “effective amount” of a compound or pharmaceutically acceptable salt thereof refers to an amount sufficient to elicit the desired biological response. As will be appreciated by those of ordinary skill in this art, the effective amount of a compound or pharmaceutically acceptable salt thereof as disclosed herein may vary depending on such factors as the desired biological endpoint, the pharmacokinetics of the compound or pharmaceutically acceptable salt thereof, the disease being treated, the mode of administration, and the age, weight, health, and condition of the subject. [0065] As used herein, and unless otherwise specified, a “therapeutically effective amount” of a compound or pharmaceutically acceptable salt thereof is an amount sufficient to provide a therapeutic benefit in the treatment of a disease, disorder or condition, or to delay or
minimize one or more symptoms associated with the disease, disorder or condition. A therapeutically effective amount of a compound or pharmaceutically acceptable salt thereof means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment of the disease, disorder or condition. The term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of disease or condition, or enhances the therapeutic efficacy of another therapeutic agent. [0066] In an alternate embodiment, provided herein are methods of treating comprising administering the compounds disclosed herein or a pharmaceutically acceptable salt or a pharmaceutically acceptable composition thereof, as a prophylactic before a subject begins to suffer from the specified disease, disorder or condition. As used herein, “prophylactic treatment” contemplates an action that occurs before a subject begins to suffer from the specified disease, disorder or condition. As used herein, and unless otherwise specified, a “prophylactically effective amount” of a compound or pharmaceutically acceptable salt thereof is an amount sufficient to prevent a disease, disorder or condition, or one or more symptoms associated with the disease, disorder or condition, or prevent its recurrence. A prophylactically effective amount of a compound or pharmaceutically acceptable salt thereof means an amount of a therapeutic agent, alone or in combination with other agents, which provides a prophylactic benefit in the prevention of the disease, disorder or condition. The term “prophylactically effective amount” can encompass an amount that improves overall prophylaxis or enhances the prophylactic efficacy of another prophylactic agent. [0067] As used herein, a “disorder associated with a gain-of-function mutation in KCNT1” refers to a disorder that is associated with, is partially or completely caused by, or has one or more symptoms that are partially or completely caused by, a mutation in KCNT1 that results in a gain- of-function phenotype, i.e. an increase in activity of the potassium channel encoded by KCNT1 resulting in an increase in whole cell current. [0068] As used herein, a “gain-of-function mutation” is a mutation in KCNT1 that results in an increase in activity of the potassium channel encoded by KCNT1. Activity can be assessed by, for example, ion flux assay or electrophysiology (e.g. using the whole cell patch clamp technique). Typically, a gain-of-function mutation results in an increase of at least or about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 125%, 150%, 175%, 200%, 225%, 250%, 275%,
300%, 325%, 350%, 375%, 400% or more compared to the activity of a potassium channel encoded by a wild-type KCNT1. Compounds and Compositions [0069] In one aspect, disclosed herein is a compound of Formula (I) having an oxadiazole core:
or a pharmaceutically acceptable salt thereof, wherein R1 is chosen from a C1-6alkyl, a C1-6haloalkyl, and a C3-10cycloalkyl, wherein the C1-6alkyl, C1-6haloalkyl, and C3-10cycloalkyl optionally comprises a substituent chosen from a C1-6alkoxy or N(R8)2; R2 is chosen from hydrogen or a C1-4alkyl; R3 is a C1-6alkyl optionally comprising a C1-6alkoxy substituent; R4 is chosen from hydrogen or a C1-6alkyl; R5 is chosen from a C1-6alkyl or a C1-6haloalkyl; R6 is chosen from hydrogen, a C1-6alkyl, a C3-10cycloalkyl, a phenyl, or a 3-10 membered heterocyclyl, wherein the C1-6alkyl, C3-10cycloalkyl, phenyl, or 3-10 membered heterocyclyl may optionally comprise one or more substituents chosen from a halogen, -CN, -OH, a C1-6alkyl, a C1- 6haloalkyl, a C1-6alkoxy, a phenyl, a C3-10cycloalkyl, or a 3-10 membered heterocyclyl; R7 is chosen from a C1-6alkyl, a C3-10cycloalkyl, a phenyl, or a 3-10 membered heterocyclyl, wherein the C1-6alkyl, C3-10cycloalkyl, phenyl, or 3-10 membered heterocyclyl may optionally comprise one or more substituents chosen from a halogen, -CN, -OH, a C1-6alkyl, a C1-6haloalkyl, a C1-6alkoxy, a phenyl, a C3-10cycloalkyl, or a 3-10 membered heterocyclyl; or R6 and R7 are taken together with the nitrogen attached to R6 and R7 to form a 3-10 membered heterocyclyl ring optionally comprising one or more substituents chosen from a halogen, -CN, -OH, a C1-6alkyl, a C1-6haloalkyl, a phenyl, a C3-10cycloalkyl, or a 3-10 membered heterocyclyl, wherein the C1-6alkyl is optionally substituted with oxo; each R8 is independently chosen from hydrogen or a C1-6alkyl; and
x is 0, 1 or 2. [0070] In some embodiments, the compound of Formula I is a compound of Formula I-a:
or a pharmaceutically acceptable salt thereof. [0071] In some embodiments, the compound of Formula I is a compound of Formula I-b:
or a pharmaceutically acceptable salt thereof. [0072] In some embodiments, the compound of Formula I is a compound of Formula I-c:
or a pharmaceutically acceptable salt thereof. [0073] In some embodiments, the compound of Formula I is a compound of Formula I-d or I-e:
or a pharmaceutically acceptable salt thereof. [0074] In some embodiments, R3 is C1-6alkyl and R4 is hydrogen. [0075] In some embodiments, R2 is hydrogen. [0076] In some embodiments, R1 is C1-6alkyl. In some embodiments, R1 is methyl. [0077] In some embodiments, x is 1 or 2. In some embodiments, x is 1. [0078] In some embodiments, R5 is C1-6haloalkyl. In some embodiments, R5 is -CF3. [0079] In some embodiments, R6 is hydrogen and R7 is C1-6alkyl.
[0080] In some embodiments, R6 and R7 are each C1-6alkyl optionally comprising a phenyl substituent. [0081] In some embodiments, R6 and R7 are taken together with the nitrogen attached to R6 and R7 to form a 3-10 membered heterocyclyl ring optionally comprising one or more substituents chosen from a halogen, a C1-6alkyl, or a C1-6haloalkyl. [0082] In some embodiments, the compound is chosen from:
, or a pharmaceutically acceptable salt thereof. [0083] In another aspect, provided herein is a pharmaceutical composition comprising a compound disclosed herein or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient. General Synthetic Schemes [0084] Exemplary methods for preparing compounds described herein are illustrated in the following synthetic schemes. These schemes are given for the purpose of illustrating exemplary embodiments, and should not be regarded in any manner as limiting the scope or the spirit of the disclosure.
SCHEME 1
[0085] The synthetic route illustrated in Scheme 1 depicts an exemplary procedure for preparing intermediate F. In the first step, amine A is treated with cyanogen bromide to provide nitrile B, which is then treated with hydroxylamine to provide N-hydroxyimidamide C. Then, N,N'-dicyclohexylcarbodiimide (DCC)-mediated cyclization of C with glycine D affords oxadiazole E. Deprotection of E under acidic conditions provides intermediate F. SCHEME 2
[0086] The synthetic route illustrated in Scheme 2 depicts an exemplary procedure for preparing H (a compound of Formula I). Coupling of intermediate F with carboxylic acid G using standard peptide coupling procedures (e.g., HATU in dichloromethane in the presence of DIPEA) provides compound H (a compound of Formula I). Methods of Treatment [0087] The compounds and compositions described above and herein can be used to treat a neurological disease, a disorder associated with excessive neuronal excitability, or disorder associated with a gain-of-function mutation in a gene (e.g., KCNT1). Exemplary diseases, disorders, or conditions include epilepsy and other encephalopathies (e.g., MMFSI or EIMFS,
ADNFLE, West syndrome, infantile spasms, epileptic encephalopathy, developmental and epileptic encephalopathy (DEE), early infantile epileptic encephalopathy (EIEE), generalized epilepsy, focal epilepsy, multifocal epilepsy, temporal lobe epilepsy, Ohtahara syndrome, early myoclonic encephalopathy, Lennox-Gastaut syndrome, drug-resistant epilepsy, seizures (e.g., frontal lobe seizures, generalized tonic clonic seizures, asymmetric tonic seizures, focal seizures), leukodystrophy, hypomyelinating leukodystrophy, leukoencephalopathy, and sudden unexpected death in epilepsy, cardiac dysfunctions (e.g., cardiac arrhythmia, Brugada syndrome, myocardial infarction), pulmonary vasculopathy / hemorrhage, pain and related conditions (e.g., neuropathic pain, acute/chronic pain, migraine, etc.), muscle disorders (e.g., myotonia, neuromyotonia, cramp muscle spasms, spasticity), itch and pruritis, movement disorders (e.g., ataxia and cerebellar ataxias), psychiatric disorders (e.g., major depression, anxiety, bipolar disorder, schizophrenia, attention-deficit hyperactivity disorder), neurodevelopmental disorder, learning disorders, intellectual disability, Fragile X, neuronal plasticity, and autism spectrum disorders. [0088] In some embodiments, the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation in a gene (e.g., KCNT1) is selected from EIMFS, ADNFLE and West syndrome. In some embodiments, the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation in a gene (e.g., KCNT1) is selected from infantile spasms, epileptic encephalopathy, focal epilepsy, Ohtahara syndrome, developmental and epileptic encephalopathy, and Lennox-Gastaut syndrome. In some embodiments, the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation in a gene (e.g., KCNT1) is seizure. In some embodiments, the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation in a gene (e.g., KCNT1) is selected from cardiac arrhythmia, Brugada syndrome, and myocardial infarction. [0089] In some embodiments, the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation in a gene (e.g., KCNT1) is chosen from a learning disorder, Fragile X, intellectual function, neuronal plasticity, psychiatric disorders, or an autism spectrum disorder. [0090] Accordingly, the compounds and compositions thereof can be administered to a subject with a neurological disorder, a disorder associated with excessive neuronal excitability, or
the disorder associated with a gain-of-function mutation in a gene such as KCNT1 (e.g., EIMFS, ADNFLE, West syndrome, infantile spasms, epileptic encephalopathy, focal epilepsy, Ohtahara syndrome, developmental and epileptic encephalopathy, Lennox-Gastaut syndrome, seizures, cardiac arrhythmia, Brugada syndrome, and myocardial infarction). [0091] EIMFS is a rare and debilitating genetic condition characterized by an early onset (before 6 months of age) of almost continuous heterogeneous focal seizures, where seizures appear to migrate from one brain region and hemisphere to another. Patients with EIMFS are generally intellectually impaired, non-verbal and non-ambulatory. While several genes have been implicated to date, the gene that is most commonly associated with EIMFS is KCNT1. Several de novo mutations in KCNT1 have been identified in patients with EIMFS, including V271F, G288S, R428Q, R474Q, R474H, R474C, I760M, A934T, P924L, G243S, H257D, A259D, R262Q, Q270E, L274I, F346L, C377S, R398Q, P409S, A477T, F502V, M516V, Q550del, K629E, K629N, I760F, E893K, M896K, R933G, R950Q, K1154Q. Barcia et al. (2012) Nat Genet. 44: 1255-1260; Ishii et al. (2013) Gene 531:467-471; McTague et al. (2013) Brain. 136: 1578-1591; Epi4K Consortium & Epilepsy Phenome/Genome Project. (2013) Nature 501:217-221; Lim et al. (2016) Neurogenetics; Ohba et al. (2015) Epilepsia 56:el21-el28; Zhou et al. (2018) Genes Brain Behav. e12456; Moller et al. (2015) Epilepsia. e114-20; Numis et al. (2018) Epilepsia.1889-1898; Madaan et al. Brain Dev. 40(3):229-232; McTague et al. (2018) Neurology. 90(1):e55-e66; Kawasaki et al. (2017) J Pediatr. 191:270-274; Kim et al. (2014) Cell Rep. 9(5):1661-1672; Ohba et al. (2015) Epilepsia. 56(9):e121-8; Rizzo et al. (2016) Mol Cell Neurosci. 72:54-63; Zhang et al. (2017) Clin Genet.91(5):717-724; Mikati et al. (2015) Ann Neurol. 78(6):995-9; Baumer et al. (2017) Neurology. 89(21):2212; Dilena et al. (2018) Neurotherapeutics. 15(4):1112-1126. These mutations may be gain-of-function, missense mutations that are dominant (i.e., present on only one allele) and result in change-in-function of the encoded potassium channel that causes a marked increase in whole cell current when tested in Xenopus oocyte or mammalian expression systems (see e.g. Milligan et al. (2015) Ann Neurol.75(4): 581-590; Barcia et al. (2012) Nat Genet.44(11): 1255-1259; and Mikati et al. (2015) Ann Neurol. 78(6): 995-999). [0092] ADNFLE has a later onset than EIMFS, generally in mid-childhood, and is generally a less severe condition. It is characterized by nocturnal frontal lobe seizures and can result in psychiatric, behavioural and cognitive disabilities in patients with the condition. While ADNFLE is associated with genes encoding several neuronal nicotinic acetylcholine receptor
subunits, mutations in the KCNT1 gene have been implicated in more severe cases of the disease (Heron et al. (2012) Nat Genet. 44: 1188-1190). Functional studies of the mutated KCNT1 genes associated with ADNFLE indicated that the underlying mutations (M896I, R398Q, Y796H and R928C) were dominant, gain-of-function mutations (Milligan et al. (2015) Ann Neurol. 75(4): 581-590; Mikati et al. (2015) Ann Neurol. 78(6): 995-999). [0093] West syndrome is a severe form of epilepsy composed of a triad of infantile spasms, an interictal electroencephalogram (EEG) pattern termed hypsarrhythmia, and mental retardation, although a diagnosis can be made one of these elements is missing. Mutations in KCNT1, including G652V and R474H, have been associated with West syndrome (Fukuoka et al. (2017) Brain Dev 39:80-83 and Ohba et al. (2015) Epilepsia 56:el21-el28). Treatment targeting the KCNT1 channel suggests that these mutations are gain-of-function mutations (Fukuoka et al. (2017) Brain Dev 39:80-83). [0094] In one aspect, disclosed herein is a method of treating treat a disorder associated with excessive neuronal excitability or a disorder associated with a gain-of-function mutation in a gene such as KCNT1 (for example, epilepsy and other encephalopathies (e.g., MMFSI or EIMFS, ADNFLE, West syndrome, infantile spasms, epileptic encephalopathy, focal epilepsy, Ohtahara syndrome, DEE, Lennox-Gastaut syndrome, seizures, leukodystrophy, leukoencephalopathy, intellectual disability, Multifocal Epilepsy, Generalized tonic clonic seizures, drug-resistant epilepsy, Temporal lobe epilepsy, cerebellar ataxia, Asymmetric Tonic Seizures); cardiac dysfunctions (e.g., cardiac arrhythmia, Brugada syndrome, sudden unexpected death in epilepsy, myocardial infarction); pain and related conditions (e.g., neuropathic pain, acute/chronic pain, migraine, etc.); muscle disorders (e.g., myotonia, neuromyotonia, cramp muscle spasms, spasticity); itch and pruritis; ataxia and cerebellar ataxias; psychiatric disorders (e.g., major depression, anxiety, bipolar disorder, schizophrenia), learning disorders, Fragile X, neuronal plasticity, and autism spectrum disorders) comprising administering to a subject in need thereof a compound disclosed herein (e.g., a compound of Formula (I), (e.g., (I-a), (I-b), (I-c), (I-d), or (I- e)) or a pharmaceutically acceptable salt thereof) or a pharmaceutical composition disclosed herein (e.g., a pharmaceutical composition comprising a compound disclosed herein (e.g., a compound of Formula (I), (e.g., (I-a), (I-b), (I-c), (I-d), or (I-e)) or a pharmaceutically acceptable salt thereof), and a pharmaceutically acceptable excipient).
[0095] In some examples, the subject presenting with a disorder that may be associated with a gain-of-function mutation in KCNT1 is genotyped to confirm the presence of a known gain- of-function mutation in KCNT1 prior to administration of the compounds or a pharmaceutically acceptable salt thereof or and compositions disclosed herein. For example, whole exome sequencing can be performed on the subject. Gain-of-function mutations associated with EIMFS may include, but are not limited to, V271F, G288S, R428Q, R474Q, R474H, R474C, I760M, A934T, P924L, G243S, H257D, A259D, R262Q, Q270E, L274I, F346L, C377S, R398Q, P409S, A477T, F502V, M516V, Q550del, K629E, K629N, I760F, E893K, M896K, R933G, R950Q, and K1154Q. Gain-of-function mutations associated with ADNFLE may include, but are not limited to, M896I, R398Q, Y796H, R928C, and G288S. Gain-of-function mutations associated with West syndrome may include, but are not limited to, G652V and R474H. Gain-of-function mutations associated with temporal lobe epilepsy may include, but are not limited to, R133H and R565H. Gain-of-function mutations associated with Lennox-Gastaut may include, but are not limited to, R209C. Gain-of-function mutations associated with seizures may include, but are not limited to, A259D, G288S, R474C, R474H. Gain-of-function mutations associated with leukodystrophy may include, but are not limited to, G288S and Q906H. Gain-of-function mutations associated with Multifocal Epilepsy may include, but are not limited to, V340M. Gain-of-function mutations associated with early-onset epilepsy (EOE) may include, but are not limited to, F346L and A934T. Gain-of-function mutations associated with Early-onset epileptic encephalopathies (EOEE) may include, but are not limited to, R428Q. Gain-of-function mutations associated with developmental and epileptic encephalopathies may include, but are not limited to, F346L, R474H, and A934T. Gain-of-function mutations associated with epileptic encephalopathies may include, but are not limited to, L437F, Y796H, P924L, and R961H. Gain-of-function mutations associated with Early Infantile Epileptic Encephalopathy (EIEE) may include, but are not limited to, M896K. Gain-of- function mutations associated with drug-resistant epilepsy and generalized tonic-clonic seizure may include, but are not limited to, F346L. Gain-of-function mutations associated with migrating partial seizures of infancy may include, but are not limited to, R428Q. Gain-of-function mutations associated with Leukoencephalopathy may include, but are not limited to, F932I. Gain-of-function mutations associated with NFLE may include, but are not limited to, A934T and R950Q. Gain- of-function mutations associated with Ohtahara syndrome may include, but are not limited to, A966T. Gain-of-function mutations associated with infantile spasms may include, but are not
limited to, P924L. Gain-of-function mutations associated with Brugada Syndrome may include, but are not limited to, R1106Q. Gain-of-function mutations associated with Brugada Syndrome may include, but are not limited to, R474H. [0096] In other examples, the subject is first genotyped to identify the presence of a mutation in KCNT1 and this mutation is then confirmed to be a gain-of-function mutation using standard in vitro assays, such as those described in Milligan et al. (2015) Ann Neurol. 75(4): 581- 590. Typically, the presence of a gain-of-function mutation is confirmed when the expression of the mutated KCNT1 allele results an increase in whole cell current compared to the whole cell current resulting from expression of wild-type KCNT1, as may be assessed using whole-cell electrophysiology (such as described in Milligan et al. (2015) Ann Neurol.75(4): 581-590; Barcia et al. (2012) Nat Genet. 44(11): 1255-1259; Mikati et al. (2015) Ann Neurol. 78(6): 995-999; or Rizzo et al. Mol Cell Neurosci. (2016) 72:54-63). This increase of whole cell current can be, for example, an increase of at least or about 50%, 100%, 150%, 200%, 250%, 300%, 350%, 400% or more. The subject can then be confirmed to have a disease or condition associated with a gain-of- function mutation in KCNT1. [0097] In particular examples, the subject is confirmed as having a KCNT1 allele containing a gain-of-function mutation (e.g. V271F, G288S, R398Q, R428Q, R474Q, R474H, R474C, G652V, I760M, Y796H, M896I, P924L, R928C or A934T). [0098] The compounds disclosed herein (e.g., a compound of Formula (I), (e.g., (I-a), (I- b), (I-c), (I-d), or (I-e)) or a pharmaceutically acceptable salt thereof) or the pharmaceutical composition disclosed herein (e.g., a pharmaceutical composition comprising a compound disclosed herein (e.g., a compound of Formula (I), (e.g., (I-a), (I-b), (I-c), (I-d), or (I-e)) or a pharmaceutically acceptable salt thereof), and a pharmaceutically acceptable excipient) can also be used therapeutically for conditions associated with excessive neuronal excitability where the excessive neuronal excitability is not necessarily the result of a gain-of-function mutation in KCNT1. Even in instances where the disease is not the result of increased KCNT1 expression and/or activity, inhibition of KCNT1 expression and/or activity can nonetheless result in a reduction in neuronal excitability, thereby providing a therapeutic effect. Thus, the compounds disclosed herein (e.g., a compound of Formula (I), (e.g., (I-a), (I-b), (I-c), (I-d), or (I-e)) or a pharmaceutically acceptable salt thereof) or the pharmaceutical composition disclosed herein (e.g., a pharmaceutical composition comprising a compound disclosed herein (e.g., a compound of
Formula (I), (e.g., (I-a), (I-b), (I-c), (I-d), or (I-e)) or a pharmaceutically acceptable salt thereof), and a pharmaceutically acceptable excipient) can be used to treat a subject with conditions associated with excessive neuronal excitability, for example, epilepsy and other encephalopathies (e.g., EIMFS, ADNFLE, West syndrome, infantile spasms, epileptic encephalopathy, focal epilepsy, Ohtahara syndrome, developmental and epileptic encephalopathy, Lennox-Gastaut syndrome, seizures) or cardiac dysfunctions (e.g., cardiac arrhythmia, Brugada syndrome, myocardial infarction), regardless of whether or not the disorder is associated with a gain-of- function mutation in KCNT1. Pharmaceutical Compositions and Routes of Administration [0099] Compounds disclosed herein and pharmaceutically acceptable salts thereof are usually administered in the form of pharmaceutical compositions. Therefore, disclosed herein are pharmaceutical compositions that contain, as the active ingredient, one or more of the compounds described, or a pharmaceutically acceptable salt or ester thereof, and one or more pharmaceutically acceptable excipients, carriers, including inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants. The pharmaceutical compositions may be administered alone or in combination with other therapeutic agents. Such compositions may be prepared in a manner disclosed in the pharmaceutical art, including, for example, in Remington’s Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, Pa.17th Ed. (1985); and Modern Pharmaceutics, Marcel Dekker, Inc. 3rd Ed. (G. S. Banker & C. T. Rhodes, Eds.). [00100] The pharmaceutical compositions may be administered in either single or multiple doses by any of the accepted modes of administration of agents having similar utilities, for example as described in those patents and patent applications incorporated by reference, including rectal, buccal, intranasal and transdermal routes, by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, as an inhalant, or via an impregnated or coated device such as a stent, for example, or an artery- inserted cylindrical polymer. [00101] One mode for administration is parenteral, particularly by injection. The forms in which the novel compositions disclosed herein may be incorporated for administration by injection include aqueous or oil suspensions, or emulsions, with sesame oil, corn oil, cottonseed
oil, or peanut oil, as well as elixirs, mannitol, dextrose, or a sterile aqueous solution, and similar pharmaceutical vehicles. Aqueous solutions in saline are also conventionally used for injection. Ethanol, glycerol, propylene glycol, liquid polyethylene glycol, and the like (and suitable mixtures thereof), cyclodextrin derivatives, and vegetable oils may also be employed. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. [00102] Sterile injectable solutions are prepared by incorporating a compound or pharmaceutically acceptable salt thereof as disclosed herein in the appropriate solvent with various other ingredients as enumerated above, as desired, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the desired other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, exemplary methods of preparation include vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. [00103] Oral administration is another route for administration of the compounds or pharmaceutically acceptable salts thereof as disclosed herein. Administration may be via capsule or enteric coated tablets, or the like. In making the pharmaceutical compositions that include at least one compound described herein, the active ingredient may be diluted by an excipient and/or enclosed within such a carrier that can be in the form of a capsule, sachet, paper or other container. When the excipient serves as a diluent, it can be in the form of a solid, semi-solid, or liquid material (as above), which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, sterile injectable solutions, and sterile packaged powders. [00104] Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and
methyl cellulose. In certain embodiments, the compositions disclosed herein can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl and propylhydroxy- benzoates; sweetening agents; and flavoring agents. [00105] The compositions disclosed herein can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art. Controlled release drug delivery systems for oral administration include osmotic pump systems and dissolutional systems containing polymer- coated reservoirs or drug-polymer matrix formulations. Examples of controlled release systems are given in U.S. Pat. Nos.3,845,770; 4,326,525; 4,902,514; and 5,616,345. Another embodiment for use in the methods disclosed herein employs transdermal delivery devices (“patches”). Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds or pharmaceutically acceptable salts thereof in controlled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is described, for example, in U.S. Pat. Nos. 5,023,252, 4,992,445 and 5,001,139. Such patches may be constructed for continuous, pulsatile, or on-demand delivery of pharmaceutical agents. [00106] The compositions disclosed herein may be formulated in a unit dosage form. The term “unit dosage forms” refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient (e.g., a tablet, capsule, ampoule). The compounds or pharmaceutically acceptable salt thereof are generally administered in a pharmaceutically effective amount. Preferably, for oral administration, each dosage unit contains from about 1 mg to about 2 g of a compound or pharmaceutically acceptable salt thereof as described herein, and for parenteral administration, preferably from about 0.1 to about 700 mg of a compound or pharmaceutically acceptable salt thereof as described herein. It will be understood, however, that the amount of the compound or pharmaceutically acceptable salt thereof actually administered usually will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound or pharmaceutically acceptable salt thereof administered and its relative activity, the age, weight, and response of the individual patient, the severity of the patient’s symptoms, and the like.
[00107] For preparing solid compositions such as tablets, the principal active ingredient may be mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound or pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. [00108] The tablets or pills disclosed herein may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action, or to protect from the acid conditions of the stomach. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer that serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate. [00109] Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described herein. In certain embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in preferably pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a facemask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, such as orally or nasally, from devices that deliver the formulation in an appropriate manner. [00110] In some embodiments, there is provided a pharmaceutical composition comprising a compound, or pharmaceutically acceptable salt thereof, as disclosed herein and a pharmaceutically acceptable carrier. EXAMPLES [00111] In order that the embodiments described herein may be more fully understood, the following examples are set forth. The synthetic and biological examples described
in this application are offered to illustrate the compounds, pharmaceutical compositions and methods provided herein and are not to be construed in any way as limiting their scope. [00112] The compounds provided herein can be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimal reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization. [00113] Additionally, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. The choice of a suitable protecting group for a particular functional group as well as suitable conditions for protection and deprotection are described in the art. For example, numerous protecting groups, and their introduction and removal, are described in T. W. Greene and P. G. M. Wuts, Protecting Groups in Organic Synthesis, Second Edition, Wiley, New York, 1991, and references cited therein. [00114] The compounds provided herein may be isolated and purified by known standard procedures. Such procedures include recrystallization, filtration, flash chromatography, trituration, high pressure liquid chromatography (HPLC), or supercritical fluid chromatography (SFC). Note that flash chromatography may either be performed manually or via an automated system. The compounds provided herein may be characterized by known standard procedures, such as nuclear magnetic resonance spectroscopy (NMR) or liquid chromatography mass spectrometry (LCMS). NMR chemical shifts are reported in part per million (ppm) and are generated using methods described in the art. [00115] List of abbreviations THF tetrahydrofuran TFA trifluoroacetic acid TFAA trifluoroacetic anhydride DMF N,N-dimethylformamide MeOH methanol DCM dichloromethane MeCN or ACN acetonitrile
PE petroleum ether EtOAc ethyl acetate DIPEA N,N,-diisopropylethylamine Et3N or TEA triethylamine HATU o-(7-azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate T3P propanephosphonic acid anhydride DCC N,N'-dicyclohexylcarbodiimide N-Boc-L-alanine (2S)-2-({[(2-methyl-2-propanyl)oxy]carbonyl}amino)propanoic acid DMSO dimethyl sulfoxide EGTA ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid NMDG N-methyl-D-glucamine HEPES 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid IC50 half maximal inhibitory concentration TLC thin layer chromatography LCMS liquid chromatography-mass spectrometry HPLC high-performance liquid chromatography SFC supercritical fluid chromatography MS mass spectrometry NMR nuclear magnetic resonance Example 1. Synthesis of 1-methyl-N-((R)-1-(3-((R)-3-methylpiperidin-1-yl)-1,2,4-oxadiazol- 5-yl)ethyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (Compound 1)
Synthesis of tert-butyl ((R)-1-(3-((R)-3-methylpiperidin-1-yl)-1,2,4-oxadiazol-5- yl)ethyl)carbamate (A-1b): [00116] To a stirred solution of A-1a (0.9 g, 5.72 mmol) in 1,4-dioxane (20 mL) was added N-Boc-D-alanine (1.08 g, 5.72 mmol) followed by DCC (1.18 g, 5.72 mmol) at room temperature, and the reaction was stirred at 100 °C for 12 hours. The reaction mixture was concentrated under reduced pressure. The residue was diluted with EtOAc (30 mL) and washed with water (15 mL). The organic layer was again washed water (10 mL x 2) and brine (10 mL). The organic layer was dried over anhydrous sodium sulphate, filtered, and evaporated to give the residue. The residue was purified by flash column chromatography using 100-200 mesh silica and 20% EtOAc in hexane as an eluent to give A-1b (0.18 g, 0.34 mmol, 6 % yield) as an oil. Synthesis of (1R)-1-[3-[(3S)-3-methyl-1-piperidyl]-1,2,4-oxadiazol-5-yl]ethanamine hydrochloride (A1): [00117] To a stirred solution of A-1b (0.18 g, 0.58 mmol) in 1,4-dioxane (2 mL) was added 4M HCl in dioxane (5 mL) at 0 °C and stirred at room temperature for 6 hours. The reaction mixture was concentrated under reduced pressure to give A1 (0.13 g, 0.35 mmol, 60 % yield) as an oil. Synthesis of Compound 1: [00118] To a stirred solution of A2 (0.1g, 0.52 mmol) in DCM (10 mL) was added A1 (0.13g, 0.52 mmol), HATU (195.88 mg, 0.52 mmol), and DIPEA (0.18 mL, 1.03 mmol) at 0 °C and stirred at room temperature for 6 hours. The reaction mixture was diluted with DCM (10 mL x 2) and water (5 mL). The organic layer was again washed water (10 mL x 2) and
brine (10 mL). The organic layer was dried over anhydrous MgSO4, filtered, and evaporated to give the residue. The residue was purified by flash column chromatography using 100-200 mesh silica and 20-25 % EtOAc in hexane to give Compound 1 (30 mg, 0.077 mmol, 15 % yield) as an oil. HPLC: Rt 9.240 min, 99.7%; Column: X-Select CSH C18 (4.6 x 150) mm, 3.5 µm; Mobile phase: A: 0.1% Formic acid in water: ACN (95:05), B: ACN; Flow Rate: 1.0 mL/min. LCMS: 386.8 (M+H), Rt 2.255 min; Column: X-select CSH C18 (3 x 50) mm, 2.5 µm. 1H NMR (400 MHz, DMSO-d6): δH = 9.29 (d, 1H), 7.42 (s, 1H), 5.23-5.19 (m, 1H), 4.12 (s, 3H), 3.74-3.70 (m, 2H), 2.86-2.79 (m, 1H), 1.76-1.44 (m, 7H), 1.13-1.06 (m, 1H), 0.87 (d, 3H), 1H merged in solvent peak. Examples 2 and 3. Synthesis of 1-methyl-N-(1-(3-(4-methylpiperazin-1-yl)-1,2,4-oxadiazol- 5-yl)ethyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (Compound 2) and N-(1-(3-(4- acetylpiperazin-1-yl)-1,2,4-oxadiazol-5-yl)ethyl)-1-methyl-3-(trifluoromethyl)-1H-pyrazole- 5-carboxamide (Compound 3)
Synthesis of tert-butyl N-[(1S)-2-amino-1-methyl-2-oxo-ethyl]carbamate (A-3b) [00119] To a stirred solution of A-3a (10.g, 52.85 mmol) in THF (100 mL) was added N-methylmorpholine (6.39 mL, 58.14 mmol) and ethyl chloroformate (5.53 mL, 58.14 mmol) at -20 ºC under N2 atmosphere and stirred for 30 minutes. To the reaction mixture, ammonia hydrate (20.36 mL, 528.51 mmol) was added at the -20 ºC and stirred for 5 hours. The solvent was evaporated under reduced pressure, and the residue was dissolved in ethyl acetate (100 mL) and washed with 1N KHSO4, water (100 mL), and brine (100 mL). The organic layer was dried over anhydrous Na2SO4, filtered, and evaporated to a give A-3b as a solid. Synthesis of tert-butyl N-[(1S)-1-cyanoethyl]carbamate (A-3c) [00120] To a stirred solution of A-3b (5 g, 26.6 mmol) in THF (40 mL) was added TFAA (5.62 mL, 39.85 mmol) and pyridine (6.3 g, 79.7 mmol) at -10 ºC and stirred at -10 ºC for 3 hours. The solvent was removed under reduced pressure to give a residue, which was dissolved in ethyl acetate, and washed with 1N aqueous KHSO4, water, and brine. The organic layer was dried over anhydrous Na2SO4, filtered, and evaporated to give a solid, which was recrystallized using ethyl acetate/hexane (2:8) to give A-3c as a solid. Synthesis of (2S)-2-aminopropanenitrile hydrochloride (A-3d) [00121] To a stirred solution of A-3d (500 mg, 2.94 mmol) in 1,4-dioxane (5 mL) was added 4M HCl/dioxane (2 mL, 2.94 mmol) at room temperature and stirred at room temperature for 1 hour. The solvent was removed under reduced pressure, dried, triturated with diethyl ether, and dried to give A-3d. Synthesis of N-[(1S)-1-cyanoethyl]-2-methyl-5-(trifluoromethyl)pyrazole-3-carboxamide (A- 3f) [00122] To a stirred solution of A-3d (600 mg, 5.63 mmol) and 2-methyl-5- (trifluoromethyl)pyrazole-3-carboxylic acid (1 g, 5.63 mmol) in DCM (10 mL) was added DIPEA (0.98 mL, 5.63 mmol) and HATU (3.2 g, 8.45 mmol) at room temperature and stirred at room temperature for 3 hours. The reaction mixture was diluted with DCM and washed with brine. The organic layer was dried over anhydrous Na2SO4, filtered, and evaporated to give a residue, which
was purified by column chromatography to afford A-3f (850 mg, 3.45 mmol, 61 % yield) as a solid. Synthesis of N-[(1S)-1-(3-bromo-1,2,4-oxadiazol-5-yl)ethyl]-2-methyl-5- (trifluoromethyl)pyrazole-3-carboxamide (A3) [00123] To a stirred solution of A-3f (2 g, 8.12 mmol) in toluene (30 mL) was added sodium bicarbonate (2.7 g, 32.5mmol) and dibromomethanone oxime (8.2 g, 40.62 mmol), and then the reaction mixture was stirred at 120 ºC for 20 hours. The reaction mixture was diluted with water and extracted with ethyl acetate thrice. The combined organic layer was washed with brine, dried over anhydrous Na2SO4, filtered, and evaporated to give a residue, which was purified by column chromatography to give A3 (810 mg, 2.2 mmol, 27 % yield) as a solid. Synthesis of Compound 2: [00124] To a stirred solution of A3 (0.15 g, 0.41 mmol) in DMF (2 mL) was added DIPEA (0.14 mL, 0.81 mmol) and heated to 60 °C for 12 hours. The reaction mixture was diluted with water (5 ml) and EtOAc (10 ml), and the organic layer was separated. The organic layer was washed with saturated brine solution (5 mL), separated and dried over MgSO4, and evaporated to give a residue, which was purified by flash column chromatography using 30 % EtOAc in hexane as an eluent to afford a residue. The residue was re-purified by prep HPLC give Compound 2 (8 mg, 0.02 mmol, 4.9 % yield) as a solid. HPLC: Rt 5.241 min, 98.1% Column: X-Select CSH C18 (4.6 x 150) mm, 3.5 µm Mobile phase: A: 0.1% Formic acid in water: ACN (95:05), B: ACN; Flow Rate: 1.0 mL/min. LCMS : 388.25 (M+H), Rt 1.416 min, Column: X-select CSH C18 (3 x 50) mm, 2.5 µm. 1H NMR (400 MHz, DMSO-d6) δH = 9.30 (d, 1H), 7.42 (s, 1H), 5.24-5.20 (m, 1H), 4.12 (s, 3H), 3.32 (t, 4H), 2.37 (t, 4H), 2.20 (s, 3H), 1.54 (d, 3H). Synthesis of Compound 3: [00125] To a stirred solution of A3 (0.15 g, 0.41 mmol) in DMF (2 mL) was added 1-piperazin-1-ylethanone (0.05 g, 0.41 mmol), DIPEA (0.14 mL, 0.81 mmol) and heated to 60 °C for 12 hours. The reaction mixture was diluted with water (5 ml) and EtOAc (10 ml), and the organic layer was separated. The organic layer was washed with saturated brine solution (1 x 5 mL), separated and dried over MgSO4, and evaporated to dryness to give a residue, which was
purified by flash column chromatography using 30% EtOAc in hexane as an eluent to give a solid, which was re-purified by prep HPLC to give Compound 3 (15 mg, 0.036 mmol, 9 % yield) as a solid. HPLC: Rt 7.160 min, 99.9% Column: X-Select CSH C18 (4.6 x 150) mm, 3.5 µm Mobile phase: A: 0.1% Formic acid in water: ACN (95:05), B: ACN; Flow Rate: 1.0 mL/min. LCMS : 416.20 (M+H), Rt 1.74 min, Column: X-select CSH C18 (3 x 50) mm, 2.5 µm [00126] 1H NMR (400 MHz, DMSO-d6) δH = 9.30 (d, 1H), 7.42 (s, 1H), 5.25-5.20 (m, 1H), 4.12 (s, 3H), 3.60-3.50 (m, 4H), 3.38-3.28 (m, 4H), 2.03 (s, 3H), 1.55 (d, 3H). Chiral HPLC shows racemic mixture. Example 4. Synthesis of 1-methyl-N-((S)-1-(3-((R)-2-methylpiperidin-1-yl)-1,2,4-oxadiazol- 5-yl)ethyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (Compound 4)
Synthesis of (R)-2-methylpiperidine-1-carbonitrile (A5): [00127] To a stirred solution of A4 (0.65 g, 6.55 mmol) in MeCN (15 mL) was added K2CO3 (1.8 g, 13.11 mmol) followed by addition of cyanogen bromide (1.04 g, 9.83mmol) at 0 °C and stirred at room temperature for 16 hours. The residue was diluted with EtOAc (30 mL) and washed with water (15 mL). The organic layer was dried over anhydrous sodium sulphate, filtered, and evaporated under reduced pressure to give A5 (0.56 g, 4.04 mmol, 62 % yield) as an oil. Synthesis of (R,Z)-N'-hydroxy-2-methylpiperidine-1-carboximidamide (A6): [00128] To a stirred solution of A5 (0.6 mg, 4.51 mmol) in ethanol (10 mL) was added hydroxyl amine hydrochloride (0.38 g, 5.41 mmol) and triethyl amine (0.91 mL, 9.02 mmol). The reaction mixture was stirred at 80 °C for 12 hours. The solvent was evaporated to give A6 (1.1 g), which was used in the next step without further purification.
Synthesis of tert-butyl ((S)-1-(3-((R)-2-methylpiperidin-1-yl)-1,2,4-oxadiazol-5- yl)ethyl)carbamate (A7): [00129] To a stirred solution of A6 (1.1 g, 7 mmol) in 1,4-dioxane (25 mL) was added N-Boc-L-alanine (1.32 g, 7 mmol) followed by DCC (1.44 g, 7 mmol) at room temperature and stirred at 100 °C for 16 hours. The reaction mixture was concentrated under reduced pressure. The residue was diluted with EtOAc (50 mL) and washed with water (20 mL). The organic layer was again washed with water (20 mL x 2) and brine. The organic layer was separated, dried over magnesium sulfate, and filtered. The organic layer was evaporated under reduced pressure to give the residue. The residue was purified by flash column chromatography using 100-200 mesh silica and 30 % EtOAc in hexane as an eluent to give A7 (150 mg, 0.14 mmol) as a liquid. Synthesis of (S)-1-(3-((R)-2-methylpiperidin-1-yl)-1,2,4-oxadiazol-5-yl)ethan-1-amine (A8): [00130] To a stirred solution of A7 (0.15 g, 0.48 mmol) in 1,4-dioxane (2 mL) was added 4M HCl in dioxane (5 mL) at 0 °C and stirred at room temperature for 6 hours. The reaction mixture was concentrated under reduced pressure and washed with diethyl ether to give A8 (100 mg, 0.17 mmol) as a solid. Synthesis of Compound 4: [00131] To a stirred solution of A8 (0.08 g, 0.39 mmol) in DCM (5 mL) was added A2 (0.1 g, 0.39 mmol), HATU (0.16 g, 0.43 mmol) and DIPEA (0.13 mL, 0.77 mmol) at room temperature and stirred for 6 hours. The reaction mixture was diluted with DCM (10 mL) and washed with water (5 mL), and the organic layer was separated. The organic layer was again washed water (10 mL x 2) and brine (10 mL). The organic layer was dried over anhydrous MgSO4, filtered, and evaporated to give the residue. The residue was purified by flash column chromatography using 100-200 mesh silica and 20-25 % EtOAc in hexane. The compound was re- purified by prep. HPLC to give Compound 4 (20 mg, 0.052 mmol, 13 % yield) as an oil. HPLC: Rt 9.234 min, 99.8% Column: X-Select CSH C18 (4.6 x 150) mm, 3.5 µm Mobile phase: A: 0.1% Formic acid in water: ACN (95:05), B: ACN; Flow Rate: 1.0 mL/min. LCMS : 387.05 (M+H), Rt 2.132 min, Column: X-select CSH C18 (3 x 50) mm, 2.5 µm. 1H NMR (400 MHz, DMSO-d6) δH = 9.28 (d, 1H), 7.42 (s, 1H), 5.23-5.19 (m, 1H), 4.15-4.10 (m, 4H), 3.63-3.59 (m, 1H), 3.03- 2.96 (m, 1H), 1.70-1.40 (m, 9H), 1.11 (d, 3H).
Example 5. Synthesis of 1-methyl-N-((S)-1-(3-((S)-2-methylpiperidin-1-yl)-1,2,4-oxadiazol- 5-yl)ethyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (Compound 5)
Synthesis of (S)-2-methylpiperidine-1-carbonitrile (A10): [00132] To a stirred solution of A9 (0.5 g, 5.04 mmol) in MeCN (10 mL) was added K2CO3 (1.4 g, 10 mmol) followed by addition of cyanogen bromide (0.8 g, 7.56 mmol) at 0 °C and stirred at room temperature for 16 hours. The residue was diluted with EtOAc (100 mL x 2) and washed with water (10 mL). The organic layer was dried over anhydrous sodium sulphate, filtered, and evaporated to give a residue, which was purified by column chromatography using 100-200 silica gel and 30-80% EtOAc/Hexane as an eluent to give A10 (0.6 g, 4.25 mmol, 84 % yield) as an oil. Synthesis of (S,Z)-N'-hydroxy-2-methylpiperidine-1-carboximidamide (A11): [00133] To a stirred solution of A10 (0.6 mg, 4.25 mmol) in ethanol (15 mL) was added hydroxyl amine hydrochloride (295.46mg, 4.25mmol) and triethyl amine (1.19 mL, 8.5 mmol). The reaction mixture was stirred at 80 °C for 6 hours. The reaction mixture was quenched using water (10 ml) and diluted with EtOAc (100 mL x 2). The organic layer was separated, dried by Na2SO4, filtered, and evaporated to give a residue, which was purified by column chromatography using 100-200 silica and 30-80% EtOAc/Hexane as an eluent to give A11 (600 mg, 3.05 mmol, 72 % yield). Synthesis of tert-butyl ((S)-1-(3-((S)-2-methylpiperidin-1-yl)-1,2,4-oxadiazol-5- yl)ethyl)carbamate (A12): [00134] To a stirred solution of A11 (0.6 g, 3.05 mmol) in 1,4- dioxane (20 mL) was added N-Boc-L-alanine (0.58 g, 3.05 mmol) followed by the addition of DCC (0.63 g, 3.05 mmol) at room temperature and stirred at 100 °C for 12 hours. The reaction mixture was concentrated under reduced pressure. The residue was diluted with EtOAc (100 mL x 2) and washed with water
(10 mL). The organic layer was again washed with water (10 mL x 2) and brine (10 mL). The organic layer was separated, dried over sodium sulphate, and filtered. The organic layer was evaporated under reduced pressure to give the residue. The residue was purified by flash column chromatography using 100-200 mesh silica and 30-80 % EtOAc in hexane as an eluent to give A12 (100 mg, 0.13 mmol) as an oil. Synthesis of (S)-1-(3-((S)-2-methylpiperidin-1-yl)-1,2,4-oxadiazol-5-yl)ethan-1-amine (A13): [00135] To a stirred solution of A12 (0.1 g, 0.32 mmol) in 1,4- dioxane (5 mL) was added 4M HCl in dioxane (10 mL) at 0 °C and stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure and washed with diethyl ether to give A13 (70mg, 0.11 mmol) as an oil. Synthesis of Compound 5: [00136] To a stirred solution of A13 (70 mg, 0.11 mmol) and A2 (26.43 mg, 0.14 mmol) in DCM (10 mL) was added HATU (64.72 mg, 0.17 mmol) and DIPEA (0.04 mL, 0.23 mmol) at room temperature and stirred for 2 hours. The reaction mixture was diluted with DCM (200 mL) and washed with water (100 mL) and brine. The organic layer was again washed with water (10 mL x 2) and brine (10 mL). The organic layer was dried over anhydrous sodium sulphate, filtered, and evaporated to give the residue. The residue was purified by flash column chromatography using 100-200 mesh silica and 30-80 % EtOAc in hexane as an eluent to give Compound 5 (15 mg, 0.038 mmol, 33.87% yield) as a solid. HPLC: Rt 9.261 min, 99.5% Column: X-Select CSH C18 (4.6 x 150) mm, 3.5 µm Mobile phase: A: 0.1% Formic acid in water: ACN (95:05), B: ACN; Flow Rate: 1.0 mL/min. LCMS : 387.20 (M+H), Rt 2.17 min, Column: X-select CSH C18 (3 x 50) mm, 2.5 µm.1H NMR (400 MHz, DMSO-d6) δH = 9.28 (d, 1H), 7.41 (s, 1H), 5.25-5.17 (m, 1H), 4.12 (s, 3H), 3.63-3.59 (m, 1H), 3.03-2.96 (m, 1H), 1.66-1.58 (m, 3H), 1.55-1.53 (m, 5H), 1.45-1.38 (m, 1H), 1.11 (d, 3H), 1.05-0.90 (m, 1H).. Example 6. Synthesis of (S)-N-(1-(3-(isobutyl(methyl)amino)-1,2,4-oxadiazol-5-yl)ethyl)-1- methyl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (Compound 6):
[00137] To a stirred solution of A3 (0.1 g, 0.27 mmol) in DMF (2 mL) was added N,2-dimethylpropan-1-amine (0.04g, 0.41 mmol) and DIPEA (0.09 mL, 0.54 mmol). The reaction mixture was stirred at 60 °C for 12 hours. The reaction mixture was diluted with EtOAc (10 mL) and washed with water (5 mL) and brine. The organic layer was again washed with brine (10 mL). The organic layer was dried over anhydrous MgSO4, filtered, and evaporated to give the residue. The residue was purified by flash column chromatography using 100-200 mesh silica and 30-80 % EtOAc in hexane. The compound was re-purified by prep. HPLC to give Compound 6 (10 mg, 0.027 mmol, 10 % yield) as an oil. HPLC: Rt 8.902 min, 99.5% Column: X-Select CSH C18 (4.6 x 150) mm, 3.5 µm Mobile phase: A: 0.1% Formic acid in water: ACN (95:05), B: ACN; Flow Rate: 1.0 mL/min. LCMS : 375.1 (M+H), Rt 2.133 min, Column: X-select CSH C18 (3 x 50) mm, 2.5 µm.1H NMR (400 MHz, DMSO-d6) δH = 9.25 (d, 1H), 7.41 (s, 1H), 5.25-5.15 (m, 1H), 4.12 (s, 3H), 3.12 (d, 2H), 2.91 (s, 3H), 2.00-1.95 (m, 1H), 1.53 (d, 3H), 0.83 (d, H). Example 7. Synthesis of 1-methyl-N-((S)-1-(3-((S)-2-methylmorpholino)-1,2,4-oxadiazol-5- yl)ethyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (Compound 7)
Synthesis of (2R)-2-methylmorpholine-4-carbonitrile (A-14b) [00138] To a stirred solution of A-14a (0.6 g, 5.93 mmol) in DMF (4 mL) was added K2CO3 (2.45 g, 17.8 mmol) followed by cyanogen bromide (0.63 g, 5.93 mmol) at 0 °C and stirred at room temperature for 16 hours. The reaction mixture was filtered through a pad of celite. The filtrate was concentrated under reduced pressure. The residue was diluted with EtOAc (30 mL) and washed with water (15 mL). The organic layer was again washed water (10 mL x 2) and brine (10 mL). The organic layer was dried over anhydrous sodium sulphate, filtered, and evaporated to give A-14b (450 mg, 3.57 mmol, 60 % yield) as an oil.
Synthesis of rac-(2S)-N-hydroxy-2-methyl-morpholine-4-carboxamidine (A-14c) [00139] To a stirred solution of A-14b (0.63 g, 4.99 mmol) in ethanol (5 mL) was added hydroxylamine hydrochloride (3 g, 14.9 mmol) and triethylamine (2.09 mL, 14.9 mmol). The reaction mixture was stirred at 70 °C for 16 hours. The reaction mixture was concentrated under reduced pressure to give A-14c (510 mg, 3.2 mmol, 64 % yield) as a solid, which was used in the next reaction without further purification. Synthesis of tert-butyl N-[(1S)-1-[3-[(2S)-2-methylmorpholin-4-yl]-1,2,4-oxadiazol-5- yl]ethyl]carbamate (A-14d) [00140] To a stirred solution of A-14c (0.5 g, 3.14 mmol) in 1,4-dioxane (7 mL) was added N-Boc-L-alanine (0.59 g, 3.14 mmol) followed by DCC (0.65 g, 3.14 mmol) at room temperature and stirred at 100 °C for 16 hours. The reaction mixture was concentrated under reduced pressure. The residue was diluted with EtOAc and washed with water. The organic layer was again washed water and brine. The organic layer was dried over anhydrous sodium sulphate, filtered, and evaporated to give the residue. The residue was purified by flash column chromatography using 100-200 mesh silica and 7 % EtOAc in hexane as an eluent to give A-14d (509 mg, 1.5 mmol, 48 % yield) as an oil. Synthesis of 1S)-1-[3-[(2S)-2-methylmorpholin-4-yl]-1,2,4-oxadiazol-5-yl]ethanamine hydrochloride (A14) [00141] To a stirred solution of A-14d (0.3 g, 0.96 mmol) in 1,4-dioxane (6 mL) was added 4M HCl in dioxane (4 mL) at 0°C and stirred at room temperature for 5 hours. The reaction mixture was concentrated under reduced pressure to give A14 (0.21 g, 0.61 mmol, 63 % yield) as an oil, which was used for next step without purification. Synthesis of Compound 7 [00142] To a stirred solution of A14 (150 mg, 0.60 mmol) in DCM (5 mL) was added A2 (175.61 mg, 0.90 mmol), DIPEA (0.32 mL, 1.81 mmol) and HATU (343.98 mg, 0.90 mmol) at room temperature and stirred for 16 hours. The reaction mixture was diluted with DCM and washed with water. The organic layer was dried over anhydrous sodium sulphate,
filtered, and evaporated to give the residue. The residue was purified by to give Compound 7 (20 mg ,0.051 mmol, 8% yield) as an oil. HPLC: Rt 8.13 min, 98.5% Column: X-Select CSH C18 (4.6 x 150) mm, 5 µm Mobile phase: A: 0.1% Formic acid in water: ACN (95:05), B: ACN; Flow Rate: 1.0 mL/min. LCMS : 389 (M+H), Rt 1.927 min, Column: X-select CSH C18 (3 x 50) mm, 2.5 µm.1H NMR (400 MHz, DMSO-d6) δH = 9.25 (d, 1H), 7.42 (s, 1H), 5.26-5.18 (m, 1H), 4.12 (s, 3H), 3.88-3.82 (m, 1H), 3.66-3.62 (m, 1H), 3.58-3.50 (m, 3H), 2.98-2.90 (m, 1H), 2.66-2.60 (m, 1H), 1.54 (d, 3H), 1.11 (d, 3H). Example 8. Synthesis of (S)-N-(1-(3-(benzylamino)-1,2,4-oxadiazol-5-yl)ethyl)-1-methyl-3- (trifluoromethyl)-1H-pyrazole-5-carboxamide (Compound 8)
[00143] To a stirred solution of A3 (25 mg, 0.070 mmol) in DMF (2 mL) was added phenylmethanamine (0.01 mL, 0.10 mmol) and DIPEA (0.02 mL, 0.14 mmol). The reaction mixture was stirred at 60 °C for 12 hours. The reaction mixture was diluted with EtOAc (10 mL) and washed with water (5 mL) and brine. The organic layer was again washed brine (10 mL). The organic layer was dried over anhydrous MgSO4, filtered, and evaporated to give the residue. The residue was purified by prep HPLC to give Compound 8 (15 mg, 0.038 mmol, 56 % yield) as an oil. HPLC: Rt 8.459 min, 99.9% Column: X-Select CSH C18 (4.6 x 150) mm, 3.5 µm Mobile phase: A: 0.1% Formic acid in water: ACN (95:05), B: ACN; Flow Rate: 1.0 mL/min. LCMS : 395.20 (M+H), Rt 1.985 min, Column: X-select CSH C18 (3 x 50) mm, 2.5 µm. 1H NMR (400 MHz, DMSO-d6) δH = 9.25 (d, 1H), 7.48-7.44 (m, 1H), 7.41 (s, 1H), 7.32-7.28 (m, 4H), 7.26- 7.21 (m, 1H), 5.22-5.18 (m, 1H), 4.25 (d, 2H), 4.12 (s, 3H), 1.53 (d, 3H). Example 9. Synthesis of (S)-N-(1-(3-(isobutylamino)-1,2,4-oxadiazol-5-yl)ethyl)-1-methyl-3- (trifluoromethyl)-1H-pyrazole-5-carboxamide (Compound 9)
Synthesis of isobutylcyanamide (A-15b) [00144] To a solution of carbononitridic bromide (5.21 g, 49.22 mmol) in MeCN (30 mL) was added K2CO3 (5.7 g, 41.02 mmol) and a solution of A-15a (3 g, 41.02 mmol) in MeCN in a dropwise manner at 0 º C under argon and stirred at room temperature for 16 hours. The reaction mixture was diluted with ethyl acetate, and insoluble materials were separated by filtration. The organic layer was washed with water and brine, dried over sodium sulphate, and evaporated to give A-15b as a liquid, which was used for next step without further purification. Synthesis of 1-hydroxy-3-isobutyl-guanidine (A-15c) [00145] A mixture of A-15b (1 g, 10.19 mmol), hydroxylamine hydrochloride (0.92 g, 13.25 mmol) and TEA (2.84mL, 20.38mmol) in ethanol (10 mL) was heated at 80 ºC for 16 hours. The solvent was removed, and the residue was triturated with diethyl ether and dried using vacuum to give A-15c as a solid, which was used directly for the next step without further purification. Synthesis of tert-butyl N-[(1S)-1-[3-(isobutylamino)-1,2,4-oxadiazol-5-yl]ethyl]carbamate (A-15e) [00146] A mixture of A-15c (1 g, 7.62 mmol), A-15d (1.59 g, 8.39 mmol), DCC (1.73 g, 8.39 mmol) in 1,4-dioxane (15mL) was heated at 100 º C for 12 hours. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layer was washed with water, saturated aqueous sodium bicarbonate, and brine, dried over sodium
sulphate, and evaporated to give residue, which was purified by column chromatography on silica gel using ethyl acetate, hexane to give A-15e as a solid (1 g , 3.52 mmol, 46% yield). Synthesis of 5-[(1S)-1-aminoethyl]-N-isobutyl-1,2,4-oxadiazol-3-amine hydrochloride (A15) [00147] To a stirred solution of A-15e (0.5g, 1.76mmol) in 1,4-dioxane (5mL) was added 4M HCl 1,4-dioxane (5 mL, 1.76 mmol) and stirred reaction at 0 ºC for 2 hours. The reaction mixture was evaporated under vacuum to give a solid, which was washed using diethyl ether to give A15 as a solid (0.3 g, 0.82 mmol, 46% yield). Synthesis of Compound 9 [00148] To a stirred solution of A15 (0.2 g, 0.91 mmol) in DCM (10 mL) was added A2 (211.08 mg, 1.09 mmol), HATU (516.85 mg, 1.36 mmol) and DIPEA (0.32 mL, 1.81 mmol) at room temperature and stirred at room temperature for 2 hours. The reaction mixture was diluted with DCM (100 mL x 2) and washed with water (100 mL). The organic layer was dried over anhydrous sodium sulphate, filtered, and evaporated to give the residue. The residue was purified by flash column chromatography using 100-200 mesh silica and 30-80 % EtOAc in hexane as an eluent to give Compound 9 (20 mg, 0.055 mmol, 6% yield) as a solid. HPLC: Rt 8.576 min, 99.7% Column: X-Select CSH C18 (4.6 x 150) mm, 5 µm. Mobile phase: A: 0.1% Formic acid in water: ACN (95:05), B: ACN; Flow Rate: 1.0 mL/min. LCMS : 361.05 (M+H), Rt 1.972 min, Column: X-select CSH C18 (3 x 50) mm, 2.5 µm.1H NMR (400 MHz, DMSO-d6) δH = 9.25 (d, 1H), 7.42 (s, 1H), 6.95-6.91 (m, 1H), 5.21-5.18 (m, 1H), 4.15 (s, 3H), 2.86-2.83 (m, 2H), 1.86- 1.80 (m, 1H), 1.55-1.51 (m, 3H), 0.90-0.85 (m, 6H). Example 10. Synthesis of 1-methyl-N-((R)-1-(3-((S)-3-methylpiperidin-1-yl)-1,2,4- oxadiazol-5-yl)ethyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (Compound 10)
Synthesis of tert-butyl N-[(1R)-1-[3-[(3S)-3-methyl-1-piperidyl]-1,2,4-oxadiazol-5- yl]ethyl]carbamate (A-16b) [00149] To a stirred solution of A-16a (1 g, 6.36 mmol) in 1,4-dioxane (20 mL) was added N-Boc-D-alanine (1.26 g, 6.36 mmol) followed by DCC (1.31 g, 6.36 mmol) at room temperature and stirred at 100 °C for 12 hours. The reaction mixture was concentrated under reduced pressure. The residue was diluted with EtOAc (30 mL) and washed with water (15 mL). The organic layer was again washed water (10 mL x 2) and brine (10 mL). The organic layer was dried over anhydrous sodium sulphate, filtered, and evaporated to give the residue. The residue was purified by flash column chromatography using 100-200 mesh silica and 20 % EtOAc in hexane as an eluent to give A-16b (0.18 g, 0.46 mmol, 7 % yield) as an oil. Synthesis of (1R)-1-[3-[(3S)-3-methyl-1-piperidyl]-1,2,4-oxadiazol-5-yl]ethanamine hydrochloride (A16) [00150] To a stirred solution of A-16b (0.18 g, 0.58 mmol) in 1,4-dioxane (2 mL) was added 4M HCl in dioxane (5 mL) at 0 °C and stirred at room temperature 6 hours. The reaction mixture was concentrated under reduced pressure to give A16 (0.16 g,0.52 mmol, 91 % yield) as an oil. Synthesis of Compound 10: [00151] To a stirred solution of A2 (0.1 g, 0.52 mmol) in DCM (15mL) was added A16 (0.13 g, 0.52 mmol), HATU (0.2 g, 0.52 mmol) and DIPEA (0.18 mL, 1.03 mmol) at 0 °C and stirred at room temperature for 6 hours. The reaction mixture was diluted with DCM (10 mL) and washed with water (5 mL). The organic layer was again washed with water (10 mL x 2) and
brine (10 mL). The organic layer was dried over anhydrous MgSO4, filtered, and evaporated to give the residue. The residue was purified by flash column chromatography using 100-200 mesh silica and 20-25 % EtOAc in hexane as an eluent to give Compound 10 (110 mg,0.277 mmol, 54% yield) as an oil. (SOR: 35.95, Concentration 0.261 w/v%). HPLC: Rt 9.257 min, 97.2% [00152] Column: X-Select CSH C18 (4.6 x 150) mm, 5 µm Mobile phase: A: 0.1% Formic acid in water: ACN (95:05), B: ACN; Flow Rate: 1.0 mL/min. LCMS : 387.25 (M+H), Rt 2.119 min, Column: X-select CSH C18 (3 x 50) mm, 2.5 µm. 1H NMR (400 MHz, DMSO-d6) δH = 9.29 (d, 1H), 7.42 (s, 1H), 5.23-5.18 (m, 1H), 4.12 (s, 3H), 3.74-3.64 (m, 2H), 2.85-2.78 (m, 1H), 2.54-2.52 (m, 1H), 1.73-1.43 (m, 7H), 1.11-1.06 (m, 1H), 0.87 (d, 3H). Example 11. Synthesis of (S)-N-(1-(3-(benzyl(methyl)amino)-1,2,4-oxadiazol-5-yl)ethyl)-1- methyl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (Compound 11):
Synthesis of benzylcyanamide (A-17b) [00153] To a stirred solution of cyanogen bromide (6.23 g, 58.8 mmol) and sodium carbonate (11.87g, 111.99 mmol) in ether (50mL) was added benzylamine (3.06 mL, 28 mmol) at 0 °C and stirred at room temperature 4 hours. The reaction mixture was filtered on a celite bed, and the filtrate evaporated to give A-17b (3.6 g, 14.4 mmol, 51 % yield) as a solid. Synthesis of benzyl(methyl)cyanamide (A-17c) [00154] To a stirred solution of A-17b (2 g, 15.13 mmol) in DMF (10 mL) was added K2CO3 (2.3g, 16.65 mmol) and methyl iodide (0.95 mL, 15.13 mmol) at 0 °C and then stirred at room temperature for 12 hours. The reaction mixture was diluted with EtOAc (30 mL) and water (20 mL), and the organic layer was separated. The organic layer was washed with water (2 x 20 mL) and a saturated brine solution (1 x 20 mL), dried over MgSO4, and evaporated to
give a residue, which was purified by flash column chromatography using 30 % EtOAc in hexane as an eluent to give A-17c (1.2 g, 7.42 mmol, 49 % yield,) as an oil. Synthesis of 1-benzyl-2-hydroxy-1-methyl-guanidine (A-17d) [00155] To a stirred solution of A-17c (1.g, 6.84mmol) in ethanol (20mL) was added hydroxyl amine hydrochloride (0.56 g, 8.07 mmol) and triethylamine (1.38 g, 13.68 mmol) and heated to 80 °C for 12 hours. The reaction mixture was evaporated, and the residue dissolved in EtOAc (50 mL) and diluted with water (20mL). The separated organic layer was dried MgSO4 and evaporated to dryness to give A-17d (0.9 g, 2.89 mmol, 42 % yield) as an oil. Synthesis of tert-butyl N-[(1S)-1-[3-[benzyl(methyl)amino]-1,2,4-oxadiazol-5- yl]ethyl]carbamate (A-17e) [00156] To a stirred solution of A-17d (0.8g, 4.46mmol) in 1,4-dioxane (20mL) was added N-Boc-L-alanine (0.84 g, 4.46 mmol) and DCC (0.92 g, 4.46 mmol) and heated to 100 °C for 12 hours. The reaction mixture was evaporated, and the residue was dissolved with EtOAc (30 mL) and diluted with water (15 mL). The separated organic layer was washed with water (2 x 10 mL) and saturated brine solution (10 mL). The separated organic layer was dried over MgSO4 and evaporated to give the residue. The residue was then purified by flash column chromatography using 20 % EtOAc in hexane as an eluent to give A-17e (0.23 g,0.61 mmol, 13% yield) as an oil. Synthesis of 5-[(1S)-1-aminoethyl]-N-benzyl-N-methyl-1,2,4-oxadiazol-3-amine hydrochloride (A17) [00157] To a stirred solution of A-17e (0.23 g, 0.69 mmol) in 1,4-dioxane (1mL) was added 4M HCl in dioxane (5.mL, 0.69 mmol) at 0 °C and stirred at room temperature for 4 hours. The reaction mixture was evaporated to give A17 (0.18 g, 0.64 mmol, 93 % yield) as a solid. Synthesis of Compound 11 [00158] To a stirred solution of A2 (0.1 g, 0.52 mmol) in DCM (10 mL) was added A17 (0.17 g, 0.62 mmol), HATU (0.24 g, 0.62 mmol) and DIPEA (0.18 mL, 1.03 mmol) at room temperature and stirred at room temperature for 6 hours. The reaction mixture was diluted with DCM (20 mL) and washed with water (10 mL). The organic layer was washed with brine (10 mL). The organic layer was dried over anhydrous MgSO4, filtered, and evaporated to give the
residue. The residue was purified by flash column chromatography using 100-200 mesh silica and 30-35% EtOAc in hexane as an eluent to give Compound 11 (50 mg,0.122 mmol, 24% yield) as an oil. HPLC: Rt 9.021 min, 99.7% Column: X-Select CSH C18 (4.6 x 150) mm, 3.5 µm Mobile phase: A: 0.1% Formic acid in water: ACN (95:05), B: ACN; Flow Rate: 1.0 mL/min. LCMS : 409.25 (M+H), Rt 2.072 min, Column: X-select CSH C18 (3 x 50) mm, 2.5 µm. 1H NMR (400 MHz, DMSO-d6) δH = 9.30 (d, 1H), 7.41 (s, 1H), 7.34-7.24 (m, 5H), 5.25-5.20 (m, 1H), 4.52 (s, 2H), 4.12 (s, 3H), 2.86 (s, 3H), 1.56 (d, 3H). Example 12. Synthesis of 1-methyl-N-((S)-1-(3-((R)-3-methylpiperidin-1-yl)-1,2,4- oxadiazol-5-yl)ethyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (Compound 12)
Synthesis of (R)-3-methylpiperidine-1-carbonitrile (A19): [00159] To a stirred solution of A18 (1 g, 7.37 mmol) in MeCN (30 mL) was added K2CO3 (3.06 g, 22.12 mmol) followed by addition of cyanogen bromide (1.17 g, 11.06 mmol) at 0 °C and stirred at room temperature for 16 hours. The reaction mixture was filtered through a pad of celite. The filtrate was concentrated under reduced pressure. The residue was diluted with EtOAc (30 mL) and washed with water (15 mL). The organic layer was again washed water (10 mL x 2) and brine (10 mL). The organic layer was dried over anhydrous sodium sulphate, filtered, and evaporated to give A19 (0.77 g, 6.2 mmol, 84 % yield) as an oil. Synthesis of (R,Z)-N'-hydroxy-3-methylpiperidine-1-carboximidamide (A20): [00160] To a stirred solution of A19 (0.77 g, 6.2 mmol) in ethanol (20 mL) was added hydroxyl amine hydrochloride (0.47 g, 6.82 mmol) and triethyl amine (1.25 g, 12.4 mmol). The reaction mixture was stirred at 80 °C for 12 hours. The reaction mixture was concentrated under reduced pressure to give A20 (2 g) as a solid. The compound was used in the next reaction without further purification.
Synthesis of tert-butyl ((S)-1-(3-((R)-3-methylpiperidin-1-yl)-1,2,4-oxadiazol-5- yl)ethyl)carbamate (A21): [00161] To a stirred solution of A20 (0.9 g, 5.72 mmol) in 1,4- dioxane (20 mL) was added N-Boc-L-alanine (1.08 g, 5.72 mmol) followed by addition of DCC (1.8 g, 5.72 mmol) at room temperature and stirred at 100 °C for 12 hours. The reaction mixture was concentrated under reduced pressure. The residue was diluted with EtOAc (30 mL) and washed with water (15 mL). The organic layer was again washed with water (10 mL x 2) and brine (10 mL). The organic layer was dried over anhydrous sodium sulphate, filtered, and evaporated to give the residue. The residue was purified by flash column chromatography using 100-200 mesh silica and 20 % EtOAc in hexane as an eluent to give A22 (0.18 g, 0.45 mmol) as an oil. Synthesis of (S)-1-(3-((R)-3-methylpiperidin-1-yl)-1,2,4-oxadiazol-5-yl)ethan-1-amine; hydrochloride (A22): [00162] To a stirred solution of A21 (0.18 g, 0.58 mmol) in 1,4- dioxane (2 mL) was added 4M HCl in dioxane (5 mL) at 0 °C and stirred at room temperature for 6 hours. The reaction mixture was concentrated under reduced pressure to give A22 (0.13 g, 0.39mmol) as an oil. Synthesis of Compound 12: [00163] To a stirred solution of A2 (0.1 g, 0.52 mmol) in DCM (10 mL) was added A22 (0.13 g, 0.52 mmol), HATU (0.2 g, 0.52 mmol) and DIPEA (0.18 mL, 1.03 mmol) at 0 °C and stirred at room temperature for 6 hours. The reaction mixture was diluted with DCM (10 mL) and washed with water (5 mL). The organic layer was again washed with water (10 mL x 2) and brine (10 mL). The organic layer was dried over anhydrous MgSO4, filtered, and evaporated to give the residue. The residue was purified by flash column chromatography using 100-200 mesh silica and 20-25% EtOAc in hexane. The compound was re-purified by prep. HPLC to give Compound 12 (57 mg, 0.147 mmol, 29 % yield) as an oil. SOR: -35.22, Concentration 0.2505 w/v%. HPLC: Rt 9.26 min, 99.9%; Column: X-Select CSH C18 (4.6 x 150) mm, 5 µm; Mobile phase: A: 0.1% Formic acid in water: ACN (95:05), B: ACN; Flow Rate: 1.0 mL/min. LCMS : 386.8 (M+H), Rt 2.246 min; Column: X-select CSH C18 (3 x 50) mm, 2.5 µm. 1H NMR (400 MHz, DMSO-d6): δH = 9.30 (d, 1H), 7.42 (s, 1H), 5.23-5.19 (m, 1H), 4.12 (s, 3H), 3.74-3.69 (m, 2H), 2.85-2.78 (m, 1H), 2.55-1.44 (m, 7H), 1.15-1.05 (m, 1H), 0.87 (d, 3H), 1H merged in solvent peak.
Example 13. Synthesis of 1-methyl-N-((S)-1-(3-((S)-3-methylpiperidin-1-yl)-1,2,4-oxadiazol- 5-yl)ethyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (Compound 13)
Synthesis of (S)-3-methylpiperidine-1-carbonitrile (A24): [00164] To a stirred solution of A23 (1 g, 7.37mmol) in MeCN (30 mL) was added K2CO3 (3.06 g, 22.12 mmol) followed by addition of cyanogen bromide (1.17 g, 11.06 mmol) at 0 °C and stirred at room temperature for 16 hours. The reaction mixture was filtered through a pad of celite. The filtrate was concentrated under reduced pressure. The residue was diluted with EtOAc (30 mL) and washed with water (15 mL). The organic layer was again washed with water (10 mL x 2) and brine (10 mL). The organic layer was dried over anhydrous sodium sulphate, filtered, and evaporated to give A24 (0.85 g, 6.71 mmol, 91.06% yield) as an oil. Synthesis of (S,Z)-N'-hydroxy-3-methylpiperidine-1-carboximidamide (A25): [00165] To a stirred solution of A24 (0.85 g, 6.84 mmol) in ethanol (20 mL) was added hydroxyl amine hydrochloride (0.48 g, 6.84 mmol) and triethyl amine (1.38 g, 13.69 mmol). The reaction mixture was stirred at 80 °C for 12 hours. The reaction mixture was concentrated under reduced pressure to give A25 (2.2 g) as a solid. The residue was used in the next reaction without further purification. Synthesis of tert-butyl ((S)-1-(3-((S)-3-methylpiperidin-1-yl)-1,2,4-oxadiazol-5- yl)ethyl)carbamate (A26): [00166] To a stirred solution of A25 (1 g, 6.36 mmol) in 1,4- dioxane (20 mL) was added N-Boc-L-alanine (1.2 g, 6.36 mmol) followed by the addition of DCC (1.31 g, 6.36 mmol) at room temperature and then stirred at 100 °C for 12 hours. The reaction mixture was concentrated under reduced pressure. The residue was diluted with EtOAc (30 mL) and washed with water (15 mL). The organic layer was again washed with water (10 mL x 2) and brine (10 mL). The organic layer was dried over anhydrous sodium sulphate, filtered, and evaporated to give the residue. The
residue was purified by flash column chromatography using 100-200 mesh silica and 20-25 % EtOAc in hexane as an eluent to give A27 (0.2 g,0.55 mmol, 9% yield) as an oil. Synthesis of (S)-1-(3-((S)-3-methylpiperidin-1-yl)-1,2,4-oxadiazol-5-yl)ethan-1-amine (A27): [00167] To a stirred solution of A26 (0.2 g, 0.64 mmol) in 1,4- dioxane (2 mL) was added 4M HCl in dioxane (5mL) at 0 °C and stirred at room temperature for 6 hours. The reaction mixture was concentrated under reduced pressure to give A27 (0.145 g,0.44 mmol) as an oil. Synthesis of Compound 13: [00168] To a stirred solution of A2 (0.1 g, 0.52 mmol) in DCM (10 mL) was added A27 (0.13 g, 0.52 mmol), HATU (0.24 g, 0.62 mmol) and DIPEA (0.18 mL, 1.03 mmol) at 0 °C and stirred at room temperature for 6 hours. The reaction mixture was diluted with DCM (10 mL) and water (5 mL). The organic layer was again washed with water (10 mL x 2) and brine (10 mL). The organic layer was dried over anhydrous sodium sulphate, filtered, and evaporated to give the residue. The residue was purified by flash column chromatography using 100-200 mesh silica and 20-25 % EtOAc in hexane as an eluent to give Compound 13 (100 mg,0.2536 mmol, 49% yield) as an oil. SOR : - 6.19, Concentration 0.2525 w/v%. HPLC: Rt 9.34 min, 97.9%; Column: X-Select CSH C18 (4.6 x 150) mm, 3.5 µm; Mobile phase: A: 0.1% Formic acid in water: ACN (95:05), B: ACN; Flow Rate: 1.0 mL/min. LCMS : 387.30 (M+H), Rt 2.12 min; Column: X-select CSH C18 (3 x 50) mm, 2.5 µm.1H NMR (400 MHz, DMSO-d6) δH = 9.30 (d, 1H), 7.42 (s, 1H), 5.23-5.19 (m, 1H), 4.12 (s, 3H), 3.74-3.70 (m, 2H), 2.86-2.78 (m, 1H), 1.76-1.44 (m, 7H), 1.11- 1.06 (m, 1H), 0.87 (d, 3H), 1H merged in solvent peak. Example 14. Synthesis of Synthesis of (S)-1-methyl-N-(1-(3-(piperidin-1-yl)-1,2,4-oxadiazol- 5-yl)ethyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (Compound 14)
Synthesis of piperidine-1-carbonitrile (A28): [00169] To a stirred solution of piperidine (500 mg, 5.87 mmol) in acetone (10 mL) at 0 °C was added K2CO3 (973 mg, 7.05 mmol) and cyanogen bromide (622 mg, 5.87 mmol). The reaction mixture was warmed to room temperature and stirred for 2 hours. The reaction mixture was concentrated, treated with water (30 mL), and extracted with ethyl acetate (2 x 50 mL). The organic layer was washed with brine (30 mL), dried over anhydrous Na2SO4, and concentrated to afford A28 (595 mg) as a liquid. The compound was used in the next step without further purification. Synthesis of (E)-N'-hydroxypiperidine-1-carboximidamide (A29): [00170] To a stirred solution of A28 (595 mg, 5.4 mmol) in ethanol (15.0 mL) was added hydroxylamine hydrochloride (561 mg, 8.07 mmol) and DIPEA (2.67 mL, 16.15 mmol). The reaction mixture was heated at 80 ºC for 3 hours. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was treated with water (20 mL) and extracted with ethyl acetate (2 x 30 mL). The organic layer was washed with brine (20 mL), dried over anhydrous Na2SO4, and concentrated to afford A29 (690 mg) which was used in the next step without further purification. Synthesis of tert-butyl (S)-(1-(3-(piperidin-1-yl)-1,2,4-oxadiazol-5-yl)ethyl)carbamate (A30): [00171] To a stirred solution of A29 (690 mg, 4.82 mmol) in 1,4-dioxane (20.0 mL) was added DCC (1.78 g, 8.67 mmol) and (2S)-2-(tert-butoxycarbonylamino)propanoic acid (1.36 g, 7.23 mmol). The reaction mixture was heated at 100 ºC for 12 hours. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The mixture was treated with water (30 mL) and extracted with ethyl acetate (2 x 30 mL). The organic layer was washed
with brine (20 mL), dried over Na2SO4, and concentrated. The residue was purified by column chromatography on silica gel with 38% EtOAc/PE to afford A30 (398 mg, 1.34 mmol, 27% yield). LCMS: 297.2 (M+H), Rt 2.36 min Column: ZORBAX XDB C-18 (50 x 4.6 mm), 3.5 µm Mobile Phase: A: 0.1% HCOOH in water:ACN (95:5), B: ACN; Flow Rate:1.5 mL/min. Synthesis of (S)-1-(3-(piperidin-1-yl)-1,2,4-oxadiazol-5-yl)ethan-1-amine (A31): [00172] To a stirred solution of A30 (398 mg, 1.34 mmol) in DCM (20.0 mL) was added TFA (1.0 mL) at 0 ºC. The reaction mixture was slowly warmed to room temperature and stirred for 4 hours. The mixture was concentrated under reduced pressure and treated with ice water (20 mL). The mixture was treated with 10% NaHCO3 solution (10 mL) and extracted with DCM (2 x 30 mL). The organic layer was washed with brine (20 mL), dried over Na2SO4, and concentrated to afford A31 (210 mg). The residue was used in the next step without further purification. Synthesis of Compound 14: [00173] To a stirred solution of 2-methyl-5-(trifluoromethyl)pyrazole-3-carboxylic acid (208 mg, 1.07 mmol) and A31 (210 mg, 1.07 mmol) in THF (20.0 mL) was added Et3N (0.45 mL, 3.21 mmol) and T3P (50% in EtOAc, 1.91 mL, 3.21 mmol) at 0 ºC. The reaction mixture was slowly warmed to room temperature and stirred for 12 hours. The reaction mixture was treated with water (40 mL) and extracted with ethyl acetate (2 x 30 mL). The organic layer was washed with brine (30 mL), dried over anhydrous Na2SO4, and concentrated. The residue was purified by preparative HPLC to afford Compound 14 (280 mg, 0.72 mmol, 67% yield) as a solid. Prep. HPLC method: Rt 9.5; Column: X-Bridge (150 x 19 mm), 5.0 µm; Mobile phase: 0.1% TFA in water/acetonitrile; Flow Rate: 15.0 mL/min. HPLC: Rt 4.79 min, 96.0% Column: X-Bridge C8 (50 x 4.6) mm, 3.5 µm Mobile phase: A: 0.1% TFA in water, B: 0.1% TFA in ACN; Flow Rate: 2.0 mL/min. LCMS: 373.1 (M+H), Rt 2.39 min, Column: ZORBAX XDB C-18 (50 x 4.6 mm), 3.5 µm Mobile Phase: A: 0.1% HCOOH in water:ACN (95:5), B: ACN; Flow Rate:1.5 mL/min. 1H NMR (400 MHz, CD3OD): δH = 7.20 (s, 1H), 5.28 (q, 1H), 4.16 (s, 3H), 3.42-3.39 (m, 4H), 1.65-1.63 (m, 9H). [00174] Example 15. Synthesis of 1-methyl-N-((1S)-1-(3-(3-methylpiperidin-1- yl)-1,2,4-oxadiazol-5-yl)ethyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (Compound 15)
Synthesis of 3-methylpiperidine-1-carbonitrile (A32): [00175] To a stirred solution of 3-methylpiperidine (1.0 g, 10.08 mmol) in acetone (20 mL) at 0 °C was added K2CO3 (1.67 g, 12.1 mmol) and cyanogen bromide (1.07 g, 10.08 mmol). The reaction mixture was warmed to room temperature and stirred for 2 hours. The reaction mixture was concentrated, treated with water (30 mL), and extracted with ethyl acetate (2 x 50 mL). The organic layer was washed with brine (30 mL), dried over anhydrous Na2SO4, and concentrated to afford A32 (970 mg) as a liquid. The compound was used in the next step without further purification. Synthesis of (E)-N'-hydroxy-3-methylpiperidine-1-carboximidamide (A33): [00176] To a stirred solution of A32 (970 mg, 7.81 mmol) in ethanol (15.0 mL) was added hydroxylamine hydrochloride (0.81 g, 11.71 mmol) and DIPEA (4.08 mL, 23.42 mmol). The reaction mixture was heated at 80 ºC for 2 hours. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was treated with water (20 mL) and extracted with ethyl acetate (2 x 30 mL). The organic layer was washed with brine (20 mL), dried over anhydrous Na2SO4, and concentrated to afford A33 (1.17 g). It was used for the next step without further purification. Synthesis of tert-butyl ((1S)-1-(3-(3-methylpiperidin-1-yl)-1,2,4-oxadiazol-5- yl)ethyl)carbamate (A34) [00177] To a stirred solution of A33 (1.17 g, 7.46 mmol) in 1,4-dioxane (20.0 mL) was added DCC (1.69 g, 8.21 mmol) and (2S)-2-(tert-butoxycarbonylamino)propanoic acid (1.41 g, 7.46 mmol). The reaction mixture was heated at 100 ºC for 16 hours. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The mixture was treated
with water (20 mL) and extracted with ethyl acetate (2 x 30 mL). The organic layer was washed with brine (20 mL), dried over Na2SO4, and concentrated. The residue was purified by column chromatography on silica gel with 35% EtOAc/PE to afford A34 (340 mg, 1.09 mmol, 14% yield). LCMS: 311.3 (M+H), Rt 2.55 min Column: ZORBAX XDB C-18 (50 x 4.6 mm), 3.5 µm Mobile Phase: A: 0.1% HCOOH in water:ACN (95:5), B: ACN; Flow Rate:1.5 mL/min. Synthesis of (1S)-1-(3-(3-methylpiperidin-1-yl)-1,2,4-oxadiazol-5-yl)ethan-1-amine (A35) [00178] To a stirred solution of A34 (340 mg, 1.09 mmol) in DCM (8.0 mL) was added TFA (3.0 mL) at 0 ºC. The reaction mixture was slowly warmed to room temperature and stirred for 2 hours. The mixture was concentrated under reduced pressure and treated with ice water (20 mL). The mixture was treated with 10% NaHCO3 solution (10 mL) and extracted with ethyl acetate (2 x 30 mL). The organic layer was washed with brine (20 mL), dried over Na2SO4, and concentrated to afford A35 (198 mg). The residue was used in the next step without further purification. Synthesis of Compound 15: [00179] To a stirred solution of 2-methyl-5-(trifluoromethyl)pyrazole-3-carboxylic acid (183 mg, 0.94 mmol) and A35 (198 mg, 0.94 mmol) in THF (10.0 mL) was added Et3N (0.39 mL, 2.83 mmol) and T3P (50% in EtOAc, 1.68 mL, 2.83 mmol) at 0 ºC. The reaction mixture was slowly warmed to room temperature and stirred for 16 hours. The reaction mixture was treated with water (20 mL) and extracted with ethyl acetate (2 x 30 mL). The organic layer was washed with brine (30 mL), dried over anhydrous Na2SO4, and concentrated. The residue was purified by preparative HPLC to afford Compound 15 (170 mg, 0.43 mmol, 46% yield) as a solid. Prep. HPLC method: Rt 10.6; Column: Sunfire C-18 (150 x 19 mm), 5.0 µm; Mobile phase: 0.1% TFA in water/acetonitrile; Flow Rate: 15.0 mL/min. HPLC: Rt 5.15 min, 99.7% Column: X-Bridge C8 (50 x 4.6) mm, 3.5 µm Mobile phase: A: 0.1% TFA in water, B: 0.1% TFA in ACN; Flow Rate: 2.0 mL/min. LCMS: 387.2 (M+H), Rt 2.54 min, Column: ZORBAX XDB C-18 (50 x 4.6 mm), 3.5 µm Mobile Phase: A: 0.1% HCOOH in water:ACN (95:5), B: ACN; Flow Rate:1.5 mL/min. 1H NMR (400 MHz, DMSO-d6): δH = 9.30 (d, 1H), 7.42 (s, 1H), 5.23-5.20 (m, 1H), 4.13 (s, 3H), 3.75-3.71 (m, 2H), 2.86-2.79 (m, 1H), 1.77-1.42 (m, 7H), 1.18-1.08 (m, 1H), 0.89 (d, 3H). Example 16. Synthesis of (S)-N-(1-(3-(3,3-dimethylpiperidin-1-yl)-1,2,4-oxadiazol-5- yl)ethyl)-1-methyl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (Compound 16)
Synthesis of 3,3-dimethylpiperidine-1-carbonitrile (A36) [00180] To a stirred solution of Na2CO3 (2.83 g, 26.73 mmol) in H2O (4.0 mL) was added 3,3-dimethylpiperidine hydrochloride (1.0 g, 6.68 mmol) at 10 ºC. The reaction mixture was stirred for 5 minutes, and cyanogen bromide (0.85 g, 8.02 mmol) in DCM (20 mL) was added drop-wise. The reaction mixture was warmed to room temperature and stirred for 1 hour. The reaction mixture was treated with water (30 mL) and extracted with DCM (2 x 30 mL). The organic layer was washed with brine (30 mL), dried over anhydrous Na2SO4, and concentrated to afford A36 (820 mg) as a liquid. The compound used in the next step without further purification. Synthesis of N'-hydroxy-3,3-dimethylpiperidine-1-carboximidamide (A37) [00181] To a stirred solution of A36 (820 mg, 5.93 mmol) in ethanol (10.0 mL) was added hydroxylamine hydrochloride (618 mg, 8.9 mmol) and DIPEA (1.8 mL, 17.8 mmol). The reaction mixture was heated at 80 ºC for 2 hours. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was treated with water (20 mL) followed by saturated sodium bicarbonate solution (20 mL) and extracted with ethyl acetate (2 x 30 mL). The organic layer was washed with brine (20 mL), dried over anhydrous Na2SO4, and concentrated to afford A37 (170 mg). The compound was used in the next step without further purification. Synthesis of tert-butyl (S)-(1-(3-(3,3-dimethylpiperidin-1-yl)-1,2,4-oxadiazol-5- yl)ethyl)carbamate (A38) [00182] To a stirred solution of A37 (170 mg, 0.99 mmol) in 1,4-dioxane (20.0 mL) was added DCC (245 mg, 1.19 mmol) and (2S)-2-(tert-butoxycarbonylamino)propanoic acid (281 mg, 1.49 mmol). The reaction mixture was heated at 100 ºC for 16 hours. The reaction mixture
was cooled to room temperature and concentrated under reduced pressure. The mixture was treated with water (20 mL) and extracted with ethyl acetate (2 x 30 mL). The organic layer was washed with brine (20 mL), dried over Na2SO4, and concentrated. The residue was purified by column chromatography on silica gel with 35% EtOAc/PE to afford A38 (320 mg, 0.99 mmol, 99% yield). LCMS: 325.3 (M+H), Rt 2.65 min Column: ZORBAX XDB C-18 (50 x 4.6 mm), 3.5 µm Mobile Phase: A: 0.1% HCOOH in water:ACN (95:5), B: ACN; Flow Rate:1.5 mL/min. Synthesis of (S)-1-(3-(3,3-dimethylpiperidin-1-yl)-1,2,4-oxadiazol-5-yl)ethan-1-amine (A39) [00183] To a stirred solution of A38 (320 mg, 0.99 mmol) in DCM (8.0 mL) was added TFA (1.0 mL) at 0 ºC. The reaction mixture was slowly warmed to room temperature and stirred for 4 hours. The mixture was concentrated under reduced pressure and treated with ice water (20 mL). The mixture was treated with 10% NaHCO3 solution (10 mL) and extracted with DCM (2 x 30 mL). The organic layer was washed with brine (20 mL), dried over Na2SO4, and concentrated to afford A39 (195 mg). The residue was used for the next step without further purification. Synthesis of Compound 16: [00184] To a stirred solution of 2-methyl-5-(trifluoromethyl)pyrazole-3-carboxylic acid (169 mg, 0.88 mmol) and A39 (195 mg, 0.87 mmol) in THF (10.0 mL) was added Et3N (0.37 mL, 2.63 mmol) and T3P (50% in EtOAc, 1.56 mL, 2.63 mmol) at 0 ºC. The reaction mixture was slowly warmed to room temperature and stirred for 16 hours. The reaction mixture was treated with water (20 mL) and extracted with ethyl acetate (2 x 30 mL). The organic layer was washed with brine (30 mL), dried over anhydrous Na2SO4, and concentrated. The residue was purified by preparative HPLC to afford Compound 16 (200 mg, 0.49 mmol, 56% yield) as a solid. Prep. HPLC method: Rt 11.31; Column: YMC C-18 (150 x 19 mm), 5.0 µm; Mobile phase: 10 mM NH4OAc in water/acetonitrile; Flow Rate: 15.0 mL/min. HPLC: Rt 5.39 min, 99.7% Column: X- Bridge C8 (50 x 4.6) mm, 3.5 µm Mobile phase: A: 0.1% TFA in water, B: 0.1% TFA in ACN; Flow Rate: 2.0 mL/min. LCMS: 401.2 (M+H), Rt 2.63 min, Column: ZORBAX XDB C-18 (50 x 4.6 mm), 3.5 µm Mobile Phase: A: 0.1% HCOOH in water:ACN (95:5), B: ACN; Flow Rate:1.5 mL/min. 1H NMR (400 MHz, CD3OD): δH = 7.20 (s, 1H), 5.28 (q, 1H), 4.17 (s, 3H), 3.38-3.32 (m, 2H), 3.11 (s, 2H), 1.69-1.63 (m, 5H), 1.45 (t, 2H), 0.96 (s, 6H).
Example 17. Synthesis of (S)-N-(1-(3-(5-azaspiro[2.5]octan-5-yl)-1,2,4-oxadiazol-5-yl)ethyl)- 1-methyl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (Compound 17)
Synthesis of 5-azaspiro[2.5]octane-5-carbonitrile (A40): [00185] To a stirred solution of sodium carbonate (1.4 g, 13.6 mmol) in water (4 mL) was added 5-azaspiro[2.5]octane hydrochloride (500 mg, 3.4 mmol) at 10 ºC. The reaction mixture was stirred for 5 minutes, and cyanogen bromide (792 mg, 7.48 mmol) in DCM (20.0 mL) was added drop-wise. The reaction mixture was warmed to room temperature and stirred for 1 hour. The reaction mixture was treated with water (30 mL) and extracted with DCM (2 x 30 mL). The organic layer was washed with brine (30 mL), dried over anhydrous Na2SO4, and concentrated to afford A40 (380 mg) as a liquid. The compound was used for the next step without further purification. Synthesis of N'-hydroxy-5-azaspiro[2.5]octane-5-carboximidamide (A41): [00186] To a stirred solution of A40 (380 mg, 2.80 mmol) in ethanol (10.0 mL) was added hydroxylamine hydrochloride (293 mg, 4.23 mmol) and DIPEA (1.47 mL, 8.46 mmol). The reaction mixture was heated at 80 ºC for 4 hours. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was treated with water (20 mL) followed by saturated sodium bicarbonate solution (20 mL) and extracted with ethyl acetate (2 x 30 mL). The organic layer was washed with brine (20 mL), dried over anhydrous Na2SO4, and concentrated to afford A41 (275 mg). The compound was used for the next step without further purification. Synthesis of tert-butyl (S)-(1-(3-(5-azaspiro[2.5]octan-5-yl)-1,2,4-oxadiazol-5- yl)ethyl)carbamate (A42):
[00187] To a stirred solution of A41 (275 mg, 1.63 mmol) in 1,4-dioxane (10.0 mL) was added DCC (401 mg, 1.95 mmol) and (2S)-2-(tert-butoxycarbonylamino)propanoic acid (460 mg, 2.44 mmol). The reaction mixture was heated at 100 ºC for 16 hours. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The mixture was treated with water (20 mL) and extracted with ethyl acetate (2 x 30 mL). The organic layer was washed with brine (20 mL), dried over Na2SO4, and concentrated. The residue was purified by column chromatography on silica gel with 38% EtOAc/PE to afford A42 (205 mg, 0.64 mmol, 39% yield). LCMS: 323.2 (M+H), Rt 2.52 min Column: ZORBAX XDB C-18 (50 x 4.6 mm), 3.5 µm Mobile Phase: A: 0.1% HCOOH in water:ACN (95:5), B: ACN; Flow Rate:1.5 mL/min. Synthesis of (S)-1-(3-(5-azaspiro[2.5]octan-5-yl)-1,2,4-oxadiazol-5-yl)ethan-1-amine (A43): [00188] To a stirred solution of A42 (205 mg, 0.64 mmol) in DCM (8.0 mL) was added TFA (2.0 mL) at 0 ºC. The reaction mixture was slowly warmed to room temperature and stirred for 4 hours. The mixture was concentrated under reduced pressure and treated with ice water (10 mL). The mixture was treated with 10% NaHCO3 solution (8.0 mL) and extracted with DCM (3 x 30 mL). The organic layer was washed with brine (20 mL), dried over Na2SO4, and concentrated to afford A43 (100 mg). The residue was used in the next step without further purification. Synthesis of Compound 17: [00189] To a stirred solution of 2-methyl-5-(trifluoromethyl)pyrazole-3-carboxylic acid (94 mg, 0.48 mmol) and (1S)-1-[3-(5-azaspiro[2.5]octan-5-yl)-1,2,4-oxadiazol-5- yl]ethanamine (100 mg, 0.45 mmol) in THF (10.0 mL) was added Et3N (0.2 mL, 1.45 mmol) and T3P (50% in EtOAc, 0.86vmL, 1.45 mmol) at 0 ºC. The reaction mixture was slowly warmed to room temperature and stirred for 16 hours. The reaction mixture was treated with water (25 mL) and extracted with ethyl acetate (2 x 40 mL). The organic layer was washed with saturated sodium bicarbonate solution (20 mL), washed with brine (20 mL), dried over Na2SO4, and concentrated. The residue was purified by preparative HPLC to afford Compound 17 (140 mg, 0.35 mmol, 72% yield) as a solid. Prep. HPLC method: Rt 6.1; Column: Atlantis C-18 (150 x 19 mm), 5.0 µm; Mobile phase: 0.1% TFA in water/acetonitrile; Flow Rate: 15.0 mL/min. HPLC: Rt 5.17 min, 99.5% Column: X-Bridge C8 (50 x 4.6) mm, 3.5 µm Mobile phase: A: 0.1% TFA in water, B: 0.1% TFA in ACN; Flow Rate: 2.0 mL/min. LCMS: 399.1 (M+H), Rt 2.44 min, Column: ZORBAX XDB C-18 (50 x 4.6 mm), 3.5 µm Mobile Phase: A: 0.1% HCOOH in water:ACN
(95:5), B: ACN; Flow Rate:1.5 mL/min. 1H NMR (400 MHz, CD3OD): δH = 7.21 (s, 1H), 5.28 (q, 1H), 4.18 (s, 3H), 3.47 (t, 2H), 3.23 (s, 2H), 1.78-1.72 (m, 2H), 1.64 (d, 3H), 1.51 (t, 2H), 0.48- 0.34 (m, 4H). Example 18. Synthesis of (S)-N-(1-(3-(azepan-1-yl)-1,2,4-oxadiazol-5-yl)ethyl)-1-methyl-3- (trifluoromethyl)-1H-pyrazole-5-carboxamide (18)
Synthesis of azepane-1-carbonitrile (A45): [00190] To a stirred solution of A44 (5 g, 50.42 mmol), in MeCN (60 mL) was added K2CO3 (13.93 g, 100.84 mmol) and cyanogen bromide (8.01 g, 75.63 mmol) at 0 ºC, and then reaction was stirred at room temperature for 16 hours. The reaction mixture was filtered through celite, and the filtrate was evaporated to give a residue, which was diluted with ethyl acetate and washed with water and brine. The organic layer was dried over sodium sulphate and evaporated to afford A46 (4 g, 32.14 mmol, 63 % yield) as a liquid, which was directly used in the next step. Synthesis of (E)-N'-hydroxyazepane-1-carboximidamide (A46): [00191] A stirred solution of A45 (2 g, 16.11 mmol), TEA (4.5 mL, 32.21 mmol) and hydroxylamine hydrochloride (1.68 g, 24.16 mmol) in ethanol (20 mL) was heated at 80 ºC for 16 hours. The solvent was evaporated to give a solid, which was triturated with diethyl ether and dried to give A46 (800 mg, 5.08 mmol, 31 % yield), which was used directly in the next step. Synthesis of tert-butyl (S)-(1-(3-(azepan-1-yl)-1,2,4-oxadiazol-5-yl)ethyl)carbamate (A47): [00192] To a stirred solution of A45 (500 mg, 3.18 mmol), DCC (720.69 mg, 3.5 mmol) and N-Boc-L-alanine (661.95 mg, 3.5 mmol) in 1,4-dioxane (5 mL) was heated at 100 ºC for 16 hours. The reaction mixture was diluted with water and extracted with ethyl acetate (3
times). The combined organic layer was washed with water and brine, dried over sodium sulphate, and evaporated to give a residue, which was purified by combi-flash chromatography using ethyl acetate:hexane as an eluent to give the product, which was further purified by prep HPLC to give A47 (600 mg, 1.89 mmol, 59 % yield). Synthesis of (S)-1-(3-(azepan-1-yl)-1,2,4-oxadiazol-5-yl)ethan-1-amine (A48): [00193] To a stirred solution of A47 (400.mg, 1.29 mmol) in 1,4- dioxane (2 mL) was added 4M HCl in 1,4-dioxane (6 mL) at 0 ºC and stirred at room temperature for 2 hours. The solvent was evaporated, and the solid was triturated with diethyl ether and dried to give A48 (200 mg, 0.81 mmol, 62 % yield), which was used for next step without further purification. Synthesis of Compound 18: [00194] To a mixture of A48 (200 mg, 0.81 mmol) and A2 (173.07 mg, 0.89 mmol) in DCM (5 mL) was added HATU (462.3 mg, 1.22 mmol), DIPEA (0.42 mL, 2.43 mmol) at room temperature and stirred for 3 hours. The reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (3 x 5ml). The combined organic layer was washed using saturated brine solution (10 ml), separated, dried over MgSO4, and evaporated to give the residue. The residue was purified by flash column chromatography using EtOAc as an eluent. The fractions were evaporated to dryness, and the residue was then purified by prep HPLC to give Compound 18 (85 mg, 0.22 mmol, 27 % yield) as a solid. HPLC: Rt 9.16 min, 99.8 % Column: X-Select CSH C18 (4.6*150) mm, 3.5 µm Mobile phase: A: 0.1% Formic acid in water B: Acetonitrile (95:05); Flow Rate: 1.0 mL/min. LCMS: 387.25 (M+H), Rt 2.18 min, Column: X-select CSH (3.0*50) mm, 2.5 µm.1H NMR (400 MHz, DMSO-d6) δH = 9.28 (d, 1H), 7.41 (s, 1H), 5.28-5.12 (m, 1H), 4.12 (s, 3H), 3.48-3.38 (m, 4H), 1.72-1.60 (m, 4H), 1.58-1.40 (m, 7H).
Example 19. Synthesis of (S)-1-methyl-N-(1-(3-(pyrrolidin-1-yl)-1,2,4-oxadiazol-5-yl)ethyl)- 3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (Compound 19)
Synthesis of pyrrolidine-1-carbonitrile (A50): [00195] To a stirred solution of A49 (5 g, 70.3 mmol) in THF (50 mL) was added TEA (9.81 mL, 70.3 mmol) and cyanogen bromide (7.45 g, 70.3 mmol) at 0 ºC and stirred at room temperature for 2 days. The reaction was quenched with water and extracted with ethyl acetate. The combined organic layer was washed with brine, dried over sodium sulphate, and evaporated to give A50 (2 g, 20.80 mmol, 29 % yield), which was directly used in the next step. Synthesis of (E)-N'-hydroxypyrrolidine-1-carboximidamide (A51): [00196] A stirred solution of A50 (2 g, 20.81 mmol), TEA (5.81 mL, 41.61 mmol) and hydroxylamine hydrochloride (2.17 g, 31.21 mmol) in ethanol (20 mL) was heated at 80 ºC for 16 hours. The solvent was evaporated and the solid was triturated with diethyl ether and dried to give A51 (500 mg, 3.87 mmol, 18 % yield) as a solid, which was used directly in the next step. Synthesis of tert-butyl (S)-(1-(3-(pyrrolidin-1-yl)-1,2,4-oxadiazol-5-yl)ethyl)carbamate (A53): [00197] A stirred solution of A51 (500 mg, 3.87 mmol), DCC (877.21 mg, 4.26 mmol) and N-Boc-L-alanine (805.71 mg, 4.26 mmol) in 1,4-dioxane (5 mL) was heated at 100 ºC for 16 hours. The reaction was diluted with water and extracted with ethyl acetate (3 times). The combined organic layer was washed with water and brine, dried over sodium sulphate, and evaporated to give a residue, which was purified by combi-flash chromatography in ethyl acetate: hexane and further by prep HPLC to afford desired A53 (400 mg, 1.41 mmol, 36 % yield) as a solid. Synthesis of (S)-1-(3-(pyrrolidin-1-yl)-1,2,4-oxadiazol-5-yl)ethan-1-amine (A54):
[00198] To a stirred solution of A54 (200 mg, 0.71 mmol) in 1,4- dioxane (2 mL) was added 4M HCl in 1,4-dioxane (6 mL) at 0 ºC and stirred at room temperature for 2 hours. The solvent was evaporated. The solid was triturated with diethyl ether and dried to give A54 (140 mg, 0.64 mmol, 90 % yield) as a solid, which was used in the next step directly. Synthesis of Compound 19: [00199] To a stirred solution of A54 (140 mg, 0.64 mmol) and A2 (136.7 mg, 0.70 mmol) in DCM (5 ml) was added HATU (365.14 mg, 0.96 mmol) followed by DIPEA (0.33 mL, 1.92 mmol) and stirred at room temperature for 3 hours. The reaction mixture was diluted with water and ethyl acetate (3 times). The organic layer was separated, washed with water and brine solution, and dried over Na2SO4 to obtain a residue. The residue was purified by combi flash column chromatography using EA:hexane as an eluent to give Compound 19 (85.1 mg, 0.23 mmol, 36 % yield) as a solid. HPLC: Rt 8.31 min, 97.9% Column: X-Select CSH C18 (4.6 x 150) mm, 5 µm Mobile phase: A: 0.1% Formic acid in water : Acetonitrile (95:05); B: Acetonitrile, Flow Rate: 1.0 mL/min. LCMS : 359.15 (M+H), Rt 1.95 min, Column: X-select CSH C18 (3 x 50) mm, 2.5 µm. 1H NMR (400 MHz, DMSO-d6) δH = 9.30 (d, 1H), 7.42 (s, 1H), 5.26-5.12 (m, 1H), 4.12 (s, 3H), 3.35-3.22 (m, 4H), 1.94 – 1.82 (m, 4H), 1.58-1.48 (m, 3H). Example 20. Synthesis of (S)-N-(1-(3-(3,3-difluoropiperidin-1-yl)-1,2,4-oxadiazol-5- yl)ethyl)-1-methyl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (Compound 20)
Synthesis of 3,3-difluoropiperidine-1-carbonitrile (A56): [00200] To a stirred solution of compound 1 (0.65 g, 4.12 mmol) in MeCN (15 mL) was added K2CO3 (1.71 g, 12.37 mmol) and cyanogen bromide (0.44 g, 4.12 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was filtered through a pad of celite, and the filtrate was concentrated under reduced pressure. The residue was diluted with EtOAc (30 mL) and water (15 mL). The separated organic layer was washed with water (10 mL x 2) and saturated brine solution (10 mL), dried over anhydrous sodium sulphate, and evaporated to dryness to give A56 (0.48 g, 3.17 mmol, 77% yield) as a solid. The residue was used without further purification. Synthesis of 3,3-difluoro-N'-hydroxy-piperidine-1-carboxamidine (A57): [00201] To a stirred solution of A56 (0.48 g, 3.28 mmol) in ethanol (10 mL) was added hydroxyl amine hydrochloride (0.23 g, 3.28 mmol) and triethylamine (0.66 g, 6.57 mmol). The reaction mixture was stirred at 80 °C for 12 hours. The reaction mixture was concentrated under reduced pressure to afford A57 (0.55 g, 2.98 mmol, 91% yield) as a solid. The residue was used without further purification. Synthesis of tert-butyl N-[(1S)-1-[3-(3,3-difluoro-1-piperidyl)-1,2,4-oxadiazol-5- yl]ethyl]carbamate (A58):
[00202] To a stirred solution of A57 (0.55 g, 3.07 mmol) in 1,4-dioxane (10 mL) was added N-Boc-L-alanine (0.58 g, 3.07 mmol) and DCC (0.63 g, 3.07 mmol), and the reaction mixture was stirred at 100 °C for 16 hours. The reaction mixture was concentrated under reduced pressure. The residue was diluted with EtOAc (50 mL) and water (20 mL). The separated organic layer was washed with water (20 mL x 2) and saturated brine solution (20 mL), dried over anhydrous MgSO4, and evaporated to dryness to give a residue, which was purified by flash column chromatography using silica gel and 30-35% EtOAc in hexane as an eluent to give A58 (0.4 g, 0.91 mmol) as a solid. Synthesis of (1S)-1-[3-(3,3-difluoro-1-piperidyl)-1,2,4-oxadiazol-5-yl]ethanamine hydrochloride (A59): [00203] To a stirred solution of A58 (0.4 g, 1.2 mmol) in 1,4- dioxane (2 mL) was added 4M HCl in dioxane (10 mL) at 0 °C and stirred at room temperature for 6 hours. The reaction mixture was evaporated under reduced pressure to obtain a solid, which was triturated with ether to give A59 (0.3 g, 1.05 mmol) as an oil. Synthesis of Compound 20: [00204] To a stirred solution of A2 (0.15 g, 0.77 mmol) in DCM (10 mL) was added A59 (0.23 g, 0.85 mmol), HATU (0.32 g, 0.85 mmol) and DIPEA (0.27 mL, 1.55 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 6 hours. The reaction mixture was diluted with DCM (20 mL) and water (10 mL). The organic layer was washed with water (10 mL x 2) and saturated brine solution (10 mL), dried over anhydrous MgSO4, and evaporated to dryness to give a residue, which was purified by flash column chromatography using 70-80 % EtOAc in hexane as an eluent to give Compound 20 (60 mg, 0.14 mmol, 18% yield) as an oil. HPLC: Rt 8.488 min, 93.7% Column: X-Select CSH C18 (4.6 x 150) mm, 3.5 µm Mobile phase: A: 0.1% Formic acid in water: ACN (95:05), B: ACN; Flow Rate: 1.0 mL/min. LCMS : 409 (M+H), Rt 2.095 min, Column: X-select CSH C18 (3 x 50) mm, 2.5 µm. 1H NMR (400 MHz, DMSO-d6) δH = 9.31 (d, 1H), 7.42 (s, 1H), 5.25-5.21 (m, 1H), 4.12 (s, 3H), 3.69 (t, 2H), 3.43-3.40 (m, 2H), 2.12-2.02 (m, 2H), 1.80-1.72 (m, 2H), 1.55 (d, 3H). Example 21. Synthesis of 2-methyl-5-(trifluoromethyl)-N-[(1S)-1-[3-[3-(trifluoromethyl)-1- piperidyl]-1,2,4-oxadiazol-5-yl]ethyl]pyrazole-3-carboxamide (21)
Synthesis of 3-(trifluoromethyl)piperidine-1-carbonitrile (A62): [00205] To a stirred solution of A61 (1.g, 6.53mmol) in MeCN (10 mL) was added K2CO3 (1.8 g, 13.06 mmol) and cyanogen bromide (1.0 g, 9.79mmol) at 0 °C. The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was quenched with water (10 mL), and EtOAc was added (100 mL x 2). The separated organic layer was dried over anhydrous sodium sulphate and evaporated to dryness to give a residue, which was purified by column chromatography using 00-200 silica and 30-80% EtOAc/Hexane as eluent to give A62 (1g, 3.93 mmol, 60 % yield). Synthesis of N'-hydroxy-3-(trifluoromethyl)piperidine-1-carboxamidine (A63): [00206] To a stirred solution of A62 (1.1g, 6.17mmol) in ethanol (20 mL) was added hydroxyl amine hydrochloride (514.89 mg, 7.41 mmol) and triethylamine (514.89 mg, 7.41 mmol). The reaction mixture was stirred at 80 °C for 6 hours. The reaction mixture was quenched using water (10 mL) and diluted with ethyl acetate (100 mL x2), and the organic layer was separated. The organic layer was then dried using sodium sulphate, filtered, and evaporated to give a residue, which was purified using column chromatography using 100-200 silica gel and 30-80% EtOAc/Hexane eluent to give A63 (1.1 g, 3.64 mmol, 59% yield).
Synthesis of tert-butyl N-[(1S)-1-[3-[3-(trifluoromethyl)-1-piperidyl]-1,2,4-oxadiazol-5- yl]ethyl]carbamate (A64): [00207] To a stirred solution of A63 (1.g, 4.74mmol)) in 1,4- dioxane (50 mL) was added N-Boc-L-alanine (895.97 mg, 4.74 mmol) and DCC (1063.26 mg, 5.16 mmol), and the reaction mixture was stirred at 100 °C for 12 hours. The reaction mixture was concentrated under reduced pressure. The residue was diluted with EtOAc (100 mL x 2) and water (10 mL). The separated organic layer was dried over anhydrous Na2SO4 and evaporated to dryness to give a residue, which was purified by flash column chromatography using silica gel and 30-80% EtOAc/Hexane as an eluent to give A64 (700 mg, 1.34 mmol, 28 % yield) as a solid. Synthesis of (1S)-1-[3-[3-(trifluoromethyl)-1-piperidyl]-1,2,4-oxadiazol-5-yl]ethanamine hydrochloride (A65): [00208] To a stirred solution of A64 (800 mg, 2.2 mmol) in 1,4-dioxane (5 mL) was added 4M HCl in dioxane (20 mL, 2.2 mmol) at 0 °C and stirred at room temperature for 2 hours. The reaction mixture was evaporated under reduced pressure to obtain a solid which was triturated with ether to give A65 (500 mg, 1.163 mmol, 53 % yield) as an oil. Synthesis of Compound 21: [00209] To a stirred solution of A2 (387.3mg, 2mmol) in DCM (10 mL) was added A65 (500 mg, 1.66 mmol), HATU (948.33 mg, 2.49 mmol) and DIPEA (0.58 mL, 3.33 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was diluted with DCM (50 mL x 2) and water (10 mL). The organic layer was washed with water (10 mL x 2) and saturated brine solution (10 mL), dried over anhydrous by Na2SO4, and evaporated to dryness to give a residue, which was purified by flash column chromatography using 30-80% EtOAc/Hexane eluent as an eluent to give 21 (122 mg, 0.27 mmol, 16 % yield) as a solid. HPLC: Rt 9.368 min, 98.6%; Column: X-Select CSH C18 (4.6 x 150) mm, 3.5 µm; Mobile phase: A: 0.1% Formic acid in water: ACN (95:05), B: ACN; Flow Rate: 1.0 mL/min; LCMS : 440.9 (M+H), Rt 2.21 min. Column: X-select CSH C18 (3 x 50) mm, 2.5 µm. 1H NMR (400 MHz, DMSO-d6) δH = 9.31 (d, 1H), 7.42 (s, 1H), 5.24-5.20 (m, 1H), 4.12 (s, 3H), 3.96-3.92 (m, 1H), 3.78-3.75 (m, 1H), 3.03-2.91 (m, 2H), 2.65-2.55 (m, 1H), 2.00-1.95 (m, 1H), 1.80-1.74 (m, 1H), 1.60-1.48 (m, 5H).
Example 22. Synthesis of 2-methyl-N-[(1S)-1-[3-(3-methylpyrrolidin-1-yl)-1,2,4-oxadiazol- 5-yl]ethyl]-5-(trifluoromethyl)pyrazole-3-carboxamide (22)
Synthesis of 3-methylpyrrolidine-1-carbonitrile (A67) [00210] To a stirred solution of A66 (1 g, 8.22 mmol) in MeCN (20 mL) was added K2CO3 (3.41 g, 24.67 mmol) and cyanogen bromide (1.31 g, 12.33 mmol) at 0 °C and stirred at room temperature for 16 hours. The reaction mixture was filtered using celite bed. The filtrate was evaporated, the residue was diluted with EtOAc (30 ml) and water (15 ml), and the organic layer was separated. The organic layer was washed with water (2 x 10 mL) and saturated brine solution (10 mL), separated, dried over anhydrous Na2SO4, and evaporated to give A67 (0.88 g, 7.99 mmol, 97 % yield) as a liquid. Synthesis of N'-hydroxy-3-methyl-pyrrolidine-1-carboxamidine (A68) [00211] To a stirred solution of A67 (0.88 g, 7.99 mmol) in ethanol (20 mL) was added hydroxyl amine hydrochloride (0.56 g, 7.99 mmol), triethyl amine (1.61 g, 15.98 mmol) and heated to 80 °C for 12 hours. The reaction mixture was evaporated to give A68 (1 g, 2.84 mmol, 35% yield) as an oil. Synthesis of tert-butyl N-[(1S)-1-[3-(3-methylpyrrolidin-1-yl)-1,2,4-oxadiazol-5- yl]ethyl]carbamate (A69) [00212] To a stirred solution of A68 (1.g, 6.98 mmol) in 1,4-dioxane (15 mL) was added N-Boc-L-alanine (1.45 g, 7.68 mmol), DCC (1.58 g, 7.68 mmol) and heated to 100 °C for 12 hours. The reaction mixture was evaporated, the residue was diluted with EtOAc (50 mL) and water (20 mL), and the organic layer was separated. The organic layer was washed with water (2
x 20 mL) and saturated brine solution (20 mL), dried over MgSO4, and evaporated to dryness to give a residue. The residue was then purified by flash column chromatography using 30 % EtOAc in hexane as an eluent to give A69 (0.3 g, 0.34 mmol, 5 % yield) as a solid Synthesis of rac-(1S)-1-[3-(3-methylpyrrolidin-1-yl)-1,2,4-oxadiazol-5-yl]ethanamine hydrochloride (A70) [00213] To a stirred solution of A69 (0.3 g, 1.01 mmol) in 1,4-dioxane (2 mL) was added 4M HCl in dioxane (10 mL, 1.01 mmol) at 0 °C and stirred at room temperature for 6 hours. The reaction mixture was evaporated to dryness in vacuo to give A70 (0.18 g, 0.45 mmol, 45 % yield) as a solid. Synthesis of 22: [00214] To a stirred solution of A2 (0.14 g, 0.72 mmol) and A70 ((0.17 g, 0.72 mmol) in DCM (10 mL) was added HATU (0.27 g, 0.72 mmol) and DIPEA (0.25 mL, 1.44 mmol) at 0 °C and stirred at room temperature for 6 hours. The reaction mixture was diluted with DCM (20 mL) and washed with water (10 mL) The organic layer was dried over anhydrous magnesium sulfate, filtered, and evaporated to give the residue. The residue was purified by prep HPLC to give 22 (90 mg, 0.24 mmol, 33% yield) as an oil. HPLC: Rt 8.759 min, 99.8%; Column: X-Select CSH C18 (4.6 x 150) mm, 5 µm; Mobile phase: A: 0.1% Formic acid in water: ACN (95:05), B: ACN; Flow Rate: 1.0 mL/min. LCMS : 373.05 (M+H), Rt 1.92 min, Column: X-select CSH C18 (3 x 50) mm, 2.5 µm.1H NMR (400 MHz, DMSO-d6) δH = 9.02 (d, 1H), 7.43 (s, 1H), 5.22-5.18 (m, 1H), 4.12 (s, 3H), 3.50-3.25 (m, 3H), 2.87-2.83 (m, 1H), 2.33-2.27 (m, 1H), 2.07- 2.00 (m, 1H), 1.58-1.49 (m, 4H), 1.03 (d, 3H). Example 23. Synthesis of N-[(1S)-1-[3-(diethylamino)-1,2,4-oxadiazol-5-yl]ethyl]-2-methyl- 5-(trifluoromethyl)pyrazole-3-carboxamide (23)
Synthesis of diethylcyanamide (A72) [00215] To a stirred solution of A71 (1.43 mL, 13.67 mmol) in ACN (20 mL) was added cyanogen bromide (2 g, 20.51 mmol), K2CO3 (3.9 g, 27.34 mmol) and stirred for 16 hours at room temperature. The reaction was quenched by water (10mL) and diluted with EtOAc (100 mL x 2). The organic layer was separated, dried over Na2SO4, filtered, and evaporated to give a residue, which was purified by column chromatography using 100-200 silica and 30-80% EtOAc/Hexane as an eluent to give A72 (1.1g, 10.08 mmol, 74% yield) as an oil. Synthesis of 1,1-diethyl-2-hydroxy-guanidine (A73) [00216] To a stirred solution of A72 (1.1 g, 10.09 mmol) in ethanol (20 mL) was added hydroxylamine hydrochloride (841.1 mg, 12.1 mmol) and TEA (2.82 mL, 20.17 mmol), and the mixture was stirred at 80 ºC for 6 hours. The reaction mixture was quenched using water (10 mL) and diluted with EtOAc (100 mL x 2). The organic layer was separated, dried over Na2SO4, filtered, and evaporated to give a residue. The residue was purified by column chromatography using 100-200 silica and 30-80% EtOAc/hexane as an eluent to give A73 (1.2 g, 8.507 mmol, 84 % yield) as a solid. Synthesis of tert-butyl N-[(1S)-1-[3-(diethylamino)-1,2,4-oxadiazol-5-yl]ethyl]carbamate (A74) [00217] To a stirred solution of A73 (1.g, 7.09 mmol) and (2S)-2-(tert- butoxycarbonylamino)propanoic acid (1341.4 mg, 7.09 mmol) in 1,4-dioxane (50mL) was added DCC (1591.88 mg, 7.73 mmol) and stirred for 12 hours at 100 ºC. The reaction mixture was quenched by water (10mL) and diluted with EtOAc (100 mL x 2). The organic layer was separated, dried over Na2SO4, filtered, and evaporated to give a residue, which was purified by column
chromatography using 100-200 silica and 30-80% EtOAc/hexane as an eluent to give A74 (200 mg, 0.2391 mmol, 3 % yield) as a solid. Synthesis of 5-[(1S)-1-aminoethyl]-N,N-diethyl-1,2,4-oxadiazol-3-amine hydrochloride (A75) [00218] To a stirred solution of A74 (200 mg, 0.24 mmol) in 1,4-dioxane (5 mL) was added 4M HCl in 1,4-dioxane (10 mL, 0.24 mmol) then stirred at 0 ºC for 2 hours. The reaction mixture was evaporated to give a residue, which was washed by diethyl ether to give A75 (100 mg, 0.1541 mmol, 64% yield) as a solid. Synthesis of 23 [00219] To a stirred solution of A75 (100.mg, 0.15 mmol) and A2 (35.88 mg, 0.18 mmol) in DCM (10 mL) was added HATU (87.86 mg, 0.23 mmol) and DIPEA (0.05 mL, 0.30 mmol) at room temperature and stirred at room temperature for 2 hours. The reaction mixture was quenched with water (10 mL) and diluted with DCM (50 mL x 2). The organic layer was dried over anhydrous sodium sulphate, filtered, and evaporated to give a residue. The residue was purified by column chromatography using 100-200 silica and 30-80% EtOAc/hexane as an eluent to give 23 (12mg, 0.033 mmol, 21 % yield) as a solid. HPLC: Rt 8.558 min, 99.5%; Column: X- Select CSH C18 (4.6 x 150) mm, 3.5 µm; Mobile phase: A: 0.1% Formic acid in water: ACN (95:05), B: ACN; Flow Rate: 1.0 mL/min. LCMS : 361.05 (M+H), Rt 1.947 min, Column: X- select CSH (3 x 50) mm, 2.5 µm; 1H NMR (400 MHz, DMSO-d6) δH = 9.27 (d, 1H), 7.40 (s, 1H), 5.19 (quin, 1H), 4.11 (s, 3H), 3.23-3.38 (m, 4H), 1.53 (d, 3H), 1.08 (t, 6H). Example 24. Synthesis of (S)-1-methyl-N-(1-(3-(4-methylpiperidin-1-yl)-1,2,4-oxadiazol-5- yl)ethyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (24)
Synthesis of 4-methylpiperidine-1-carbonitrile (A77) [00220] To a stirred solution of A76 (1 g, 10.08 mmol) in MeCN (20 mL) was added K2CO3 (2.8 g, 20.17mmol) followed by addition of cyanogen bromide (1.07 g, 10.08 mmol) at 0 °C under nitrogen and stirred at room temperature for 16 hours. The residue was diluted with EtOAc, and insoluble material was separated by filtration. The organic layer was washed with water and brine, dried over anhydrous sodium sulphate, filtered, and evaporated under reduced pressure to give A77 (1.1 g, 6.2 mmol, 61 % yield) as a liquid. Synthesis of N'-hydroxy-4-methyl-piperidine-1-carboxamidine (A78) [00221] To a stirred solution of A77 (1.1 g, 6.2 mmol) in ethanol (15 mL) was added hydroxyl amine hydrochloride (0.43 g, 6.2 mmol) and triethyl amine (1.73 mL, 12.4 mmol). The reaction mixture was stirred at 80 °C for 16 hours. The solvent was removed to give a residue, which was triturated with diethyl ether and dried under reduced pressure to give A78 (1.2g, 4.58 mmol, 74 % yield) as a solid which was used for next step without further purification. Synthesis of tert-butyl N-[(1S)-1-[3-(4-methyl-1-piperidyl)-1,2,4-oxadiazol-5- yl]ethyl]carbamate (A79): [00222] To a stirred solution of A78 (1.2g, 4.58mmol) in 1,4-dioxane (30 mL) was added N-Boc-L-alanine (866.6 mg, 4.58 mmol) followed by the addition of DCC (1.0 g, 4.99mmol) at room temperature and stirred at 100 °C for 16 hours. The reaction mixture was quenched with water and extracted with ethyl acetate (3 times). The combined organic layer was washed with water, saturated aqueous sodium bicarbonate, and brine. The organic layer was then dried over sodium sulphate and evaporated to give a residue, which was purified by column chromatography using silica gel and ethyl acetate:hexane as an eluent to give A79 (0.3 g, 0.68 mmol, 15 % yield) as a solid. Synthesis of ((1S)-1-[3-(4-methyl-1-piperidyl)-1,2,4-oxadiazol-5-yl]ethanamine hydrochloride (A80) [00223] To a stirred solution of A79 (0.3 g, 0.97 mmol) in 1,4-dioxane (10 mL) was added 4M HCl in dioxane (10 mL, 0.97 mmol) at 0 °C and stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure, triturated with diethyl ether, and
dried to give A80 (200 mg, 0.53 mmol, 55 % yield) as a solid, which was used for next step without further purification. Synthesis of 24 [00224] To a stirred solution of A79 (200 mg, 0.53 mmol) in DCM (5 mL) was added A2 (124.61 mg, 0.64 mmol), HATU (305.12 mg, 0.8 mmol) and DIPEA (0.19 mL, 1.07 mmol) in water (1 mL) at room temperature and stirred at room temperature for 2 hours. The reaction mixture was quenched by water and diluted with DCM. The organic layer was dried over sodium sulphate and concentrated to give a residue, which was purified by prep HPLC to give 24 (20 mg, 0.051 mmol, 9 % yield) as a solid. HPLC: Rt 9.411 min, 98.1%; Column: X-Select CSH C18 (4.6 x 150) mm, 3.5 µm; Mobile phase: A: 0.1%; Formic acid in water: ACN (95:05), B: ACN; Flow Rate: 1.0 mL/min. LCMS : 387.30 (M+H), Rt 2.077 min, Column: X-select CSH (3 x 50) mm, 2.5 µm. 1H NMR (400 MHz, DMSO-d6) δH = 9.29 (d, 1H), 7.42 (s, 1H), 5.21 (quin, 1H), 4.12 (s, 3H), 3.79 (d, 2H), 2.86 (t, 2H), 1.62-1.72 (m, 2H), 1.54 (d, 4H), 1.02-1.30 (m, 2H), 0.91 (d, 3H). Example 25. Synthesis of (S)-N-(1-(3-(4,4-dimethylpiperidin-1-yl)-1,2,4-oxadiazol-5- yl)ethyl)-1-methyl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (25)
Synthesis 4,4-dimethylpiperidine-1-carbonitrile (A82): [00225] To a stirred solution of A81 (500 mg, 4.42 mmol) was added carbononitridic bromide (701.77 mg, 6.63 mmol) and K2CO3 (1220.85 mg, 8.83 mmol), and the mixture was stirred at room temperature for 16 hours. The reaction mixture was quenched using water (10 mL) and diluted with EtOAc (50 x 2mL). The organic layer was separated, dried over Na2SO4, filtered,
and evaporated under reduced pressure to get a residue. The residue was purified by column chromatography using 100-200 silica and 30-80% EtOAc/Hexane eluent as an eluent to get A82 (400 mg, 1.74 mmol, 39 % yield) Synthesis of N'-hydroxy-4,4-dimethyl-cyclohexanecarboxamidine (A83): [00226] To a stirred solution of A82 (400 mg, 2.89 mmol) was added hydroxylamine hydrochloride (144.8 mg, 2.08 mmol) and TEA (0.48 mL, 3.47 mmol), and the mixture was stirred for 6 hours at 80 ºC. The reaction mixture was quenched using water (10 mL) and diluted with EtOAc (50x2 ml). The organic layer was separated, dried over Na2SO4, filtered, and evaporated to give a residue, which was purified by column chromatography using 100-200 silica and 30-80% EtOAc/Hexane as an eluent to give A83 (450 mg, 1.98 mmol, 68 % yield). Synthesis of tert-butyl N-[(1S)-1-[3-(4,4-dimethyl-1-piperidyl)-1,2,4-oxadiazol-5- yl]ethyl]carbamate (A84): [00227] To a stirred solution of A83 (450 mg, 2.63 mmol) and (2S)-2-(tert- butoxycarbonylamino)propanoic acid (497.22 mg, 2.63 mmol) in 1,4-Dioxane (15 mL) was added DCC (590.07 mg, 2.86 mmol), and the mixture was stirred for 12 hours at 100 ºC. The reaction mixture was quenched with water (10 mL) and diluted with EtOAc (50 x 2mL). The organic layer was separated, dried over Na2SO4, filtered, and evaporated under reduced pressure to get a residue, which was purified by column chromatography using 100-200 silica and 30-80% EtOAc/Hexane as an eluent to get A84 (100 mg, 0.123 mmol, 5 % yield) as a solid. Synthesis of (1S)-1-[3-(4,4-dimethyl-1-piperidyl)-1,2,4-oxadiazol-5-yl]ethanamine hydrochloride (A85): [00228] To a stirred solution of A84 (100 mg, 0.31 mmol) in 1,4-Dioxane (5 mL) was added 4M HCl in 1,4-dioxane (5.mL, 0.31 mmol) and the mixture was stirred at 0 ºC for 2 hours. The reaction mixture was evaporated under reduced pressure, and the resulting solid was washed using diethyl ether to get A85 (70 mg, 0.08 mmol, 26 % yield) as an oil. Synthesis of (S)-N-(1-(3-(4,4-dimethylpiperidin-1-yl)-1,2,4-oxadiazol-5-yl)ethyl)-1-methyl-3- (trifluoromethyl)-1H-pyrazole-5-carboxamide (25):
[00229] To a stirred solution of A85 (70 mg, 0.27 mmol) and A2 (62.53 mg, 0.32 mmol) in DCM (10mL) was added HATU (153.11 mg, 0.4 mmol) and DIPEA (0.09 mL, 0.54 mmol) at room temperature, and the mixture was stirred for 2 hours at room temperature. The reaction mixture was quenched using water (10 mL) and diluted with DCM (50mL), and the organic layer was separated. The organic layer was dried over Na2SO4, filtered, and evaporated under reduced pressure to get a residue, which was purified by column chromatography using 100- 200 silica and 30-80% EtOAc/Hexane as an eluent to give 25 (5mg, 0.0119mmol, 4 % yield) as a solid. HPLC: Rt 9.395 min, 95.6%; Column: X-Select CSH C18 (4.6 X 150) mm, 3.5 µm; Mobile phase: A: 0.1% Formic acid in water: ACN (95:05), B: ACN; Flow Rate: 1.0 mL/min. LCMS : 399 (M-H), Rt 2.417 min, Column: X-select CSH C18 (3*50) mm, 2.5 µm; 1H NMR (400 MHz, DMSO-d6) δH = 9.29 (d, 1H), 7.42 (s, 1H), 5.22-5.19 (m, 1H), 4.12 (s, 3H), 3.32-3.31 (m, 4H), 1.54 (d, 3H), 1.36-1.33 (m, 4H), 0.94 (s, 6H). Chiral method: Rt 7.534 min, 94.9% min; column: DIACEL CHIRALPAK-IG (250x4.6mm,5u), - Mobile Phase: A) n-Hexane+0.1%Iso-propyl- amine B) DCM: MeOH (1:1), Isocratic:10%B; Wavelength: 254 nm, Flow: 1.0 mL/min. Example 26. Efficacy of exemplary compounds in the inhibition of KCNT1 KCNT1-WT-Basal – Patch Clamp Assay [00230] Inhibition of KCNT1 (of KCNT1 (KNa1.1, Slack) was evaluated using a tetracycline inducible cell line (HEK-TREX). Currents were recorded using the SyncroPatch 384PE automated, patch clamp system. Pulse generation and data collection were performed with PatchController384 V1.3.0 and DataController384 V1.2.1 (Nanion Technologies). The access resistance and apparent membrane capacitance were estimated using built-in protocols. Current were recorded in perforated patch mode (10 µM escin) from a population of cells. The cells were lifted, triturated, and resuspended at 800,000 cells/ml. The cells were allowed to recover in the cell hotel prior to experimentation. Currents were recorded at room temperature. The external solution contained the following (in mM): NaCl 105, NMDG 40, KCl 4, MgCl21, CaCl2 5 and HEPES 10 (pH = 7.4, Osmolarity ~300 mOsm). The extracellular solution was used as the wash, reference and compound delivery solution. The internal solution contained the following (in mM): NaCl 105, NMDG 40, KCl 4, MgCl2 1, CaCl2 5 and HEPES 10 (pH = 7.4, Osmolarity ~300 mOsm). The extracellular solution was used as the wash, reference and compound delivery solution. The internal solution contained the following (in mM): NaCl 70, KF 70, KCl 10, EGTA
5, HEPES 5 and Escin 0.01 (pH = 7.2, Osmolarity ~295 mOsm). Escin is made at a 5mM stock in water, aliquoted, and stored at -20°C. The compound plate was created at 2x concentrated in the extracellular solution. The compound was diluted to 1:2 when added to the recording well. The amount of DMSO in the extracellular solution was held constant at the level used for the highest tested concentration. A holding potential of -80 mV with a 100ms step to 0mV was used. Mean current was measured during the step to 0 mV. 100 µM Bepridil was used to completely inhibit KCNT1 current to allow for offline subtraction of non-KCNT1 current. The average mean current from 3 sweeps was calculated and the % inhibition of each compound was calculated. The % Inhibition as a function of the compound concentration was fit with a Hill equation to derive IC50, slope, min and max parameters. If KCNT1 inhibition was less than 50% at the highest tested concentration or if an IC50 could not be calculated, then a percent inhibition was reported in place of the IC50. [00231] Results from this assay are summarized in Table 1 below. In this table, “A” indicates IC50 of less than or equal to1 µM; “B” indicates inhibition of between 1 µM to 20 µM; and “C” indicates inhibition of greater than or equal to 20 µM. N/A indicates not tested. [00232] Table 1
Equivalents and Scope [00232] In the claims articles such as “a,” “an,” and “the” may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The invention includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The disclosure includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process. [00233] Furthermore, the embodiments encompass all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the listed claims is introduced into another claim. For example, any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim. Where elements are presented as lists, e.g., in Markush group format, each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It should it be understood that, in general, where the embodiment, or aspects of the embodiment, is/are referred to as comprising particular elements and/or features, certain embodiments or aspects of the embodiments consist, or consist essentially of, such elements and/or features. For purposes of simplicity, those embodiments have not been specifically set forth in haec verba herein. It is also noted that the terms “comprising” and “containing” are intended to be open and permits the inclusion of additional elements or steps. Where ranges are given, endpoints are included. Furthermore, unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value or sub–range within the stated ranges
in different embodiments of the disclosure, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise. [00234] This application refers to various issued patents, published patent applications, journal articles, and other publications, all of which are incorporated herein by reference. If there is a conflict between any of the incorporated references and the instant specification, the specification shall control. In addition, any particular embodiment of the present disclosure that falls within the prior art may be explicitly excluded from any one or more of the claims. Because such embodiments are deemed to be known to one of ordinary skill in the art, they may be excluded even if the exclusion is not set forth explicitly herein. Any particular embodiment can be excluded from any claim, for any reason, whether or not related to the existence of prior art. [00235] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation many equivalents to the specific embodiments described herein. The scope of the present embodiments described herein is not intended to be limited to the above Description, but rather is as set forth in the appended claims. Those of ordinary skill in the art will appreciate that various changes and modifications to this description may be made without departing from the spirit or scope of the present invention, as defined in the following claims.
Claims
CLAIMS 1. A compound of Formula I having an oxadiazole core:
, or a pharmaceutically acceptable salt thereof, wherein R1 is chosen from a C1-6alkyl, a C1-6haloalkyl, or a C3-10cycloalkyl, wherein the C1-6alkyl, C1-6haloalkyl, and C3-10cycloalkyl optionally comprises a substituent chosen from C1-6alkoxy or N(R8)2; R2 is chosen from hydrogen or a C1-4alkyl; R3 is chosen from a C1-6alkyl optionally comprising a C1-6alkoxy substituent; R4 is chosen from hydrogen or a C1-6alkyl; R5 is chosen from a C1-6alkyl or a C1-6haloalkyl; R6 is chosen from a hydrogen, a C1-6alkyl, a C3-10cycloalkyl, a phenyl, or a 3-10 membered heterocyclyl, wherein the C1-6alkyl, C3-10cycloalkyl, phenyl, or 3-10 membered heterocyclyl may optionally comprise one or more substituents chosen from a halogen, -CN, - OH, a C1-6alkyl, a C1-6haloalkyl, a C1-6alkoxy, a phenyl, a C3-10cycloalkyl, or a 3-10 membered heterocyclyl; R7 is chosen from a C1-6alkyl, a C3-10cycloalkyl, a phenyl, or a 3-10 membered heterocyclyl, wherein the C1-6alkyl, C3-10cycloalkyl, phenyl, or 3-10 membered heterocyclyl may optionally comprise one or more substituents chosen from a halogen, -CN, -OH, a C1-6alkyl, a C1-6haloalkyl, a C1-6alkoxy, a phenyl, a C3-10cycloalkyl, or a 3-10 membered heterocyclyl; or R6 and R7 are taken together with the nitrogen attached to R6 and R7 to form a 3-10 membered heterocyclyl ring optionally comprising one or more substituents chosen from a halogen, -CN, -OH, a C1-6alkyl, a C1-6haloalkyl, a phenyl, a C3-10cycloalkyl, or a 3-10 membered heterocyclyl, wherein the C1-6alkyl is optionally substituted with oxo; each R8 is independently chosen from hydrogen or a C1-6alkyl; and x is 0, 1 or 2.
6. The compound of any one of claims 1-3, wherein R3 is C1-6alkyl and R4 is hydrogen.
7. The compound of any one of claims 1-3 and 6, wherein R2 is hydrogen.
8. The compound of any one of claims 1-7, wherein R1 is C1-6alkyl.
9. The compound of any one of claims 1-8, wherein R1 is methyl.
10. The compound of any one of claims 1-9, wherein x is 1 or 2.
11. The compound of any one of claims 1-10, wherein x is 1.
12. The compound of any one of claims 1-11, wherein R5 is C1-6haloalkyl.
13. The compound of any one of claims 1-12, wherein R5 is -CF3.
14. The compound of any one of claims 1-13, wherein R6 is hydrogen and R7 is C1-6alkyl.
15. The compound of any one of claims 1-13, wherein R6 and R7 are each C1-6alkyl optionally comprising a phenyl substituent.
16. The compound of any one of claims 1-13, wherein R6 and R7 are taken together with the nitrogen attached to R6 and R7 to form a 3-10 membered heterocyclyl ring optionally comprising one or more substituents chosen from a halogen, a C1-6alkyl, or a C1-6haloalkyl.
18. A pharmaceutical composition comprising a compound of any one of claims 1-17 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
19. A method of treating a neurological disorder, wherein the method comprises administering to a subject in need thereof an effective amount of a compound of any one of claims 1-17 or a pharmaceutically acceptable salt thereof or a pharmaceutical composition of claim 18.
20. A method of treating a disorder associated with excessive neuronal excitability, wherein the method comprises administering to a subject in need thereof an effective amount of a compound of any one of claims 1-17 or a pharmaceutically acceptable salt thereof or a pharmaceutical composition of claim 18.
21. A method of treating a disorder associated with a gain-of-function mutation of a gene (e.g., KCNT1), wherein the method comprises administering to a subject in need thereof an effective amount of a compound of any one of claims 1-17 or a pharmaceutically acceptable salt thereof or a pharmaceutical composition of claim 18.
22. The method of any one of claims 19-21, wherein the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation of a gene (e.g., KCNT1) is epilepsy, an epilepsy syndrome, or an encephalopathy.
23. The method of any one of claims 19-21, wherein the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation of a gene (e.g., KCNT1) is a genetic or pediatric epilepsy or a genetic or pediatric epilepsy syndrome.
24. The method of any one of claims 19-21, wherein the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation of a gene (e.g., KCNT1) is a cardiac dysfunction.
25. The method of any one of claims 19-21, wherein the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation of a gene (e.g., KCNT1) is chosen from epilepsy and other encephalopathies (e.g., malignant migrating focal seizures of infancy (MMFSI) or epilepsy of infancy with migrating focal seizures (EIMFS), autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), West syndrome, infantile spasms, epileptic encephalopathy, focal epilepsy, Ohtahara syndrome, developmental and epileptic encephalopathy, and Lennox-Gastaut syndrome), seizures (e.g., Generalized tonic clonic seizures, Asymmetric Tonic Seizures), leukodystrophy, leukoencephalopathy, intellectual disability, Multifocal Epilepsy, drug-resistant epilepsy, Temporal lobe epilepsy, or cerebellar ataxia.
26. The method of any one of claims 19-21, wherein the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation of a gene (e.g., KCNT1) is chosen from cardiac arrhythmia, Brugada syndrome, and myocardial infarction.
27. The method of any one of claims 19-21, wherein the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function
mutation of a gene (e.g., KCNT1) is selected from pain and related conditions (e.g., neuropathic pain, acute/chronic pain, migraine).
28. The method of any one of claims 19-21, wherein the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation of a gene (e.g., KCNT1) is a muscle disorder (e.g., myotonia, neuromyotonia, cramp muscle spasms, spasticity).
29. The method of any one of claims 19-21, wherein the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation of a gene (e.g., KCNT1) is selected from itch and pruritis, ataxia, or cerebellar ataxias.
30. The method of any one of claims 19-21, wherein the neurological, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation of a gene (e.g., KCNT1) is selected from psychiatric disorders (e.g., major depression, anxiety, bipolar disorder, schizophrenia).
31. The method of any one of claims 19-21, wherein the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation in a gene (e.g., KCNT1) is chosen from a learning disorder, Fragile X, neuronal plasticity, or an autism spectrum disorder.
32. The method of any one of claims 19-21, wherein the neurological disorder, the disorder associated with excessive neuronal excitability, or the disorder associated with a gain-of-function mutation of a gene (e.g., KCNT1) is chosen from epileptic encephalopathy with SCN1A, SCN2A, and/or SCN8A mutations, early infantile epileptic encephalopathy, Dravet syndrome, Dravet syndrome with SCN1A mutation, generalized epilepsy with febrile seizures, intractable childhood epilepsy with generalized tonic-clonic seizures, infantile spasms, benign familial neonatal-infantile seizures, SCN2A epileptic encephalopathy, focal epilepsy with SCN3A mutation, cryptogenic pediatric partial epilepsy with SCN3A mutation, SCN8A epileptic encephalopathy, Rasmussen encephalitis, malignant migrating partial seizures of infancy,
autosomal dominant nocturnal frontal lobe epilepsy, KCNQ2 epileptic encephalopathy, or KCNT1 epileptic encephalopathy.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163181498P | 2021-04-29 | 2021-04-29 | |
US63/181,498 | 2021-04-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022231872A1 true WO2022231872A1 (en) | 2022-11-03 |
Family
ID=83848537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/025045 WO2022231872A1 (en) | 2021-04-29 | 2022-04-15 | Kcnt1 inhibitors and methods of use |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022231872A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080045571A1 (en) * | 2004-02-18 | 2008-02-21 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
US20180072708A1 (en) * | 2015-03-25 | 2018-03-15 | National Center For Geriatrics And Gerontology | Novel oxadiazole derivative and pharmaceutical containing same |
WO2020227101A1 (en) * | 2019-05-03 | 2020-11-12 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
WO2020227097A1 (en) * | 2019-05-03 | 2020-11-12 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
-
2022
- 2022-04-15 WO PCT/US2022/025045 patent/WO2022231872A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080045571A1 (en) * | 2004-02-18 | 2008-02-21 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
US20180072708A1 (en) * | 2015-03-25 | 2018-03-15 | National Center For Geriatrics And Gerontology | Novel oxadiazole derivative and pharmaceutical containing same |
WO2020227101A1 (en) * | 2019-05-03 | 2020-11-12 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
WO2020227097A1 (en) * | 2019-05-03 | 2020-11-12 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3962479B1 (en) | Kcnt1 inhibitors and methods of use | |
WO2021195066A2 (en) | Kcnt1 inhibitors and methods of use | |
WO2022140547A2 (en) | Kcnt1 inhibitors and methods of use | |
AU2022267220A1 (en) | Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity | |
JPWO2020138398A1 (en) | A novel compound that inhibits lysine-specific demethylase 1, its production method and its use | |
CA3188825A1 (en) | Kcnt1 inhibitors and methods of use | |
WO2022231873A1 (en) | Kcnt1 inhibitors and methods of use | |
IL295940A (en) | Kcnt1 inhibitors and methods of use | |
WO2022231872A1 (en) | Kcnt1 inhibitors and methods of use | |
WO2023122152A1 (en) | Kcnt1 inhibitors and methods of use | |
WO2024123717A1 (en) | Kcnt1 inhibitors comprising a phenyl, pyridine, or pyrimidine core and methods of use | |
WO2023211854A1 (en) | Kcnt1 inhibitors comprising a thiazole core and methods of use | |
WO2023211855A1 (en) | Kcnt1 inhibitors comprising a thiophene core and methods of use | |
WO2023211850A1 (en) | Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use | |
WO2023211853A1 (en) | Kcnt1 inhibitors comprising a pyrazole core and methods of use | |
WO2024123716A1 (en) | Kcnt1 inhibitors comprising a sulfonamide ring core and methods of use | |
WO2023249871A1 (en) | Substituted pyrrolidinyl and piperidinyl compounds and related methods of treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22796392 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22796392 Country of ref document: EP Kind code of ref document: A1 |